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Introduction
Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity 
and mortality worldwide. Patients suffer from progressive dyspnea at rest or on 
exertion, chronic cough and sputum expectoration. The disease is characterized by 
progressive and largely irreversible airways obstruction, which is demonstrated by 
an accelerated decline of lung function (FEV1: forced expiratory volume in 1 second) 
with age. In addition, a subgroup of patients experience frequent exacerbations, 
which may require hospital admission. The disease leads to impaired quality of life, 
disablement and eventually death. The main risk factor for development of COPD 
is cigarette smoking, and smoking-induced inflammation in the lung is thought to 
play a key role in the pathogenesis of COPD. In the studies described in this thesis 
we therefore focused on the role of airway inflammation in relation to lung function, 
smoking and therapeutic intervention.
Definition of COPD
COPD is defined by the Global Initiative for Chronic Obstructive Lung Disease 
(GOLD) as “a preventable and treatable disease with some significant extrapulmonary 
effects that may contribute to the severity in individual patients. Its pulmonary component 
is characterized by airflow limitation that is not fully reversible. The airflow limitation is 
usually progressive and associated with an abnormal inflammatory response of the lung 
to noxious particles or gases” (1;2). Consequently, spirometry is essential for the 
diagnosis and is used for classification of the severity of COPD (table 1). The 
characteristic symptoms of COPD are chronic and progressive dyspnea, cough 
and sputum production.
Table 1. GOLD classification of COPD severity based on post-bronchodilator FEV1 (1;2).
Stage I: Mild COPD
FEV1/FVC < 0.70
FEV1 ≥ 80% predicted
Stage II: Moderate COPD
FEV1/FVC < 0.70
50% ? FEV1 < 80% predicted
Stage III: Severe COPD
FEV1/FVC < 0.70
30% ? FEV1 < 50% predicted
Stage IV: Very Severe COPD
FEV1/FVC < 0.70
FEV1 < 30% predicted or FEV1 
< 50% predicted plus chronic respiratory failure
Abbreviations: FEV1: Forced Expiratory Volume in one second; FVC: Forced Vital Capacity; respiratory 
failure: arterial pressure of oxygen (PaO2) less than 8.0 kPa (60 mmHg) with or without arterial pressure 
of CO2 (PaCO2) greater than 6.7 kPa (50 mmHg) while breathing air at sea level.
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Epidemiology of COPD
COPD is one of the leading causes of mortality and morbidity worldwide (3). The 
prevalence of COPD defined by lung function criteria in adults aged ≥40 years is 
~9-10% (4). According to the latest WHO estimates (2007), currently 210 mil-
lion people have COPD and 3 million people died of COPD in 2005 (5). In the 
Netherlands, the prevalence of COPD was 316,400 individuals in 2003, there 
were 18,500 hospital admissions due to COPD in 2004, and 5,662 people died 
of COPD in 2004 (6). However, underrecognition and underdiagnosis of COPD 
leads to significant underreporting, and therefore underestimation of prevalence 
data. The prevalence, morbidity, and mortality of COPD vary across countries 
and different groups within countries, but are directly related to tobacco smok-
ing. In addition, these figures are projected to increase in the coming decades as 
smoking frequencies rise and the population ages (7;8). The WHO predicts that 
COPD will become the fourth leading cause of death worldwide by 2030 (5).
Risk factors for COPD
Cigarette smoking is the most common risk factor for COPD. Indeed, Fletcher et 
al. have shown that the decline in lung function is faster in smokers compared to 
non-smokers (9). However, only 15-20% of all smokers, and up to 50% of elderly 
(>75 years) smokers (10), developed COPD suggesting a role for age and indi-
vidual susceptibility. Alpha-1 antitrypsin deficiency (SERPINE1 gene; a serine pro-
tease inhibitor protein) is the most important known genetic risk factor for COPD 
(11). Polymorphisms in another related gene, SERPINE2, has also been proposed 
as a potential risk factor (12;13). Other candidate genes have not been reliably 
replicated (14), such as tumor necrosis factor (TNF)-B gene (15), transforming 
growth factor (TGF)-C1 gene (16), microsomal epoxide hydrolase (mEPHX)1 
gene (17), and A Disintegrin and Metalloprotease (ADAM) 33 gene (18). Further 
risk factors include: exposure to occupational dust and chemicals, air pollution, 
reduced lung growth and development, oxidative stress, female gender, infec-
tions, low socioeconomic status, inadequate nutrition, cooking and heating in 
poorly ventilated spaces, and asthma (1;2). Furthermore, it has been reported that 
increased airway hyperresponsiveness (19), elevated serum IgE and peripheral blood 
eosinophilia are associated with a more rapid decline of FEV
1 in smokers (20).
Heterogeneity of COPD
COPD has been recognized as a heterogeneous disorder in terms of clinical presen-
tation, physiological and pathological characteristics (21;22). Clinical phenotypic 
distinctions in COPD include: symptoms of chronic bronchitis, frequent exacer-
bations, weight loss, rapid lung function decline, airways hyperresponsiveness, 
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impaired exercise tolerance, and in some patients perhaps features of asthma (23). 
This is accompanied by pathophysiological characteristics such as partial revers-
ibility to bronchodilators, air trapping, impaired diffusing capacity, and airway 
hyperresponsiveness (24). Pathological findings include: features of emphysema, 
large and small airways disease, epithelial goblet cell hyperplasia, squamous cell 
metaplasia, and presence of eosinophilic airway inflammation in some patients 
with COPD (25). The presence and contribution of these features to the severity of 
COPD varies between patients and may be related to distinct pathophysiological 
mechanisms involved in development, clinical presentation, and course of the dis-
ease. It is increasingly recognized that disease heterogeneity provides opportunities 
for targeted interventions (23;26;27).
Pathology of COPD
Pathological changes are present at different levels and compartments of the lungs 
of patients with COPD: proximal airways, peripheral airways, lung parenchyma, 
and pulmonary vasculature. Induced sputum and endobronchial biopsies mainly 
represent the central airways. Bronchoalveolar lavage fluid (BAL) and surgical 
resection samples represent peripheral airways and lung parenchyma. Changes 
in the central airway wall include increased numbers of macrophages, CD8+ 
T-lymphocytes and B-lymphocytes, increased epithelial goblet cell numbers and 
squamous cell metaplasia, and enlarged submucosal glands (28). The peripheral 
airways show increased numbers of macrophages, T-lymphocytes (predominantly 
CD8+), B-lymphocytes, and mast cells (29). In addition, localization of neutrophils 
and CD8+ cells has been observed in the airway smooth muscle layer in smok-
ers with COPD (30). Structural changes of peripheral airways consist of airway 
wall thickening, with increased extracellular matrix components (31) and smooth 
muscle mass (32;33), peribronchial fibrosis, luminal inflammatory exudates, and 
airway narrowing (34). The lung parenchyma also demonstrates increased num-
bers of macrophages and CD8+ T-lymphocytes, next to alveolar wall destruction, 
and apoptosis of epithelial and endothelial cells (35). The pulmonary vasculature 
shows increased numbers of macrophages and CD8+ T-lymphocytes, thickening 
of the intima, endothelial cell dysfunction, and increased smooth muscle mass. 
Finally, the airway lumen of patients with COPD contains predominantly neutro-
phils (36) and increased numbers of CD8+ T-lymphocytes (37) in larger airways, 
and increased numbers of macrophages and neutrophils in the periphery of the 
lung (38). In some studies increased numbers of eosinophils have been described 
in the airway lumen of (a subgroup of) COPD patients (39).
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Pathogenesis of COPD
The pathogenesis of COPD is strongly linked to the effects of cigarette smoke 
on the lungs. Different important processes have been suggested to play a role 
in the development and progression of COPD. The key processes include pulmo-
nary inflammation, oxidants-antioxidants imbalance, and protease-antiprotease 
imbalance (40-42). In addition, it is thought that the observed airway remodeling, 
including epithelial alterations and changes in the composition of the extracellular 
matrix, may be caused by an aberrant repair process following initial injury. The 
enhanced or abnormal inflammatory response to cigarette smoke is a character-
istic feature of COPD and has the potential to produce lung injury (Figure 1). 
Both innate and adaptive inflammatory and immune responses are involved in 
pulmonary inflammation in COPD. Since inflammation and epithelial remodeling 
are the main topics of this thesis, the role of inflammatory cells and epithelial cells 
in COPD will be discussed more extensively below.
Figure 1. Inflammatory cascade in COPD.
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Innate immune responses and COPD
Neutrophils
The role of neutrophils in the pathogenesis of COPD is not entirely clear. Mul-
tiple studies have shown increased neutrophil counts in sputum (36;43;44) and 
airway lavage fluid (38;45-47) from patients with COPD, whereas studies about 
their presence in the airway wall are inconsistent (30;48;49). Relationships have 
been shown between airflow limitation and sputum (36;43), BAL (46;47), and 
bronchial neutrophils (49), and between rate of FEV1 decline and sputum neu-
trophils (50) in patients with COPD. Neutrophils can migrate to the respiratory 
tract under control of chemotactic factors, such as LTB4, IL-8, and other CXC 
chemokines, which are increased in COPD airways (51). Neutrophils are a source 
of reactive oxygen metabolites, inflammatory cytokines, lipid mediators, antimi-
crobial peptides, and tissue damaging proteinases, such as neutrophil elastase, 
cathepsin G, and proteinase 3, as well as matrix metalloproteinase (MMP)-8 and 
MMP-9. These compounds are implicated in the generation of mucous metapla-
sia in chronic bronchitis and the destruction of lung tissue in emphysema (52), 
and thereby may play a role in progression of airflow limitation in COPD.
Macrophages
Increased macrophage numbers have been observed in lavage fluid (38), the airway 
wall (48;53;54), the lung parenchyma (55), and bronchial glands (56) of patients 
with COPD. Macrophage numbers in the airways correlate with the severity of 
COPD (49). Macrophages play a central role in inflammation and host defense 
against microorganisms, but they also participate actively in the resolution of 
inflammation after alternative activation. It is unclear which of these macrophage 
sub-phenotypes predominates in the airways of COPD patients. Macrophages 
may release reactive oxygen species, chemotactic factors, inflammatory cytok-
ines, smooth muscle constrictors, mucus gland activators, extracellular matrix 
proteins, and matrix metalloproteinase enzymes (MMPs). Particularly, the latter 
are thought to be involved in emphysema. In vivo studies have indeed observed 
increased expression of MMP-2, MMP-9, and MMP-12 in patients with COPD 
compared with healthy controls (57). In addition, alveolar macrophage number 
in lung parenchyma has been correlated to the severity of lung destruction (55), 
suggesting a role for macrophages in the development of emphysema.
Eosinophils
Airway eosinophilia can be observed in patients with stable COPD in sputum 
(39;58-60), BAL fluid (59), and the airway wall (45;59;61). In addition, sputum 
eosinophilia has been found to be associated with airways obstruction (39) and 
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with hyperresponsiveness to adenosine 5'-monophosphate (AMP) in COPD (62). 
During exacerbations of chronic bronchitis eosinophil counts can even be as high 
as in asthma (63-65). These findings suggest that airway eosinophilia is function-
ally important in patients with COPD. It has been suggested that eosinophilia 
in COPD is related to the intensity of the inflammatory process in the airways, 
leading to a nonspecific recruitment and activation of eosinophils (59). How-
ever, the eosinophilic inflammation seen in patients with COPD might also iden-
tify a subgroup of COPD patients that shares some characteristics with patients 
with asthma, including not only eosinophilia, but also a partial bronchodilator 
response to inhaled salbutamol (60).
Mast cells
A role for mast cells in the pathogenesis of COPD is yet unclear. Whereas increased 
numbers of mast cells have been found in the airways of COPD patients by our 
group (29), and in patients with chronic bronchitis by other investigators (66;67), 
most previous studies show no evidence of mast cell abundance in the airways or 
parenchyma of COPD patients (49;56;68;69). Mast cells and their secreted cytok-
ines (IL-8, TNF-B) and enzymes (tryptase, chymase), have been shown to initiate 
and drive a variety of processes relevant to airway inflammation and remodeling. 
These include airway fibrosis and extracellular matrix turnover (70;71), angio-
genesis, airway smooth muscle and epithelial cell hyperplasia, inflammation, 
alterations in bronchial tone, and mucus hypersecretion (72;73). It is yet unclear 
whether these mast cell induced mechanisms play a role in the pathogenesis of 
COPD. Interestingly, a more recent study demonstrated similar distributions of 
tryptase and chymase positive mast cells in the airways of COPD patients com-
pared to controls (74). Moreover, higher numbers of these cells in peripheral air-
ways were associated with less severe airflow limitation in COPD. It is unclear 
whether these results reflect a protective role of mast cells in the pathogenesis of 
COPD or increased degranulation of mast cells.
Dendritic cells
Dendritic cells initiate and regulate both innate and adaptive immune responses 
to inhaled antigens, viruses and bacteria. Recently, increased numbers of dendritic 
cells have been observed in small airways and induced sputum from patients with 
COPD compared to smokers without COPD, increasing with disease severity (75). 
CCL20, the most potent chemokine in attracting dendritic cell precursors to sites 
of inflammation, is also increased in the airways of COPD patients (75). The role 
of dendritic cells in de pathophysiology of COPD remains to be clarified.
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Epithelial cells
The airway epithelium of patients with COPD undergoes alterations, including 
squamous cell metaplasia, and goblet and basal cell hyperplasia (76). Bronchial 
epithelial cells contribute to an adequate maintenance of lung homeostasis by 
mucus production, ciliary beating, secretion of antimicrobial products and ade-
quate immunological drive in response to noxious stimuli. Therefore, epithelial 
remodelling in COPD may be involved in the pathogenesis of the disease. Goblet 
cell hyperplasia is more pronounced in smokers with COPD compared to those 
without airflow limitation (77). In addition, it contributes to mucus hypersecre-
tion, which is associated with morbidity and mortality in COPD (78;79). Squamous 
cell metaplasia impairs mucociliary clearance and contributes to the increased risk 
of squamous cell carcinoma as observed in COPD (80). The mechanisms underly-
ing epithelial alterations in COPD are incompletely understood. The epidermal 
growth factor receptor (EGFR) cascade has been shown to be involved in mucin 
production and goblet cell hyperplasia (81;82), repair of damaged epithelium 
(81;82), as well as development of squamous cell carcinoma (83). In addition to 
EGFR ligands, a wide variety of stimuli can induce EGFR activation in vitro and in 
animals, including cigarette smoke (81;82). Additionally, epithelial EGFR expres-
sion is increased in bronchial biopsies from smokers with (84;85) and without 
(85;86) COPD compared to non-smokers. Previously, we have observed higher 
epithelial EGFR expression in ex-smokers with COPD compared to non-COPD, 
but not in current smokers, suggesting that current smoking may obscure dif-
ferences in EGFR expression (87). Therefore, EGFR activation may play a role in 
epithelial phenotypic alterations observed in COPD through active smoking.
Adaptive immune responses and COPD
T-Lymphocytes
In COPD the CD8+ T-cell is the most prominent lymphocyte subtype. Increased 
CD8+ T-lymphocyte numbers have been found in sputum (37), the airway wall 
(32;53;88), and lung parenchyma (69;89) of COPD patients. Moreover, a strong 
correlation has been found between severity of airflow limitation and the number 
of CD8+ cells (53;88). Mucosal CD8+ cells have also been associated with air-
way hyperresponsiveness to AMP (62). Additionally, sputum CD8+ cells of COPD 
patients have elevated cytotoxic activity (90). A key function of CD8+ cells is to com-
bat viruses, which may consequently lead to collateral tissue damage via release of 
lytic substances such as perforins and granzymes (25). CD8+ cells can induce struc-
tural cell apoptosis (25), as suggested for alveolar endothelial and epithelial cells 
(89). A more recent study demonstrated that patients with COPD had a blunted 
regulatory T-cell response to tobacco smoke, and higher CD8+CD45RA+ and lower 
| Chapter 118
CD8+CD45R0+ than smokers with normal lung function, indicating a shift to more 
final maturation-activation state of CD8+ T-lymphocytes (91). In addition, It has 
been hypothesized that smoking and inflammation induced injury to the lung may 
result in structural alterations of cell- and tissue proteins into “autoantigens” that 
are recognized by T-lymphocytes leading to further lung injury (89). Alternatively, 
a persistent intracellular pathogen, such as adenovirus (92), may provide a foreign 
antigenic stimulus that activates T-lymphocytes.
The role of CD4+ cells in COPD is unknown. CD4+ cells are a diverse group of lym-
phocytes in which various subtypes are recognized that may contribute to COPD 
pathogenesis. These include not only Th1 and Th2 cells, but also regulatory and 
Th17 cells. CD4+ cells may contribute to the inflammatory process by production of 
pro-inflammatory cytokines, providing help for B cell responses, and may be impor-
tant by their actions as T-helper cells, priming CD8+ cytotoxic responses, maintain-
ing their memory and ensuring survival (25).
B-lymphocytes and plasma cells
It has been demonstrated that B-lymphocyte numbers and lymphoid follicles in the 
small airways of COPD patients are increased (34;93), and associated with disease 
severity (34). While previous studies observed similar B cell counts in large airways 
of COPD patients compared to controls (53;54), we have shown increased num-
bers in bronchial biopsies associated with severity of airflow limitation (94). These 
B cells can result from a local inflammatory process, an altered T-helper (Th)1-Th2 
balance and/or can reflect an antigen-specific reaction to pathogens, components 
of cigarette smoke, or auto-antigens. In line with this, B-cell follicles with an oli-
goclonal, antigen-specific reaction were found in men and mice with emphysema 
(95). Furthermore, the presence of anti-elastin antibodies (96) and IgG anti-epi-
thelial cell antibodies, and the potential to mediate cytotoxicity (97), support a 
role for auto-reactive adaptive immune responses in patients with COPD. Plasma 
cells are terminally differentiated effector B cells, and are the cellular source of 
mucosal immunoglobulin production. There is limited data on their role in COPD. 
One single study by Zhu et al. examined their numbers in patients with chronic 
bronchitis with or without airflow limitation (67). It was concluded that patients 
with chronic bronchitis have increased plasma cell counts in submucosal glands 
and subepithelial compartments compared to controls, which was not significant 
for patients with airflow limitation.
Pathophysiology of COPD
Irreversible airflow limitation, the main characteristic of impaired lung function 
in COPD, results from the loss of elastic recoil of the parenchyma and from the 
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increase in airway resistance. The pathological substrate of airflow limitation is 
predominantly located in the periphery of the lung (98). In the emphysematous 
lungs, parenchyma destruction and loss of alveolar integrity is observed, which 
leads to reduced recoil and collapsed small airway lumens. Additionally, due 
to destruction of the parenchyma, gas exchange may be impaired, resulting in 
reduced diffusing capacity. The current working hypothesis is that inflammatory 
cell infiltration of small airways, together with fibrosis and smooth muscle cell 
proliferation results in reduced diameter and increased resistance. In addition, 
mucus hypersecretion may also contribute to airflow limitation. The altered com-
pliance and resistance of small airways may result in uneven distribution of venti-
lation and early airway closure, as can be measured by "small airways tests", such 
as the single-breath nitrogen test (sbN2-test) (99). The physiological abnormali-
ties observed in COPD are progressive and finally cause hypoxia.
Management of stable COPD
Current guidelines recommend smoking cessation and on demand use of short-
acting bronchodilators for all GOLD severity stages of COPD (1;2). Addition of 
long-acting bronchodilators is advised for patients with at least GOLD stage II 
COPD, and treatment with inhaled corticosteroids for patients with at least GOLD 
stage III COPD and frequent exacerbations (1;2). In the following paragraphs, the 
effects of smoking cessation, bronchodilators, inhaled steroids, and combination 
therapy of inhaled steroids with long-acting bronchodilators on clinical and, in 
particular, inflammatory parameters in COPD patients will be discussed more 
extensively.
Smoking cessation
Smoking cessation is able to reduce COPD progression (100) and improve survival 
(101). Moreover, patients who quit smoking experience fewer respiratory symp-
toms and less hyperresponsiveness as compared to those who continue smoking 
(102;103). These beneficial clinical effects of smoking cessation do not appear to 
be accompanied by a simultaneous simple reduction of airway inflammation char-
acteristic for COPD. Induced sputum from COPD smokers and ex-smokers reveal 
similar inflammatory cell counts in one study (44), and higher macrophage counts 
in smokers in another (104). There are only few cross-sectional studies compar-
ing smokers and ex-smokers regarding bronchial inflammation in heterogeneous 
and relatively small groups of patients without an established diagnosis of COPD 
(105). Most of these previous studies were performed in patients with chronic 
bronchitis (66;106). In patients with symptoms of chronic cough and expectora-
tion, ex-smokers tended to have lower mast cell numbers in the lamina propria 
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than current smokers (66), whereas the number of neutrophils, macrophages, 
eosinophils, and lymphocytes in bronchial biopsies have been reported to be simi-
lar (106). Recently, it was observed that in patients with established COPD there 
are also no differences in bronchial T-lymphocytes, neutrophils, macrophages 
and mast cells between current and ex-smokers (107), but that current smokers 
have lower numbers of dendritic cells (108). In contrast, another study observed a 
positive relation between macrophages in bronchial biopsies and current smoking 
in COPD (104). Finally, in a prospective study of COPD patients bronchial inflam-
mation also persisted after smoking cessation, while the number of sputum neu-
trophils, lymphocytes, IL-8 and ECP levels significantly increased (109). It needs 
to be emphasized that the majority of studies did not take duration of smoking 
cessation into account when comparing current and ex-smokers. However, it has 
been shown that this may influence the inflammatory response in small airways 
(61). In summary, airway inflammation characteristic for COPD seems to persist 
after smoking cessation, in contrast to clinical beneficial effects on symptoms 
and decline of lung function. Possible explanations for this ongoing inflamma-
tory response have been proposed, and include persistent presence of a microbial 
stimulus or the development of autoimmune disease or alternatively to represent 
the inflammatory component of tissue repair.
Pharmacological intervention
Bronchodilators
Inhaled bronchodilator medications (C
2-agonists and anticholinergics) are central 
to the symptomatic management of COPD (110;111). The principal action of 
C2-agonists is to relax airway smooth muscle by C2-adrenergic receptor stimulation, 
which increases cAMP and produces functional antagonism to bronchoconstric-
tion. The most important effect of anticholinergics is to block the acetylcholine 
effect on muscarinic receptors. Long-acting C2-agonists (salmeterol) and long-act-
ing anticholinergics (tiotropium) are more effective than short-acting bronchodi-
lators (112;113). Both salmeterol and tiotropium have beneficial effects on symp-
toms, exacerbation rates and lung function level in COPD patients (114-117). In 
addition, salmeterol has an effect on decline in lung function (118), which was not 
observed with tiotropium treatment (117). It has been suggested that broncho-
dilators also exhibit some anti-inflammatory effects. In fact, salmeterol inhibits 
inflammatory responses by neutrophils and mononuclear cells in vitro (119;120), 
and in mouse models of lung inflammation in vivo (121). In addition, salmeterol 
has anti-inflammatory effects in LPS exposed healthy volunteers (122) and in mild 
asthmatics (123;124). To our knowledge, the effects of salmeterol mono-therapy 
on airway inflammation in COPD have not been studied. Although tiotropium is 
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able to suppress acetylcholine-induced release of chemotactic mediators in vitro 
(125) and inhibit allergen-induced increase in MUC5AC-positive goblet cell num-
bers and eosinophil infiltration in vivo in guinea pigs (126), it does not seem to 
attenuate sputum and systemic inflammatory markers in COPD patients (127).
Inhaled steroids
Regular therapy with inhaled corticosteroids leads to clinical benefit in terms of symp-
toms, exacerbation rate, and initial improvement in FEV1 (128;129). In addition, 
withdrawal of inhaled steroids in COPD results in deterioration of lung function, 
symptoms and exacerbation rate (130;131). So far, it has not been settled whether 
ICS alone or combined with LABA changes FEV1-decline in COPD (132-137) and if 
so, in which COPD phenotypes. ICS may have the potential of ‘disease modification’ 
since long-term therapy improves airway hyperresponsiveness (138), a disease fea-
ture that is present in about 70% of the COPD population and by itself constitutes 
a risk factor for accelerated FEV1 decline (139;140). Interestingly, a recent analysis 
of the TORCH study suggests that prolonged therapy with ICS and/or LABA attenu-
ates FEV1-decline in COPD (118). Several short-term studies have investigated the 
anti-inflammatory effects of ICS in patients with COPD. 2-3 Months treatment 
with inhaled steroids in patients with COPD reduces bronchial mast cells, but not 
CD8+ cells, neutrophils or macrophages (141;142), and may reduce sputum total 
cell counts, neutrophils and lymphocytes (143). In addition, the presence of spu-
tum eosinophilia predicts the response of airways obstruction to oral and inhaled 
corticosteroid treatment in COPD (58;144-146), and can even be used to guide 
it (27). Therefore, the clinical effects of long-term treatment with inhaled steroids in 
COPD may be mediated, at least partially, by anti-inflammatory effects. However, 
the longer-term anti-inflammatory effects of inhaled corticosteroids have not been 
studied before.
Combination therapy
Addition of LABA to inhaled corticosteroids treatment in COPD is more effective 
in improving lung function level (147;148), health status (114;149) and reducing 
exacerbations (114;150), although it does not have supplementary effects on FEV1 
decline (118). Combination treatment with a LABA for 3 months may have addi-
tional anti-inflammatory effects on bronchial CD8+ and CD68+ cells compared 
to mono-therapy with inhaled steroids (151), and reduces sputum neutrophils 
and eosinophils compared to placebo (152). To our knowledge, the longer-term 
anti-inflammatory effects of combination therapy have not been studied previously. 
Finally, although triple therapy with salmeterol/fluticasone propionate and tiotro-
pium seems to have additional bronchodilator effect after 2 weeks treatment 
(153), long-term effects of this combination have not been studied so far.
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Aims of the present studies
In summary, this thesis addresses airway pathology in relation to three differ-
ent aspects of COPD: pathophysiology, smoking cessation and pharmacological 
treatment. The questions mentioned in the introduction have been addressed in 
cross-sectional and longitudinal analyses from the Groningen Leiden Universities 
Corticosteroids in Obstructive Lung Disease (GLUCOLD) study.
The GLUCOLD study
The GLUCOLD study is a two-centre, randomized, double-blind, four armed, pla-
cebo-controlled, parallel-group trial. It was designed to investigate the effect of 
long-term versus short-term treatment with inhaled corticosteroids, either or not 
combined with a long-acting C2-agonist, on bronchial inflammation in patients 
with stable COPD. The in- and exclusion criteria are presented in table 2. 
114 COPD patients were randomized to 30 months treatment with fluticasone 
propionate, fluticasone propionate/salmeterol combination therapy, placebo, 
and 6 months fluticasone propionate followed by 24 months placebo (figure 2). 
Patients visited the out-patient clinic every three months to perform spirometry 
and obtain symptoms- and health status questionnaires. At baseline, after 6, and 
30 months treatment more extensive measurements were performed including: 
peripheral blood analysis, diffusion capacity, bodyplethysmography, methacho-
line provocation, sputum induction, and bronchoscopy (figure 3).
30
fluticasone propionate 500μg bid
placebo bid
placebo bid
0 6 12 18 24
Months
fluticasone
500μg bid
fluticasone propionate/salmeterol 500/50μg bid
Figure 2. Design of the GLUCOLD study.
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Table 2. In- and exclusion criteria of the GLUCOLD study.
Inclusion criteria
Age: 45-75 years
≥ 10 Packyears of smoking
≥ 1 of the following symptoms: chronic cough, chronic sputum production, frequent 
exacerbations, or dyspnoea on exertion
No course of oral corticosteroids during last 3 months, no maintenance treatment with 
inhaled or oral steroids during last 6 months
Postbronchodilator FEV1 (after 400 Ng of inhaled salbutamol) < 90% confidence interval (90% 
CI) of the predicted FEV1, and postbronchodilator FEV1/IVC ratio below the 90% CI of the 
predicted FEV1/IVC ratio (154)
Postbronchodilator FEV1 > 1.3 litre and > 20% of predicted value.
Exclusion criteria
Prior or concomitant history of asthma
Alpha-1 antitrypsin deficiency (SZ, ZZ, zero phenotype)
Other active lung disease, except for mild bronchiectasis
Contra-indications for elective bronchoscopy, such as: O2 saturation <90%, abnormal 
coagulability, anti-coagulant therapy which cannot be temporarily withheld for performance 
of bronchoscopy, history of pneumothorax, uncontrolled angina pectoris
Other diseases likely to interfere with the purpose of the study.
Inability to keep diary and to understand written and oral instructions in Dutch
Figure 3. Measurements during the GLUCOLD study.
months
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Research questions
Relation between airway inflammation and pathophysiology in COPD
1. Are the various functional and inflammatory features of COPD separate, complementary 
domains of this heterogeneous disease? 
 In chapter 2 we applied a factor analysis including lung function indices and 
markers of inflammation in induced sputum and exhaled air from patients with 
clinically stable COPD.
2. Is small airways dysfunction in patients with COPD associated with the inflammatory profile 
characteristic for COPD? 
 In chapter 3 we examined, in a cross-sectional study in 51 patients with COPD, 
the relationship of uneven ventilation and airway closure, measured by the 
single breath nitrogen (sbN2)-test, with the number of inflammatory cells in 
bronchial biopsies, bronchoalveolar lavage (BAL) fluid, and induced sputum, 
together with the levels of neutrophil elastase (NE), IL-8, and secretory leuko-
cyte proteinase inhibitor (SLPI) in BAL fluid.
Effect of smoking cessation on airway pathology in COPD
3. Does bronchial inflammation in patients with established COPD differ between active smok-
ers and patients who stopped smoking? Is airway inflammation associated with duration of 
smoking cessation? 
 In chapter 4 the number of inflammatory cells in bronchial biopsies of current 
and ex-smokers with COPD was investigated, and related to duration of smok-
ing cessation.
4. Is bronchial epithelial cell proliferation and differentiation in patients with COPD different 
between active smokers and those who stopped smoking, and is this difference influenced 
by the duration of smoking cessation? Are the epithelial changes associated with epithelial 
growth factor receptor (EGFR) expression? In chapter 5 the extent of epithelial goblet 
cell hyperplasia, proliferation, squamous cell metaplasia, and EGFR expression 
in bronchial biopsies of current and ex-smokers with established COPD was 
measured and related to smoking cessation duration.
Treatment effects on airway pathology in COPD
5. Are there additional anti-inflammatory effects of long-term treatment compared to short-
term treatment with inhaled steroids in patients with COPD? Does discontinuation of 
inhaled steroids lead to a flare up of inflammation? Does addition of long-acting ß
2
-agonists 
to inhaled steroids lead to additional anti-inflammatory effects after long-term therapy? 
 In chapter 6 a longitudinal randomized trial was performed examining the 
effects of 30 months treatment with fluticasone propionate, fluticasone propi-
onate/salmeterol combination therapy, placebo, or 6 months fluticasone pro-
pionate followed by 24 months placebo on sputum and bronchial inflamma-
tory cells and bronchial epithelial remodelling.
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Abstract
Chronic obstructive pulmonary disease (COPD) is defined by progressive, irre-
versible airflow limitation and an inflammatory response of the lungs, usually to 
cigarette smoke. However, COPD is a heterogeneous disease in terms of clini-
cal, physiological, and pathological presentation. We aimed to evaluate whether 
airflow limitation, airway responsiveness, and airway inflammation are separate 
entities underlying the pathophysiology of COPD by using factor analysis. A total 
of 114 patients (99 males/15 females, age 62 ? 8 years, 42 pack-years smok-
ing, no inhaled or oral steroids >6 months) with irreversible airflow limitation 
(postbronchodilator FEV1 63 ? 9% predicted, FEV1/inspiratory vital capacity 
[IVC] 48 ? 9%) and symptoms of chronic bronchitis or dyspnea were studied in 
a cross-sectional design. Postbronchodilator FEV1 and FEV1/IVC, reversibility to 
inhaled C2-agonists, diffusing capacity, provocative concentration of methacho-
line required to produce a 20% drop in FEV1, total serum IgE, exhaled nitric oxide, 
and induced sputum cell counts (% eosinophils, % neutrophils) were collected. 
Factor analysis yielded 4 separate factors that accounted for 63.6% of the total 
variance. Factor 1 was comprised of FEV1, FEV1/IVC, and residual volume/total 
lung capacity. Factor 2 included reversibility, IgE, provocative concentration of 
methacholine required to produce a 20% drop in FEV1, and diffusing capacity. Fac-
tor 3 contained exhaled nitric oxide and factor 4 included sputum % neutrophils 
and % eosinophils. We conclude that airflow limitation, airway inflammation, and 
features commonly associated with asthma are separate and largely independent 
factors in the pathophysiology of COPD.
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Introduction
Chronic obstructive pulmonary disease (COPD) is a disease characterized by pro-
gressive airflow limitation, which is not fully reversible (1). However, COPD has 
been recognized as a heterogeneous disorder (2), with components of chronic bron-
chitis, small airways disease, emphysema, and in some patients perhaps, features 
of asthma (3). This is accompanied by pathophysiological characteristics, such 
as partial reversibility to bronchodilators, air trapping, impaired diffusing capac-
ity, and airway hyperresponsiveness (4). The presence and contribution of these 
features to the severity of COPD varies between patients and may reflect distinct 
pathophysiological mechanisms in development, clinical presentation, and course 
of the disease. It is increasingly recognized that such disease heterogeneity provides 
opportunities for targeted interventions (3;5).
Airway inflammation is thought to play an important role in the pathogenesis of 
COPD (6). The cellular inflammatory response is characterized by an increase in 
neutrophils, macrophages, and CD8-positive T-lymphocytes in small and large air-
ways as well as in lung parenchyma (7). The major cell type in induced sputum is 
the neutrophil, the quantity of which is associated with the severity of airflow limi-
tation (8;9). Although induced sputum does not cover all the inflammatory and 
structural changes of the lungs in patients with COPD, it does represent a non-
invasive marker of inflammation that is potentially useful for disease monitoring. 
Sputum eosinophilia has also been observed in patients with stable COPD, but its 
relationship to airflow limitation is controversial (8;10;11). It has been argued that 
sputum eosinophilia is related to concomitant features of asthma (12). This link 
would indicate that the pathophysiological entities underlying the clinical pheno-
types in COPD may be diverse and are still largely unknown.
The aim of this study was to objectively specify the heterogeneity of COPD by cat-
egorizing various functional and inflammatory features of COPD into separate, 
complementary domains without a priori assumptions. Factor analysis allows reduc-
ing multiple disease characteristics to a few independent factors, in which each fac-
tor groups associated parameters. Because this is essentially accomplished free of 
predetermined hypothesis on any interrelated parameters, this technique can be 
considered as a hypothesis-generating analysis.
Factor analysis has been applied previously in studies of patients with asthma (13-
16) and COPD (17). In patients with asthma, it has demonstrated that lung func-
tion, baseline airway hyperresponsiveness, and eosinophilic inflammation in spu-
tum are nonoverlapping dimensions (13), suggesting that evaluation of patients 
with asthma should include measurement of all these parameters. In COPD, factor 
analysis has been applied to study the relationship between dyspnea ratings, exer-
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cise capacity, lung function and hyperinflation (17-23). However, these studies did 
not include inflammatory markers and were unable to study the interrelationships 
between airway inflammation and the functional features of COPD. Therefore, in 
the present study, we performed factor analysis, including lung function indices 
and markers of inflammation in induced sputum and exhaled air, in 114 patients 
with clinically stable COPD. Some of the results of this study have been previously 
reported in the form of an abstract (24).
Material and Methods
Patients
Hundred fourteen patients (15 women) aged between 45 and 75 years with COPD, 
participating in a multi-center trial (Groningen Leiden Universities and Corticoster-
oids in Obstructive Lung Disease; GLUCOLD study), were included in this study. 
Patients were recruited from our outpatient clinics, as well as by advertisements in 
local newspapers, and by screening lung functions from patients in general practice 
in and around Leiden and Groningen, The Netherlands. All patients were current or 
ex-smokers and had a history of at least 10 pack years of smoking. They had irre-
versible airflow limitation (postbronchodilator FEV1 and FEV1/IVC < 90% confidence 
interval (CI) of the predicted value (25), FEV1 ? 1.3 liter and > 20% of the predicted 
value) and at least one of the following symptoms: chronic cough, chronic sputum 
production, or dyspnea on exertion. In choosing the 90% CI of predicted values 
as selection criterion, as opposed to percentage of predicted values per se, we fol-
lowed the recommendation by the European Respiratory Society (25). Patients with 
a prior or concomitant history of asthma, alpha-1 antitrypsin deficiency (SZ, ZZ, 
zero phenotype), or other active lung disease except for mild bronchiectasis were 
not permitted to the study. The patients did not use a course of oral or inhaled 
steroids during the last three months, and did not have maintenance treatment 
with inhaled or oral steroids during the last six months. Maintenance drug therapy 
of non-selective beta-antagonists, long-acting bronchodilators, methylxanthines, 
N-acetylcysteine or NSAID’s was not permitted. Patients were allowed to use short 
acting C2-agonists and ipratropium bromide as rescue medication. The patients were 
in clinically stable condition and had no symptoms of respiratory tract infection for 
at least two weeks prior to the study. The Medical Ethics Committees of each center 
approved the study and all patients gave their written informed consent.
Study Design
The present study had a cross-sectional design, consisting of baseline measure-
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ments of the GLUCOLD Study. At visit 1 spirometry was performed before and 
after inhalation of salbutamol and blood was collected for measurement of total 
IgE. Body plethysmography, CO-diffusing capacity, and bronchial responsiveness 
to methacholine were obtained at a second visit. Finally, at the third visit exhaled 
NO was measured and hypertonic saline-induced sputum was collected. Inhaled 
bronchodilators were withheld for at least 8 hrs prior to visit day 1 and 2. All visits 
were performed within six weeks.
Lung Function
Spirometry was performed according to international guidelines (26). A daily-cal-
ibrated pneumotachograph (Masterscreen Pneumo or Masterscreen IOS; Jaeger, 
Würzburg, Germany) was used throughout the study. First, 3 slow inspiratory vital 
capacity maneuvers (IVC, largest value used) were carried out. Second, maximally 
8 forced expiratory vital capacity (FVC) maneuvers were performed to obtain at 
least 3 technically satisfactory expiratory flow-volume curves from which the forced 
expiratory volume in 1 second (FEV1) and FVC did not deviate > 5% or 100 ml from 
the largest FEV1 and FVC. From these curves, we used values of the curve with the 
largest sum of FEV1 and FVC (26).
Reversibility of airflow limitation (%FEV1) was measured 15 min after administra-
tion of 400 Ng salbutamol per metered dose-inhaler connected to a spacer (27). The 
response was expressed as change in FEV1 as percentage of predicted value (27).
Total lung capacity (TLC) and residual volume (RV) were measured using a con-
stant volume body plethysmograph (Masterscreen body or Masterlab body; Jaeger, 
Würzburg, Germany), using panting at 0.5 Hz (25).
The diffusing capacity (transfer factor) for carbon monoxide (TLCO) and TLCO per 
liter alveolar volume (KCO) were measured using the single breath holding method 
with a rolling seal closed system (Masterscreen MS-CS-FRC, Masterlab transfer or 
Compactlab transfer; Jaeger, Würzburg, Germany) (28). Reference values for all 
lung function measurements were obtained from Quanjer et al. (25).
Methacholine challenge tests were performed according to the tidal breathing 
method (29), using serial doubling concentrations methacholine-bromide (0.038 
to 39.2 mg/ml) in saline. Methacholine was aerosolized (DeVilbiss 646, Somerset, 
PA) and inhaled by the 2-min tidal breathing method at 5-minute intervals until 
FEV1 dropped by ? 20% (lowest of two FEV1 values; at 30 and 90 seconds) from 
baseline. The response was expressed as the provocative concentration causing 20% 
fall in FEV1 (PC20).
Sputum induction and processing
Sputum was induced and processed according to a validated technique (30), with 
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some modifications. Prior to sputum induction, 200 Ng salbutamol was admin-
istered and baseline FEV1 was recorded. Hypertonic sodium chloride aerosols 
(4.5 w/v %) were generated by a DeVilbiss Ultraneb 2000 ultrasonic nebulizer 
with a calibrated particle size (MMAD 4.5 Nm) at maximal output (2.5 ml/min). 
The aerosols were inhaled via the mouth through a two-way valve (No. 2700; 
Hans-Rudolph, Kansas City, MO, USA), with the nose clipped. Subsequently, the 
patients inhaled hypertonic saline aerosols during 3 periods of 5 min and sputum 
was expectorated after each inhalation. Salbutamol was administered when FEV1 
dropped by > 10% from post-salbutamol baseline value and the procedure was 
interrupted when FEV1 dropped by > 20%.
Whole sputum samples were processed. The sample was then mixed with an equal 
volume of dithiothreitol 0.1% w/v (Sputolysin, Calbiochem, USA) and placed in a 
shaking water bath at 37ºC for 15 min. Then sputum was filtered through a nylon 
gauze (pore-size approximately 48 Nm) and centrifuged (450 x g) for 10 minutes 
at 20oC. The cell pellet was then resuspended in phosphate-buffered saline (PBS) 
containing 1 % (w/v) human serum albumin (HSA), pH 7.4. Cell viability and 
total cell counts were performed by Trypan blue exclusion using a hemacytometer. 
Subsequently, cytocentrifuge slides were prepared (450 rpm, 6 minutes, 100 Nl/
slide, Cytospin 3, Shandon, Life Sciences International, Veldhoven, NL) and dif-
ferential cell counts were performed on May-Grünwald-Giemsa-stained cytospins 
by a qualified technician. Differential leucocyte and cylindric epithelial cell counts 
were expressed as a percentage of nucleated cells excluding squamous cells. A 
sputum sample was considered adequate when the percentage squamous cells 
was less than 80% (30).
Exhaled nitric oxide
Exhaled NO (eNO) levels were determined according to a standardized procedure 
(31) with some modifications, using a chemiluminescence analyzer (Sievers NOA 
270B or ECO physics CLD 700 AL). Patients were asked not to smoke for at least 
1 hour prior to the test. A slow vital expiratory capacity maneuver with a con-
stant expiratory flow of 100 mL/sec against an expiratory resistance of 5 cm H2O 
was performed. Expiratory NO concentration was sampled continuously from the 
center of the mouthpiece and the average concentration was determined during a 
period of 10 seconds. Three reproducible successive recordings were made at 30-s 
intervals, from which the mean values of exhaled NO were used in the analysis.
Peripheral blood measurements
Total serum IgE concentrations were measured by fluoroimmunoassay (FEIA) 
using the Pharmacia CAP system (Pharmacia Diagnostics, Uppsula, Sweden).
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Statistical analysis
Mean values and SD were computed. When appropriate variables were logarithmi-
cally transformed before statistical analysis and presented as median with inter-
quartile range.
Exploratory factor analysis included the following variables: postbronchodilator 
FEV1 (%pred), postbronchodilator FEV1/IVC (%), %FEV1 (%pred), KCO (%pred), 
PC20 (mg/ml), RV/TLC (%), eNO (ppb), sputum % neutrophils and % eosinophils 
and total serum IgE (IU/ml). The possibility to perform factor analysis was tested 
by Bartlett’s test of sphericity. The Kaiser-Meyer-Olkin (KMO), a measure of sam-
pling adequacy based on correlation and partial correlation, was also evaluated. 
A high KMO (maximum 1.0) indicates that data are likely to factor well since 
correlations between pairs of variables can be explained by the other variables 
(low partial correlation coefficients). Correlation coefficients were analyzed by 
principal component factor analysis and subsequent rotation according to the 
standard Varimax criterion (32). In this type of analysis, the correlation between 
parameters is attributed to their common dependence on independent entities 
called “factors”. The parameters are separated into independent subgroups, and 
the correlation of parameters within subgroups is due to their common factor. 
The coefficients that link parameters to factors are called “factor loadings”, and 
are the correlation coefficient between parameters and factors. The number of 
factors is chosen to be as small as possible but large enough to account for most 
of the variation within the data. The number of factors was determined by the 
number of eigenvalues, an index of the proportion of variance explained by suc-
cessive factors, whose magnitude was ? 1 on the Scree plot. However, also the 
percentage of total variance explained by the factors was taken into account. The 
Varimax rotation procedure aims to increase the interpretability of the factors by 
rotation to a simple structure with optimal loadings, such that they are high or 
low. Ideally, each variable would have a high loading on one factor, whereas its 
loadings on other factors would be low. In the Varimax rotation this is technically 
achieved by maximalizing the variation within a factor. Finally, we conducted three 
additional factor analyses to determine the stability of the factor structures, and 
thus the robustness of our findings. First, we excluded outliers from the data set, 
defined as data outside the range of mean ? 3 x SD, and repeated the factor analysis. 
Next, the analysis was repeated with number of neutrophils and eosinophils per 
ml sputum, instead of % neutrophils and eosinophils. Since smoking is the main 
risk factor for development of COPD, an additional factor analysis was performed 
in which the number of pack years was added. Univariate correlations were evalu-
ated using Pearson correlation coefficient. All analyses were performed with the 
Statistical Package of Social Sciences (SPSS 11.0).
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Results
Patient characteristics
Patient characteristics of the 114 participants are presented in Table 1. The mean 
(SD) postbronchodilator FEV1 was 63.0 (8.8) %pred, with a range from 40.8 to 
77.7 %pred. This result indicates that all patients were classified as having moderate 
to severe COPD according to Global Initiative for Chronic Obstructive Lung Disease 
(GOLD) criteria (GOLD stage II and III) (1). The patients were heavy smokers with 
a median of 41.8 pack-years and most of them were current smokers (63.2%).
Table 1. Patient characteristics.
n Mean (SD or IQR)
Clinical characteristics
   Sex, male/female 114 99 / 15
   Age, yr 114 62 (8)
   Smoking history, pack-years * 114 41.8 (31.2-54.8)
   Current smoker, yes/no, n 114 72 / 42
   IgE, IU/ml* 113 40 (11.5-125)
Lung Function
   Post FEV1, %pred 114 63.0 (8.8)
   Post FEV1/IVC, % 114 48.2 (8.5)
   %FEV1, %pred 113 6.9 (4.9)
   KCO, %pred 112 75.9 (25.5)
   PC20, mg/ml† 110 0.60 (2.76)
   RV/TLC, % 113 48.5 (8.8)
Airway inflammation
   eNO, ppm 92 13.1 (12.7)
   Sputum eosinophils, %* 106 1.1 (0.3-2.2)
   Sputum neutrophils, % 106 69.4 (16.0)
   Sputum eosinophils, n (x 104/ml)* 106 1.4 (0.4-4.5)
   Sputum neutrophils, n (x 104/ml)* 106 102 (47-229)
Definition and abbreviations: %FEV1 = change in FEV1 as percentage of predicted (reversibility to salbutamol); 
eNO = exhaled nitric oxide; IQR = interquartile range (25th and 75th percentile”); IVC = inspiratory vital 
capacity; KCO = diffusing capacity for carbon monoxide per liter alveolar volume; %pred = percentage of pre-
dicted; PC20 = provocative concentration of methacholine causing a 20% fall in FEV1; RV = residual volume, 
TLC = total lung capacity. * Median (IQR). † Geometric mean ? doubling dose.
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Factor analysis
Bartlett’s test of sphericity indicated a correlation between the presently used 
variables because the correlation matrix was statistically different from an iden-
tity matrix (approximate D2 = 165.864, degrees of freedom = 45, p<0.001). The 
Kaiser-Meyer-Olkin value was 0.594. Factor analysis yielded 3 separate factors, 
explaining only 53.7% of the total variance in the data set when the eigenvalue 
1 criterion was applied. Therefore, an additional factor analysis was performed 
with the same data in which 4 factors were selected. This resulted in an increase 
of total explained variance to 63.6%.
The correlations with the original variables obtained for each Varimax-rotated 
factor (called factor loadings) and the eigenvalues are displayed in Table 2. FEV1, 
FEV1/IVC, and RV/TLC loaded significantly on factor 1. Factor 2 included %FEV1, 
total IgE, PC20, and KCO. eNO loaded on factor 3, whereas sputum % neutrophils 
and eosinophils loaded on factor 4. Interestingly, KCO contributed also to factor 1, 
and % neutrophils contributed also to factor 3.
Additional Factor Analyses
Factor analysis without outliers in the data set resulted in a similar four-factor struc-
Table 2. Varimax Rotated Factor-loading Matrix from Factor Analysis.
    Factor 1    Factor 2    Factor 3    Factor 4
Postbr. FEV1, %pred 0.89 -0.16 -0.09 -0.07
Postbr. FEV1/IVC, % 0.82 0.04 -0.23 0.22
RV/TLC, % -0.59 -0.36 -0.03 0.15
%FEV1, %pred -0.06 -0.72 0.08 0.11
IgE, IU/ml -0.09 0.61 0.10 -0.07
PC20, mg/ml 0.36 0.51 -0.35 0.14
KCO, %pred 0.44 0.49 0.25 0.31
eNO, ppb -0.09 0.10 0.89 -0.11
Sputum eosinophils, % -0.09 0.02 0.19 -0.84
Sputum neutrophils, % -0.18 -0.25 0.47 0.54
Eigenvalue 2.67 1.50 1.20 0.99
Total variance explained, % 26.7 15.0 12.0 9.9
Definition and abbreviations: %FEV1 = change in FEV1 as percentage of predicted (reversibility to salbutamol); 
eNO = exhaled nitric oxide; IVC = inspiratory vital capacity; KCO = diffusing capacity for carbon monoxide per 
liter alveolar volume; %pred = percentage of predicted; PC20 = provocative concentration of methacholine 
causing a 20% fall in FEV1; RV = residual volume, TLC = total lung capacity. Bold values represent the highest 
loadings of a variable.
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ture as the original one, accounting for 63.4% of the total variance, with the excep-
tion that % neutrophils loaded on factor 3 with eNO and not on factor 4.
Factor analysis with number of neutrophils and eosinophils per ml sputum, 
instead of % neutrophils and eosinophils, did not change the contents of the fac-
tors essentially. Again four factors, accounting for 66.0% of the total variance, 
were found using the eigenvalue 1 criterion. Factor 1 was the same as in the origi-
nal analysis. Factor 2 included numbers of neutrophils and eosinophils, both with 
a positive factor loading. Factor 3 contained the variables that originally loaded on 
factor 2: %FEV1, total IgE, and PC20. Finally, factor 4 included eNO and KCO.
Factor analysis with inclusion of number of pack-years as an additional variable 
revealed four factors explaining 59.1% of total variance, according to the eigen-
value 1 criterion. All factors were similar to the original analysis described previ-
ously, with the exception that KCO and PC20 switched from factor 2 to factor 1. 
Number of pack-years smoked loaded on factor 2 together with %FEV1 and total 
IgE (Table 3).
Table 3. Varimax Rotated Factor-loading Matrix from Factor Analysis with pack years.
   Factor 1    Factor 2    Factor 3    Factor 4
Postbr. FEV1/IVC, % 0.77 -0.0002 -0.33 0.20
Postbr. FEV1, %pred 0.72 -0.19 -0.24 -0.03
RV/TLC, % -0.68 -0.05 -0.20 0.25
KCO, %pred 0.59 0.25 0.37 0.24
PC20, mg/ml 0.59 0.28 -0.13 -0.03
Pack-years -0.22 0.70 -0.32 0.06
%FEV1, %pred -0.29 -0.62 -0.11 0.20
IgE, IU/ml 0.07 0.61 0.18 -0.05
eNO, ppb -0.18 0.05 0.84 0.02
Sputum eosinophils, % -0.23 0.09 0.16 -0.74
Sputum neutrophils, % -0.28 -0.08 0.25 0.68
Eigenvalue 2.67 1.56 1.22 1.06
Total variance explained, % 24.2 14.2 11.1 9.6
Definition and abbreviations: %FEV1 = change in FEV1 as percentage of predicted (reversibility to salbutamol); 
eNO = exhaled nitric oxide; IVC = inspiratory vital capacity; KCO = diffusing capacity for carbon monoxide per 
liter alveolar volume; %pred = percentage of predicted; PC20 = provocative concentration of methacholine 
causing a 20% fall in FEV1; RV = residual volume, TLC = total lung capacity. Bold values represent the highest 
loadings of a variable.
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Univariate correlations
The univariate relationships among physiological and inflammatory param-
eters (sputum neutrophils, eosinophils, and eNO) were as follows. %FEV1 was 
not associated with inflammatory parameters; however, RV/TLC was associated 
with sputum % neutrophils (r=0.203, p=0.04), and postbronchodilator FEV1, RV/
TLC, and PC20 were associated with number of neutrophils/ml sputum (r=-0.246, 
p=0.01; r=0.213, p=0.03 and r=-0.338, p<0.001, respectively). Postbronchodila-
tor FEV1, PC20, and FEV1/IVC were associated with eNO levels (r=-0.203, p=0.05; 
r=-0.207, p=0.05 and r=-0.304, p=0.003, respectively). FEV1/IVC was also related 
to sputum % eosinophils (r=-0.219, p=0.02), while postbronchodilator FEV1, KCO, 
PC20, and FEV1/IVC were also associated with number of eosinophils/ml sputum 
(r=-0.207, p=0.03; r=-0.204, p=0.04; r=-0.243, p=0.01 and r=-0.242, p=0.01, 
respectively).
Discussion
The aim of this study was to objectively specify the heterogeneity of COPD, by cat-
egorizing the various functional and inflammatory features of COPD into separate, 
complementary domains without a priori assumptions. Therefore, we performed 
a factor analysis using physiological and inflammatory data of 114 patients with 
moderate to severe COPD, not treated with inhaled steroids. This resulted in a four-
factor structure, explaining 63.6% of the total variance. Factor 1 included: FEV1, 
FEV1/IVC and hyperinflation; factor 2: C2-response, total serum IgE, airway hyper-
responsiveness and KCO; factor 3 included: eNO, and factor 4 included: sputum 
% neutrophils and eosinophils. These four factors indicate that airflow limitation, 
features commonly associated with asthma, and airway inflammation are separate, 
largely independent dimensions that characterize patients with COPD.
To our knowledge, this is the first study in patients with COPD combining functional 
parameters and markers of airway inflammation in a factor analysis. Previous stud-
ies have applied factor analysis on quality-of-life, symptoms scores, exercise capac-
ity, and lung function parameters in patients with stable COPD, without evaluating 
inflammatory indices (17-23). However, the latter have been part of factor analysis 
in recent asthma research (13;15;16). In patients with mild to moderate asthma, 
Rosi and colleagues demonstrated by factor analysis that airway function, bron-
chial responsiveness with reversibility, and eosinophilic inflammation, as assessed 
in sputum, are independent dimensions (13). Our current results demonstrate that 
airway function, bronchial responsiveness with reversibility, and inflammation as 
assessed in sputum or exhaled are predominantly nonoverlapping dimensions in 
patients with COPD as well.
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Interestingly, this study showed that measurements of airflow limitation, tradi-
tionally used to determine disease severity in COPD (33), and hyperinflation, a 
measure of air trapping, were combined in the first factor. According to the sta-
tistical method of factor analysis, these measurements represent an important, 
separate dimension in the assessment of patients with stable COPD. This result 
is consistent with some (17;23), but not all (21;22) previous factor analyses of 
lung function parameters in COPD. The second factor extracted from the data 
included reversibility of FEV1, airway hyperresponsiveness, total serum IgE, and 
diffusing capacity. Similarly, Ries and colleagues reported that bronchodilator 
response and diffusing capacity of COPD patients were grouped into separate fac-
tors from expiratory flow rates and hyperinflation (17). To our knowledge, there 
are no other studies in patients with COPD that have included these variables in 
a factor analysis. Finally, the third and fourth factor included eNO and sputum 
% neutrophils and eosinophils, respectively. This is a novel finding, illustrating 
the partial independency of these markers of inflammation from the traditionally 
used functional disease markers in COPD.
We included a large (n=114) group of patients with stable COPD, not using inhaled 
steroids for at least 6 months and without a clinical diagnosis of asthma. In terms 
of disease severity, patient characteristics included COPD patients of GOLD Stage 
II and III. Inclusion of very mild or very severe patients could have produced differ-
ent results, and therefore our results potentially lack generalizability. In contrast 
to some other studies, we did not exclude patients with COPD who were partially 
reversible to a bronchodilator, because the selection of non-reversible patients 
only would have excluded a large group of patients with COPD (34-36). Further-
more, it needs to be emphasized that this is a cross-sectional analysis of patients 
with stable COPD, and that the results do not account for exacerbations and 
other temporal events. Sputum cell counts and eNO were measured as noninva-
sive markers of inflammation. Obviously, this does not cover all the inflammatory 
and structural changes of the airways in COPD, but it does represent the markers 
that are potentially useful for disease monitoring.
Factor analysis is not an approach that is widely applied, presumably because 
of its complexity. A simple example that clarifies its value and interpretation has 
recently been described by Juniper and colleagues (14). The purpose of this pro-
cedure is to reduce a large set of variables and to clarify (absence of) relation-
ships between various parameters without reference to a specific criterion. Fac-
tor analysis does not regroup variables that are highly correlated, but factors are 
created based on calculated estimates of shared variance among variables, with 
the restriction that the factors reflect independent sources of variation. This pro-
cedure allows the user to determine whether associations between parameters are 
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attributable to noise of measurements. In clinical research, factor analysis allows 
the many parameters that characterize the disease to be reduced to a few, rela-
tively independent factors. We applied standard procedures of exploratory factor 
analysis with respect to the number of variables used in the analysis, the selection 
of number of factors, and the factor rotation (32). Additional factor analyses with 
replacement of % neutrophils and % eosinophils by cell counts per ml sputum, 
exclusion of outliers from the data set, and addition of the cumulative amount of 
smoking resulted in similar factor structures as the original analysis. This demon-
strates the robustness of the current findings.
The disease heterogeneity in COPD in terms of lung function and inflammation 
suggests that distinct pathophysiological pathways contribute to COPD. In agree-
ment with this concept, we observed that multiple functional and inflammatory 
characteristics were categorized into four independent dimensions. Interestingly, 
none of the parameters of factors 1 or 2 showed significant additional loadings 
on factors 3 or 4, and vice versa, which strengthens the independence of func-
tional and inflammatory dimensions. One exception to this was K
CO, which loaded 
together with eNO in the additional factor analysis using number of sputum cells 
instead of cell percentages. The value of using factor analysis in mapping disease 
heterogeneity is illustrated by our finding that some of the parameters were found 
to provide complementary information (loading on different factors) despite the 
existence of mutual correlation in univariate analyses.
The first factor can be interpreted as irreversible airflow limitation. The fact that 
diffusing capacity also had modest loading on this factor confirms earlier findings 
that the destruction of lung tissue is associated with increased airflow limitation 
and hyperinflation (37). Alternatively, diffusing capacity could also be a descrip-
tor of the status of altered pulmonary circulation in COPD: another structural 
component of COPD. Hence, restructuring of airways as well as lung tissue seems 
to be an important mechanism resulting in airflow limitation. Interestingly, our 
data suggest that this process is greatly independent of neutrophilic and eosino-
philic inflammation in the larger airways (grouped into factor 4). Neutrophils 
are able to induce tissue damage through the release of serine proteases and 
oxidants. However, this is not a prominent feature of other pulmonary diseases 
where chronic airway neutrophilia is even more prominent, such as cystic fibro-
sis and bronchiectasis (38). This suggests that other factors are involved in the 
generation of emphysema. In addition, increased neutrophil numbers are found 
in the airway lumen, but they are not a prominent feature of the airway wall or 
parenchyma in patients with COPD (7). Furthermore, the presence and role of 
eosinophils in COPD are uncertain (38). The observed increased levels of eosino-
phil cationic protein and eosinophil peroxidase in induced sputum from COPD 
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patients suggest the eosinophils are degranulated (39), which may be the result 
of the high neutrophil elastase levels in COPD (40). Our data supports this close 
relationship between neutrophils and eosinophils in COPD, but apparently, air-
flow limitation requires more than the presence of these granulocytes per se.
Parameters that are known to be associated with asthma predominantly grouped 
into the second factor. This may not be unexpected, since airway hyperrespon-
siveness, partial reversibility of airflow limitation, and increased serum IgE levels 
are not uncommon in COPD (41). An alternative interpretation would be that 
this second factor represents risk factors for progression of COPD, because bron-
chodilator response, airway hyperresponsiveness, and serum IgE levels have been 
associated with lung function decline (42). The finding that number of pack-years 
also loaded on factor 2 strengthens this concept, because smoking is known to 
be the main risk factor for progression of COPD (43). Although factor 2 also 
included KCO, its parallel loading on factor 1 suggests that gas exchange impair-
ment is associated with diverse pathophysiology.
The current separation of airway hyperresponsiveness and FEV1 into different fac-
tors supports epidemiological evidence that these disease characteristics provide 
complementary information on COPD (44), the PC20 in COPD not simply being a 
result of airflow limitation per se. However, the fact that PC20 also had moderate 
loading on the first factor and even highest loading the first factor in some of the 
additional factor analyses on, is in agreement with previous studies that suggest 
that PC20 is to some extent dependent on airway caliber in COPD (45). Although 
it has been reported previously that partial reversibility of airflow limitation is 
associated with sputum eosinophilia and elevated eNO in COPD (34), our fac-
tor analysis suggests that these features are largely independent. This confirms 
a previous factor analysis in asthma (13) and again may challenge the concept 
that eosinophilic airways inflammation is closely related to the “twitchiness” of 
the airways. Interestingly, we found that number of pack-years also loaded on 
the second factor with IgE and C2-response, and not with airflow limitation or 
sputum neutrophils. A significant relationship between total IgE and the degree of 
tobacco smoking has been reported previously (46), suggesting that the increase 
in IgE may be partly due to tobacco smoking. Although, in this study, univariate 
analysis revealed significant correlations between eNO and FEV1, FEV1/IVC, and 
PC20, eNO was extracted into a factor independent from functional parameters 
as well as sputum cell counts. This indicates that this exhaled marker might be a 
rather autonomic phenomenon and bodes ill for the use of eNO in monitoring of 
disease activity.
In conclusion, this analysis has categorized multiple disease features of COPD 
without a priori assumptions on their interrelationships. Our data suggest that 
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airflow limitation, asthma-like components, eNO and sputum inflammatory cell 
counts offer separate and additive information about the pathophysiological con-
dition of COPD patients. This confirms the complex heterogeneity of the disease 
and may change some of the current concepts on the distinct pathophysiologi-
cal pathways involved. Accordingly, it needs to be examined whether the clinical 
evaluation of patients with COPD should include each of these complementary 
entities.
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Abstract
Background: The single-breath N2 test (sbN2-test) is closely related to small air-
ways pathology in resected lung specimens of smokers. We investigated whether 
uneven ventilation and airway closure are associated with specific markers of 
airway inflammation as obtained by bronchial biopsies, bronchoalveolar lavage 
(BAL), and induced sputum in patients with manifest chronic obstructive pulmo-
nary disease (COPD).
Methods: Fifty-one patients with stable COPD not receiving corticosteroids were 
examined in a cross-sectional study (43 men; mean [SD] age, 63 ? 8 years; ex-
smokers and smokers; median pack-years, 41 [interquartile range, 31 to 51 pack-
years]). Postbronchodilator spirometry (FEV1, 63 ? 8% of predicted) and sbN2-
test (slope of phase III [%N2], closing capacity [CC]/total lung capacity [TLC] % of 
predicted) were performed. Inflammatory cell counts were assessed in bronchial 
biopsies, BAL (only in the first half of patients), and induced sputum. Neutrophil 
elastase (NE), secretory leukocyte proteinase inhibitor (SLPI), and interleukin-8 
levels were determined in BAL fluid.
Results: %N2 increased with subepithelial neutrophil numbers in bronchial biopsies 
(rs=0.337, p=0.017), and with NE levels (rs=0.443, p=0.039), NE/neutrophil ratio 
(rs=0.575, p=0.005), and SLPI levels (rs=0.484, p=0.022) in BAL. CC/TLC was 
associated with BAL neutrophil numbers (rs=0.448, p=0.048). The sbN2-test was 
not associated with any other inflammatory cell type in BAL or biopsies, nor with 
inflammatory cell counts in sputum. Of importance, the correlations between %N2 
and BAL NE/neutrophil ratio, and between CC/TLC and BAL neutrophil numbers, 
remained significant when adjusting for FEV1 % of predicted.
Conclusions: The results of the sbN2-test are associated with neutrophilic inflam-
mation in bronchial biopsies and BAL in patients with COPD. Our findings sup-
port a role of neutrophilic inflammation in the pathogenesis of small airways dys-
function in COPD.
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Introduction
COPD is characterized by progressive airflow limitation that is not fully reversible 
(1). The pathological substrate of airflow limitation is predominantly located in 
the small airways and lung parenchyma (2). The bronchi and bronchioli exhibit 
accumulation of inflammatory cells, mucus and plasma exudates, which are 
accompanied with fibrosis and proliferation of smooth-muscle cells, resulting in 
airway wall thickening. Together with destruction of lung parenchyma, these mul-
tiple features are implicated in the development of irreversible narrowing of the 
airways (2;3).
 The pathological changes in the periphery of the lung are reflected by func-
tional impairment as measured by physiological tests (4). Amongst these so-
called “small airways tests”, the single-breath N2 test (sbN2-test) has been used 
to evaluate the presence of uneven distribution of ventilation (slope of nitrogen 
alveolar plateau; phase III) and airway closure (phase IV) (5). Phase III and phase 
IV reflect differences in time constants, which are dependent on both local resis-
tances (small airways disease) and local compliances (emphysema) (6). The sbN2-
test is not specific for the periphery of the lung, but it has been validated against 
small airways pathology scores (7). Because of this landmark study, the sbN2-test 
is still one of the few physiological measures that have been anchored to small 
airways pathology in smokers. Furthermore, the combination of spirometry and 
the sbN2-test has been suggested to be predictive of the annual decline of FEV1 in 
smokers (8). Therefore, the sbN2-test might be a complementary noninvasive tool 
to monitor pathology in the periphery of the lungs in patients with COPD.
 The airway inflammation in COPD is characterized by influx of neutrophils and 
macrophages in the airway lumen (9-11), as well as elevated macrophage(12;13) 
and T-lymphocyte and B-lymphocyte (3;12;14;15) numbers in the airway wall. In 
addition, both interleukin (IL)-8 and neutrophil elastase (NE) are elevated in BAL 
fluid of smokers who acquire COPD (16;17). IL-8 is a main mediator of neutrophil 
chemotaxis in the airways, and NE is a neutrophil-derived serine proteinase that is 
able to cause structural changes in the lung, impairment of mucociliary clearance 
and host defense, and induction of mucus secretion (18). Secretory leukocyte 
proteinase inhibitor (SLPI) is a locally produced inhibitor of NE, and it has been 
suggested that SLPI plays a role in maintaining the protease-antiprotease balance 
in the lung, regulation of leukocyte function, host defense against infection, tissue 
repair, and matrix production (19).
 Previous studies investigating the sbN2-test in smokers in relation to small air-
ways disease have examined pathology scores, including scores of the degree of 
inflammatory cell infiltration in resected lung tissue (7;20-22) or autopsy (23;24) 
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material without further characterization of the inflammatory profile because of 
lack of specific stainings at that time. In addition, measuring inflammation with 
less invasive tools, such as induced sputum and bronchoscopy with BAL and biop-
sies, has not been examined in relation to the sbN2-test in patients with COPD. 
Therefore, we postulated that small airways function in patients with COPD, as 
reflected by the sbN2-test, is associated with the inflammatory profile character-
istic for COPD. To that end, we investigated the number of inflammatory cells in 
bronchial biopsies, BAL fluid, and induced sputum, together with the levels of NE, 
IL-8, and SLPI in BAL fluid in a cross-sectional study in 51 patients with COPD.
Materials and methods
Subjects
Fifty-one patients with COPD, participating in the Groningen Leiden Universities 
and Corticosteroids in Obstructive Lung Disease (GLUCOLD) study were included 
in this study. The sbN2-test was performed in the Leiden center only. Patient char-
acteristics and methods have been described in detail previously (25;26). In short, 
all patients had irreversible airflow limitation (postbronchodilator FEV1 and FEV1/
inspiratory vital capacity [IVC] < 90% confidence interval [CI] of predicted value 
[comparable with Global Initiative for Chronic Obstructive Lung Disease (GOLD) 
stages II and III], FEV1 ? 1.3 L and > 20% of predicted value) and respiratory symp-
toms. Patients with a history of asthma, α1-antitrypsin deficiency, other active lung 
disease, or receiving maintenance treatment with inhaled or oral steroids during 
the last 6 months were excluded from the study. They were allowed to use short-
acting bronchodilators and were in clinical stable condition (no symptoms of 
respiratory tract infection for at least 2 weeks prior to the study, no course of oral 
or inhaled steroids during the last 3 months). Patients were (ex-) smokers, with 
at least 10 pack-years of smoking. The medical ethics committees of each center 
approved the study and all patients gave written informed consent.
Design and sbN2-test
The study had a cross-sectional design including four visits. The sbN2-test was per-
formed 15 min after administration of 400 Ng salbutamol per metered-dose inhaler 
connected to a spacer, in order to minimize contribution of smooth-muscle contrac-
tion. The measurement was performed using a dry rolling-seal spirometer (Spiro-
flow; Morgan; Kent, UK) filled with 100 % oxygen and equipped with a N2 meter 
(Morgan) connected to the mouthpiece allowing continuous sampling as described 
previously (5;27;28). During this test, seated patients performed a slow full inspira-
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tory and expiratory slow vital capacity (VC) maneuver at inspiratory and expiratory 
flow rates of approximately 0.5 L/s, which was controlled by a flow restrictor. The 
expiratory N2 concentration was plotted against volume changes between total lung 
capacity (TLC) and residual volume (RV), and the slope of the nitrogen alveolar pla-
teau (slope of phase III [%N2]) was calculated by drawing the best-fit line through 
phase III of the expiratory volume concentration curve by a blinded observer (29). 
The first departure from this straight line was considered as indicative of airway 
closure, and closing volume (CV) [phase IV] and closing capacity (CC) [RV+CV] 
were calculated (5). This procedure has previously been validated in our laboratory 
(27;29), and the within-observer and between observer reproducibility (determined 
by calculation of the intraclass correlation coefficient, Ri) of determining %N2 (Ri = 
0.940, Ri = 0.995, respectively) and CV (Ri = 0.929, Ri = 0.935, respectively) were 
high. Two measurements were performed, of which the one with the highest VC was 
selected for further analysis. The measurements were only accepted if the IVC and 
expiratory VC during the sbN2-test did not differ > 15% or 0.5 L from each other. 
All volumes from the sbN2-test were corrected for body temperature and pressure, 
saturated with water vapor (BTPS), and the parameters derived from the sbN2-test 
(%N2, CV, CC) were expressed as percentage of predicted value (5;30).
Lung function and sputum induction
Postbronchodilator spirometry, reversibility to 400 Ng salbutamol, bodyplethys-
mography, diffusing capacity, and sputum induction (full-sample method) were 
performed according to previously described methods (25).
Bronchoscopy and biopsy analysis
Fiberoptic bronchoscopy was performed using a previously described standardized 
protocol (26) according to recent recommendations (31). Biopsy processing, stain-
ing, and analysis have also been described in detail previously (26). In short, 4-Nm 
thick paraffin-embedded sections were stained using specific antibodies against 
T-lymphocytes (CD3, CD4, CD8), macrophages (CD68), neutrophil elastase (NE), 
mast cell tryptase (AA1), eosinophils (EG2), and plasma cells (CD138). Digital 
images per coded biopsy section were prepared, and fully automated inflamma-
tory cell counting procedures were performed according to previously described vali-
dated methods (32). The number of subepithelial positively staining inflammatory 
cells was counted within the largest possible area, of maximal 125-Nm deep beneath 
the basement membrane, per biopsy section, and expressed as the mean number of 
cells per 0.1 mm2 of two tissue samples per patient.
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Bronchoalveolar lavage
We also performed BAL before biopsy samples were obtained. Because of ethical 
considerations, the BAL procedure was stopped during the course of the study 
because four patients had a serious adverse event that was considered to be pos-
sibly related to the BAL (pleural pain, fever, pneumonia, short-term cardiac isch-
emia). BAL was performed and processed according to previously described rec-
ommendations (33;34). First, 50 mL of NaCl 0.9% at 30ºC was instilled, which 
was retrieved after 10 s of dwelling with gentile suction at ≤ 20 cm H2O pressure. 
This portion was not used for analysis. Thereafter, three times 50 mL of saline 
solution was instilled with dwelling times of 10 s. BAL processing and differential 
cell counts were performed analogous to the methods described for sputum pro-
cessing (25), with the major exception that no dithiothreitol (DTT, Sputolysin) 
was used for homogenization. In addition, if required, lysis of red blood cells was 
performed before processing. A BAL sample was considered adequate when the 
amount of fluid instilled was at least 100 mL, and recovered BAL fluid was at 
least 10 mL (excluding the first portion). The levels of soluble NE, SLPI, and IL-8 
were determined in BAL using enzyme-linked immunosorbent assay (IL-8; CLB; 
Amsterdam, The Netherlands; NE and SLPI enzyme-linked immunosorbent assays 
developed in our laboratory) (35;36). For IL-8 measurements, BAL supernatant 
was first concentrated using filters (Centricon-3; Millipore; Bedford, MA) (17).
Statistical analysis
Mean values and SD were computed. When appropriate, variables were loga-
rithmically transformed before statistical analysis and presented as median with 
interquartile range (IQR). Univariate correlations between postbronchodilator 
sbN
2-test parameters (% predicted) (5;30) and inflammatory parameters were 
evaluated using Spearman rank correlation coefficient (rs). Multivariate linear 
regression analysis was used to adjust for FEV1 to evaluate whether contribution 
of inflammation to small airways function was independent of the degree of air-
flow limitation. Statistical significance was assumed at p< 0.05.
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Results
Patient characteristics
Table 1 shows the characteristics of the 51 patients who performed the sbN2-test 
after bronchodilation. The patients had moderate-to-severe COPD (GOLD stages 
II and III) based on a postbronchodilator FEV1 of 63.3 ? 8.4% of predicted, and 
had a median smoking history of 41 pack-years (IQR, 31 to 51 pack-years). They 
demonstrated elevated values of %N2 and early airway closure (Table 1). In two 
patients, we were unable to determine a CV. Induced sputum and BAL cell counts 
are presented in Table 2, and bronchial inflammatory cell numbers are shown in 
Table 3. BAL was performed only in the first half of patients (n=22).
Table 1. Patient Characteristics (n=51).
General characteristics
   Male/female gender, No. 43/8
   Age, yr 62.7 (8.1)
   Smoking history, pack-yr 41 (31-51)
   Current/not current smoker, No. 30/21
Lung Function
   Postbronchodilator FEV1, % predicted 63.3 (8.4)
   Postbronchodilator FEV1/IVC, % 48.5 (8.5)
   %FEV1, % predicted 7.4 (5.7)
   KCO, % predicted 73.5 (23.7)
   RV/TLC, % 48.2 (9.2)
Postbronchodilator sbN2-test
   %N2, % N2/L) 4.3 (2.9-6.6)
   CV, L 1.1 (0.45)
   CV/VC, % 25.6 (9.2)
   CC/TLC, % 62.5 (9.7)
   %N2, % predicted 314 (220-447)
   CV/VC, % predicted 114 (40.3)
   CC/TLC, % predicted 135 (19.7)
Data represent mean (SD) or median (IQR: 25th - 75th percentile). FEV1= Forced expiratory volume in one 
second, IVC= Inspiratory vital capacity, %FEV1= Reversibility to salbutamol (change in FEV1 as percentage of 
predicted), KCO= Diffusing capacity for carbon monoxide per liter alveolar volume, RV= Residual volume, TLC= 
Total lung capacity, %N2= slope of phase III, CV= Closing Volume, VC= Vital Capacity, CC= Closing Capacity. 
% Predicted values calculated according Buist et al.(5;30)
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Relation between small airways function and airway inflammation
Small airway parameters as assessed with the sbN2-test were predominantly associ-
ated with neutrophilic inflammation in BAL (Figure 1). Postbronchodilator %N2 % 
of predicted increased with NE levels (median, 20.7 ng/mL; IQR 7.5 to 36.4 ng/
mL], NE/neutrophil number ratio, and SLPI levels (median, 110 ng/mL; IQR 41.5 
to 258 ng/mL) in BAL (rs=0.443, p=0.039; rs=0.575, p=0.005; rs=0.484, p=0.022; 
respectively; Figure 1). However, %N2 % of predicted was not related with IL-8 
levels (median 64.5 pg/mL; IQR 28.4 to 192 pg/mL) or other inflammatory cell 
counts in BAL. Furthermore, postbronchodilator CC/TLC % of predicted was also 
associated with BAL neutrophil numbers (rs=0.448, p=0.048; Figure 1). Post-
bronchodilator CV/VC % of predicted was not related with any of the BAL inflam-
matory markers. Postbronchodilator FEV1 % of predicted was inversely associ-
Table 2. Cell counts in induced sputum and BAL.
Sputum BAL
No. 50 22
Volume recovered, mL – 64.1 (26.8)
Recovery, % – 44.2 (16.5)
Epithelial cells, % 1.3 (0.3-3.1) 1.9 (0.8-7.9)
Neutrophils, % 68.9 (15.1) 3.5 (1.8-6.7)
Macrophages, % 23.7 (18.2-31.2) 89.5 (76.1-94.8)
Eosinophils, % 1.0 (0.2-1.8) 0.2 (0-0.6)
Lymphocytes, % 1.9 (1.3-2.6) 2.6 (1.0-5.3)
Total cell counts, x 104/mL 182 (101-333) 30.9 (13.7-66.4)
Data represent mean (SD) or median (IQR: 25th - 75th percentile). BAL= Bronchoalveolar Lavage.
Table 3. Bronchial inflammatory cell counts (n=50).
CD3 141 (59-204)
CD4 51 (29-79)
CD8 19 (8.0-32)
NE (neutrophils) 4.0 (1.9-8.5)
CD68 (macrophages) 8.5 (5.4-12)
EG2 (eosinophils) 2.0 (1.0-6.3)
AA1 (mast cells) 26 (21-34)
CD138 (plasma cells) 8.5 (3.5-12)
Data are presented as median cell number / 0.1 mm2 (IQR: 25th - 75th percentile).
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Figure 1. Correlation between small airways dysfunction and inflammatory markers in BAL.
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Figure 2. Correlation between small airways dysfunction and bronchial inflammation.
Correlations between postbronchodilator %N2 % of predicted and NE levels in BAL (rs=0.443, p=0.039) 
[top left], NE/neutrophil ratio in BAL (rs=0.575, p=0.005) [top right], and SLPI in BAL (rs=0.484, p=0.022) 
[bottom left]. Correlation between postbronchodilator CC/TLC % of predicted and neutrophil numbers in 
BAL (rs=0.448, p=0.048) [Bottom right]. 
Correlation between postbronchodilator %N2 % of predicted and neutrophil numbers in the lamina propria 
of bronchial biopsies, presented as the number of cells / 0.1 mm2 tissue examined (rs =0.337, p=0.017)
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ated with %N2 (R=-0.522, p<0.001). Interestingly, the correlations between %N2 
and BAL NE/neutrophil ratio, and between CC/TLC and BAL neutrophil numbers 
remained significant when adjusting for FEV1 % of predicted (p=0.008, p=0.041; 
respectively).
 Bronchial biopsies showed associations with sbN2-test that were largely consis-
tent with those found in BAL. Again, postbronchodilator %N2 % of predicted was 
positively associated with subepithelial neutrophil numbers in bronchial biopsies 
(rs =0.337, p=0.017; Figure 2), but not with other bronchial inflammatory cell 
counts. Significance of this latter correlation was lost when adjusting for FEV1 % 
of predicted. The sbN2-test was not significantly correlated with inflammatory cell 
counts in induced sputum.
Discussion
This study shows that %N2 (nitrogen alveolar plateau) is associated with NE, NE/
neutrophil ratio, and SLPI levels in BAL, as well as with neutrophil numbers in 
bronchial biopsies in COPD. In addition, closing capacity appeared to be associ-
ated with neutrophil numbers in BAL. These relations were independent of the 
degree of airflow limitation. Our results indicate that uneven ventilation and air-
way closure in COPD indirectly reflect neutrophilic inflammation in the wall of 
large airways as well as in the lumen of peripheral airways and alveoli as mirrored 
by BAL.
 To our knowledge, this is the first study in patients with COPD examining the 
relation between the sbN2-test and airway inflammation in bronchial biopsies, 
BAL, and induced sputum. Multiple studies have focused on the relation between 
indexes of the sbN2-test and small airways pathology, including inflammation 
scores, in resected lung tissue (7;20-22) or autopsy material (23;24). However, 
the type of inflammatory cells was not specified in these pathology studies. It has 
been demonstrated that peripheral airways dysfunction in COPD, as determined 
by quantitative high-resolution CT, is associated with sputum neutrophilia (37). 
Our results extend these previous results by showing that neutrophilic inflam-
mation in the airway wall of large airways, as well as in the lumen of peripheral 
airways and alveoli as reflected by BAL, correlates with uneven ventilation and 
airway closure as revealed by a relatively simple single-breath test in patients with 
COPD.
 There are a few considerations when interpreting our results. First, the patients 
represented COPD patients of GOLD stages II and III (1). Because of ethical con-
siderations, the BAL procedure was discontinued (ie, a few patients reported side 
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effects in relation to the BAL), and therefore BAL was performed only in the first 
half of patients. Since this was not anticipated, it is unlikely that this has intro-
duced selection bias for the BAL-results. Second, we used % of predicted values 
and post-bronchodilator sbN2-tests for exploration of relations with inflamma-
tory markers in order to prevent possible variability by age, sex, and smooth-mus-
cle tone. Finally, we chose to use the sbN2-test to evaluate the presence of uneven 
distribution of ventilation (∆N2, phase III) and airway closure (phase IV). Phase III 
and phase IV reflect differences in time-constants, which are dependent on both 
local resistances (small airways disease) and local compliances (emphysema) (6). 
It is known that besides small airways, other factors contribute to the outcomes 
of the sbN2-test test, such as topographical distribution of ventilation (38;39). In 
addition, there is evidence that multiple breath washout curves can distinguish 
uneven ventilation in the conducting small airways from the acinar lung zones 
(40). However, the latter technique still lacks external validation by relating it to 
small airways pathology. Therefore, we gave preference to the sbN2-test based 
on its well-described relationship with small airways pathology in resected lung 
tissue (7).
 How can the present results be interpreted? The association of the sbN2-test 
with neutrophil numbers in BAL and bronchial biopsies, and with NE and NE/
neutrophil ratio supports a role for airway neutrophil accumulation and activation 
in the pathogenesis of small airways and/or alveolar dysfunction in COPD. Neu-
trophils migrate into the lung in response to the presence or release of chemoat-
tractants, such as IL-8. It is therefore tempting to speculate that accumulation of 
neutrophils in the airway wall of small airways also contributes to small airways 
dysfunction in COPD. However, we have recently demonstrated that the number 
of neutrophils in the lamina propria of the small airway is larger than in the lamina 
propria of the large airways in smokers (41). This suggests that the distribution of 
neutrophils along the tracheobronchial tree may not be uniform. This should be 
addressed in studies directly examining peripheral lung tissue.
 The recruited neutrophils in the airways can release NE, which is able to cause 
tissue destruction, but also plays a role in mucus hypersecretion (18). Conse-
quently, NE may contribute to loss of alveolar attachments and/or mucus hyper-
secretion, which both may lead to small airways narrowing and accordingly to 
inhomogeneous distribution of ventilation and early airway closure in patients 
with COPD (3;42). It has been shown previously in our laboratory that numbers 
of SLPI-containing epithelial cells increase with more severe small airways dis-
ease and destruction of alveolar attachments (43), which may possibly be part 
of the defense against inflammatory and destructive processes in small airways. 
This may explain the observed association between small airways function and 
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SLPI levels in BAL in the present study. Furthermore, the lack of an association 
between small airways function and inflammatory cells in induced sputum may 
not be unexpected because induced sputum is likely to represent a different com-
partment than BAL and bronchial biopsies in COPD(44), presumed to originate 
from large airways (45). Finally, lymphocytes, especially CD8+ T-cells, have been 
implicated to play a role in the pathogenesis of COPD. In the present study, we did 
not observe a relation between these cells and the sbN2-test. This may be due to 
non-uniform distribution of inflammatory cells along the tracheobronchial tree, 
even though CD8+ cell numbers do not appear to be different between large and 
small airways in smokers (41).
 What is the clinical relevance of our results? It appears from our results that the 
sbN2-test is a non-invasive tool, complementary to spirometry, which is associ-
ated with neutrophilic airway inflammation in COPD. It has been observed that 
the sbN2-test contributes to prediction of the decline in FEV1 in patients with 
established airflow limitation (8). Therefore, we may speculate that neutrophilic 
inflammation is involved in progression of COPD by contributing to small airways 
and/or alveolar pathology. Consequently, monitoring the sbN2-test might add to 
the management of patients with COPD.
 In conclusion, uneven ventilation and airway closure in patients with stable 
COPD are associated with neutrophil numbers in bronchial biopsies and BAL, 
and with NE and its local inhibitor SLPI in BAL. These findings suggest a role for 
neutrophilic inflammation in small airways dysfunction in COPD.
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Abstract
Background: Chronic obstructive pulmonary disease (COPD) is associated with 
airway inflammation. Although smoking cessation improves symptoms and 
decline in lung function in COPD, it is unknown whether bronchial inflammation 
in patients with established COPD varies with the duration of smoking cessa-
tion.
Methods: 114 patients (99 men) with COPD of mean (SD) age 62 (8) years, a 
median (IQR) smoking history of 42 (31-55) pack-years, no inhaled or oral cor-
ticosteroids, all current or ex-smokers (n=42, quit >1 month, median cessation 
duration 3.5 years), postbronchodilator FEV1 63 (9)% predicted, and FEV1/IVC 
48 (9)% were studied cross sectionally. The number of subepithelial T-lympho-
cytes (CD3, CD4, CD8), neutrophils, macrophages, eosinophils, mast cells, and 
plasma cells were measured in bronchial biopsy specimens [median (IQR) /0.1 
mm2] using fully automated image analysis.
Results: Ex-smokers with COPD had higher CD3+, CD4+, and plasma cell num-
bers than current smokers with COPD [149 (88-225) v 108 (61-164), p=0.036; 
58 (32-90) v 40 (25-66), p=0.023; 9.0 (5.5-20) v 7.5 (3.1-14), p=0.044, respec-
tively], but no difference in other inflammatory cells. Short-term ex-smokers (<3.5 
years) had higher CD4+ and CD8+ cell numbers than current smokers (p=0.017, 
p=0.023; respectively). Conversely, long-term ex-smokers (quit ?3.5 years) had 
lower CD8+ cell numbers than short-term ex-smokers (p=0.009), lower CD8/CD3 
ratios than both current smokers and short-term ex-smokers (p=0.012, p=0.003; 
respectively), and higher plasma cell numbers than current smokers (p=0.003).
Conclusions: With longer duration of smoking cessation, CD8 cell numbers 
decrease and plasma cell numbers increase. This indicates that bronchial T-lym-
phocyte and plasma cell counts, but not other inflammatory cells, are related to 
duration of smoking cessation in patients with COPD.
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Introduction
Chronic obstructive pulmonary disease (COPD) is characterised by progressive 
airflow limitation and abnormal inflammatory responses in the airways (1). Per-
sistent smoking-induced inflammation is thought to play an important role in the 
pathogenesis of COPD. It is characterised by influx of neutrophils into the airway 
lumen and increased macrophage and T-lymphocyte numbers in the airway wall 
(2;3). In particular, bronchial CD8+ T-lymphocytes appear to be associated with the 
severity of the disease (3;4). Moreover, sputum CD8+ cells of patients with COPD 
have increased cytotoxic activity (5) which may contribute to the tissue damage 
which occurs in these patients. It has recently been shown that B cell numbers in the 
small airways of patients with COPD are also increased (3). Plasma cells (terminally 
differentiated effector B cells) are the cellular source of mucosal immunoglobulin 
production and consequently play a central role in host defence against infection. 
However, there are limited data on their role in COPD, and their presence in the 
lung has not been investigated in relation to smoking status.
Smoking cessation is the only intervention able to reduce the progression of COPD 
(6). Moreover, patients who quit smoking experience less respiratory symptoms 
and hyperresponsiveness as compared to those who continue smoking (7;8). The 
largest improvements in lung function and symptoms occur within the first year 
after cessation. It is not yet clear whether these beneficial effects are accompanied 
by reversal of smoking induced pathology.
At present there is insufficient evidence that smoking cessation reduces inflam-
mation in COPD. Few cross sectional studies have compared smokers and ex-
smokers with regard to bronchial inflammation in heterogeneous and relatively 
small groups of patients without an established diagnosis of COPD (9). Most 
previous studies have been performed in patients with chronic bronchitis (10;11). 
In patients with symptoms of chronic cough and expectoration, ex-smokers tend 
to have lower mast cell numbers in the lamina propria than current smokers (10), 
whereas the number of neutrophils, macrophages, eosinophils, and lymphocytes 
in bronchial biopsies have been reported to be similar (11). Most studies did not 
take duration of smoking cessation into account when comparing current and 
ex-smokers. However, it has been shown that this may influence the inflammatory 
response in small airways (12). The available studies may not be representative 
of COPD since relatively low numbers of patients with airflow limitation were 
included. It therefore remains to be investigated whether bronchial inflamma-
tion varies with current smoking status and the duration of smoking cessation in 
patients with an established diagnosis of COPD.
In the current study we postulated that bronchial inflammation in patients with 
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established COPD differs between active smokers and patients who stopped 
smoking, and that this difference is influenced by the duration of smoking ces-
sation. We therefore investigated the number of inflammatory cells (neutrophils, 
macrophages, eosinophils, mast cells, T-lymphocytes, plasma cells, and granzyme 
B+ cells as a marker of activated cytotoxic cells) in bronchial biopsy specimens 
from current and ex-smokers with COPD in a large cross sectional study.
Methods
Subjects
One hundred and fourteen patients with COPD participating in the Groningen 
Leiden Universities and Corticosteroids in Obstructive Lung Disease (GLUCOLD) 
study were included in the study. Patient characteristics and methods have been 
described in detail previously (13). In short, all patients had irreversible airflow 
limitation compatible with GOLD stages II and III (postbronchodilator FEV1 
and FEV1/IVC <90% confidence interval [CI] of the predicted value, FEV1 ?1.3 l 
and >20% predicted) and at least one of the following symptoms: chronic cough, 
chronic sputum production, or dyspnea on exertion. Patients with a history of 
asthma, B1-antitrypsin deficiency, or other active lung disease were not included in 
the study. Study subjects had not taken a course of oral steroids during the previ-
ous 3 months and had not received maintenance treatment with inhaled or oral 
steroids during the previous 6 months. Patients were allowed to use short acting 
bronchodilators and were in a stable clinical condition. They were current or ex-
smokers (quit smoking for at least 1 month) with a smoking history of at least 
10 pack-years. A validated questionnaire was used to assess the smoking history 
(14). Those who had quit were asked at what age they stopped in order to calcu-
late the duration of smoking cessation (years). The medical ethics committees of 
the Leiden University Medical Center and the Groningen University Medical Cen-
ter approved the study, and all patients gave their written informed consent.
Study design and lung function
The study had a cross sectional design and consisted of four visits. Spirometry, 
reversibility to salbutamol, and carbon monoxide transfer coefficient were mea-
sured according to previously described methods in order to characterise the 
patients (13).
Bronchoscopy
Fiberoptic bronchoscopy was performed using a standardised protocol according 
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to recent recommendations (15). Smokers were requested to refrain from smoking 
on the day of the bronchoscopy. Patients were premedicated with 400 Ng salbuta-
mol p.i., 20 mg codeine p.o., and 0.5 mg atropine s.c., and local anesthesia with lido-
caine (?3 mg/kg). During the procedure 100% oxygen was delivered through a nasal 
canula (2 L/min) if required while transcutaneous oxygen was monitored continu-
ously by oximeter with a finger probe. Bronchoscopic examinations were performed 
by experienced pulmonary physicians using a fiberoptic bronchoscope (18X, outer 
diameter 6 mm, Pentax Optical Co., Japan) and pairs of cup forceps (Reda, Tut-
tlingen, Germany). Six macroscopically adequate bronchial biopsy specimens were 
randomly taken from (sub) segmental carinae in the right or left lower lobe (left and 
right lungs were alternated per patient, all biopsies from one lung).
Biopsy processing and staining
Four biopsy specimens were immediately fixed in 4% neutral buffered formalin for 24 
hours, then processed and embedded in paraffin, and two were immediately snap 
frozen and stored at –80?C. Paraffin embedded biopsies were cut in 4 Nm thick sec-
tions and haematoxylin/eosin staining was used for evaluation and selection of the 
two morphological best biopsies per patient for analysis (without crushing artifacts, 
large blood clots, or only epithelial scrapings). If required, immunohistochemistry 
included antigen retrieval. Specific antibodies against T-lymphocytes (CD3, CD4, 
CD8), macrophages (CD68), neutrophil elastase (NE), mast cell tryptase (AA1), 
eosinophils (EG2), plasma cells (CD138), and granzyme B were used (Table 1). 
Besides staining the plasma cells, CD138 (syndecan-1) antibody also stains the 
Table 1. Antibodies used for immunohistochemistry.
Antibody Pretreatment Species Dilution Clone Origin*
CD3 (lymphocyte) Citrate Rabbit 1:500 Polyclonal DAKO
CD4 (T helper) Citrate Mouse 1:300 CD4-368 Novocastra
CD8 (T cytotoxic) Citrate Mouse 1:50 CD8-144B DAKO
Neutrophil elastase 
(neutrophil)
Protease Mouse 1:3200 NP57 DAKO
CD68 (macrophage) Citrate Mouse 1:3000 KP1 DAKO
Tryptase (mast cell) Citrate Mouse 1:16000 AA1 DAKO
EG2 (eosinophil) Trypsin Mouse 1:150 EG-2 Pharmacia
CD138 (plasma cell) EDTA Mouse 1:6400 B-B4 IQ products
Granzyme B Citrate Mouse 1:200 CLB-GB7 CLB/Sanquin
* Dako, Glostrup, Denmark; Novocastra, Newcastle upon Tyne, UK; Pharmacia Diagnostics, Uppsala, 
  Sweden; IQ products, Groningen, The Netherlands; CLB/Sanquin, Amsterdam, The Netherlands
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bronchial epithelium and submucosal glands (16), but these structures were not 
present in the areas of subepithelial cell quantification. All stainings except for CD3 
and CD4 were performed using an automatic staining machine (Dako) in two ses-
sions, with one section per patient in each session. In short, the sections were incu-
bated with an optimal dilution of the primary antibodies in 1% BSA/PBS at room 
temperature for 60 min. As a secondary antibody, the horseradish peroxidase con-
jugated anti-mouse or anti-rabbit EnVision system (DAKO, Glostrup, Denmark) was 
used, with NovaRED (Vector, Burlingame, CA) as the chromagen. The sections were 
counterstained with Mayer’s haematoxylin (Klinipath, Duiven, the Netherlands). For 
negative controls, the first antibody was omitted from this procedure.
Analysis of bronchial biopsies
Multiple digital images per coded biopsy section were prepared using a colour camera 
(Basler A101fc-le) and a dedicated software program (RVC-software, Amersfoort, 
The Netherlands). These images were united into one large image that consisted of 
the entire biopsy section (100 Nm = 115.7 pixels). Fully automated inflammatory 
cell counting procedures were performed according to previously described vali-
dated methods (17). The number of subepithelial positively staining inflammatory 
cells was counted within the largest possible area of maximal 125 Nm deep beneath 
the basement membrane, per biopsy section, and expressed as the mean number of 
cells/0.1 mm2 of the two biopsies. Because of very low numbers of granzyme B+ cells, 
these were analysed using a semi-quantitative score of the entire biopsy section: 
0 (absent staining), 1 (1-10 positive cells), or 2 (> 10 positive cells).
Statistical analysis
Mean values and standard deviations (SD) were computed for normally dis-
tributed variables. Cell counts and other variables that did not show a normal 
distribution were logarithmically transformed (square root in case of CD8/CD3 
ratio) before statistical analysis and presented as medians with interquartile range 
(IQR). Normally distributed log transformed cell counts were analysed using 
parametric tests. EG2 data remained skewed after log transformation and were 
therefore analysed using non-parametric tests. Differences between smokers and 
ex-smokers were explored using D2-square tests, two tailed unpaired t tests, or 
Mann-Whitney tests. To study the influence of duration of smoking cessation on 
cell counts, we compared smokers with ex-smokers who quit <3.5 years and those 
who quit ?3.5 years ago, since this was the median duration of smoking cessation, 
using one way ANOVA (Kruskal-Wallis tests in case of EG2). If these were statisti-
cally significant, two tailed unpaired t tests were applied for further exploration 
of between group differences. Multivariate linear regression analysis was applied 
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to adjust for significant differences in patient characteristics between the groups 
such as sex, age, pack-years, and FEV1/IVC. Univariate correlations were evalu-
ated using Spearman and Pearson’s correlation coefficient. SPSS 12.0 (SPSS Inc., 
Chicago, IL, USA) was used for statistical analysis.
Results
Patient characteristics
Table 2 shows the characteristics of the 72 smoking and 42 ex-smoking patients 
included in the study. Patients had moderate to severe COPD, based on a post-
bronchodilator FEV1 of 63.0 (8.8)% predicted, and a median smoking history of 
42 pack-years. Median (IQR) duration of smoking cessation in ex-smokers was 
3.5 (1-10) years. The differences in patient characteristics between current and 
ex-smokers, and between current smokers, short-term ex-smokers (quit <3.5 
years ago), and long-term ex-smokers (quit ?3.5 years) are shown in Table 2.
Table 2. Characteristics of current smokers and ex-smokers groups with COPD.
Current 
smokers
Ex-smokers
(combined group)
Ex-smokers
(quit ?3.5 years)
Ex-smokers
(quit ??3.5 years)
General
Sex (M/F, n) 59 / 13 40 / 2 * 20 / 1 20 / 1
Age (years) 60 (8) 64 ? 7 * 61 (8) 67 (4) *†
Pack-years (years) 43 (32-56) 37 (28-53) 45 (29-65) 35 (26-41) *
Duration of smoking 
cessation (years)
– 3.5 (1-10) 1.0 (1.0-2.0) 10 (6.5-14.5)
Smoking duration 
(years)
44 (8) 41 (10) 43 (11) 39 (8)
Chronic bronchitis (%) 55.6 31.0 * 23.8 * 38.1
Lung Function
Post-bronchodilator 
FEV1 (% pred)
63.3 (8.3) 62.5 (9.6) 62.6 (10) 62.5 (9.4)
Post-bronchodilator 
FEV1/IVC (%)
49.5 (8.5) 46.0 (8.3) * 45.3 (8.6) * 46.7 (8.1)
%FEV1 (% pred) 6.9 (5.2) 6.8 (4.5) 6.9 (3.9) 6.8 (5.1)
KCO (% pred) 73.3 (25.1) 80.4 (25.9) 75.3 (24.9) 85.7 (26.5) *
Data are presented as mean (SD) or median (IQR: 25-75th percentile). Ex-smokers are divided in two groups 
based on median duration of smoking cessation (3.5 years). FEV1 = Forced expiratory volume in one second, 
IVC = Inspiratory vital capacity, %FEV1 = Reversibility to salbutamol (change in FEV1 as % of predicted), KCO= 
Carbon monoxide transfer coefficient.
* p<0.05 compared with COPD current smokers (D2 tests for sex differences, two tailed unpaired t tests 
for other [log-transformed] data]. † p<0.05 compared with COPD ex-smokers who quit <3.5 years (two 
tailed unpaired t tests).
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Bronchial inflammatory cell counts in smokers versus ex-smokers
All 114 patients underwent bronchoscopy; from one patient (ex-smoker) none of 
the biopsy specimens taken were adequate for analysis. Figure 1 shows examples 
of biopsy sections stained with haematoxylin/eosin, CD138, CD8, and CD4. The 
median analysed surface area of biopsy sections (mucosal area per patient, aver-
age of all antibodies, in which cells were counted, not corrected for shrinkage) 
was 0.35 (0.26-0.42) mm2. Ex-smokers had higher CD3+, CD4+, and CD138+ cell 
numbers than current smokers (p=0.036, p=0.023, p=0.044; respectively), but 
there was no significant difference in other inflammatory cell counts (Table 3). 
When differences in sex, age, and FEV1/IVC were taken into account in multivari-
ate linear regression analyses, the differences in CD3, CD4, and CD138 remained 
Figure 1. Bronchial biopsy sections from patients with COPD.
(A) Bronchial biopsy section of a patient with COPD stained with haematoxylin/eosin showing goblet cell 
hyperplasia of the bronchial epithelium (arrow), fibrosis (FI), and scattered inflammatory cells in the sub-
mucosa. (B) Plasma cell staining (CD138). The epithelial layer also stained positive but, for the analysis, 
only the subepithelial layer was taken into account. (C) CD8+ T-lymphocyte staining. (D) CD4+ T-lympho-
cyte staining also showing squamous cell metaplasia of the epithelium (arrow). Scale bars: (A) 100 Nm, (B, 
C and D) 20 Nm.
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significant. There were very few granzyme B+ cells in most patients (median 0.5 
[IQR: 0-1]), and the score was not different between current and ex-smokers with 
COPD.
Bronchial inflammatory cell counts and duration of smoking cessation
There were significant differences for CD4+, CD8+, CD8+/CD3+, and CD138+ cells 
between current smokers, short-term ex-smokers, and long-term ex-smokers with 
COPD (Table 3). Short-term ex-smokers had higher CD4+ and CD8+ cell numbers 
than current smokers (p=0.017, p=0.023, respectively; Table 3, Figure 2). These 
differences persisted after adjustment for differences in postbronchodilator FEV1/
IVC between the groups. In contrast, long-term ex-smokers had lower CD8+ cell 
numbers than short-term ex-smokers (p=0.009), lower CD8+/CD3+ ratios than 
both current smokers (p=0.012) and short-term ex-smokers (p=0.003), and 
Figure 2. Bronchial inflammatory cell counts in smokers and ex-smokers with COPD.
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higher plasma cell numbers than current smokers (p=0.003; Table 3, Figure 2), 
and a trend towards significance versus short-term ex-smokers (p=0.069). When 
adjusting for differences in patient characteristics between the groups, all differences 
remained significant except for the difference in CD8+ cells between short-term and 
long-term quitters. On the other hand, the difference in plasma cells between short-
term and long-term quitters became significant when adjusting for age.
Correlations between bronchial inflammation and smoking behavior
When defining current smoking as 0 years stopped, longer duration of smoking 
cessation was associated with higher numbers of CD3+ cells (rs=0.221, p=0.019), 
CD4+ cells (rs=0.194, p=0.040), CD138
+ cells (rs=0.217, p=0.021), and a trend with 
CD4/CD8 ratios (rs=0.181, p=0.056). Excluding current smokers, longer dura-
tion of smoking cessation was associated with lower CD8/CD3 ratios (rs=-0.395, 
p=0.011) and a trend with higher numbers of CD138+ cells (rs=0.307, p=0.051). 
The number of pack-years smoked was inversely correlated with CD138+ cells (R=-
0.295, p=0.002).
Discussion
This study aimed to determine whether the inflammatory cell profile in the bron-
chial mucosa is different between current smokers and ex-smokers with COPD, 
and whether this profile is influenced by duration of smoking cessation. Ex-smok-
ers had higher numbers of CD3+, CD4+, and plasma cells, whereas numbers of 
neutrophils, macrophages, eosinophils, mast cells, and CD8+ cells were not differ-
ent from current smokers. Interestingly, short-term smoking cessation (below the 
median value of our cohort, that is <3.5 years) was associated with higher CD4+ 
and CD8+ T-lymphocytes whereas long-term smoking cessation (?3.5 years) was 
associated with higher plasma cell numbers and lower CD8/CD3 ratios. These 
results indicate that the number of bronchial T-lymphocytes and plasma cells 
in patients with COPD is related to current smoking status and the duration of 
smoking cessation.
To our knowledge, this is the first study to compare bronchial inflammation in 
current and ex-smokers within a group of COPD patients and to examine the 
association with duration of smoking cessation. The observed higher numbers 
of CD3+ and CD4+ lymphocytes and plasma cells in ex-smokers with COPD com-
pared to current smokers with COPD is novel. Consistent with our results, Mullen 
et al (18) also reported increased inflammation in peripheral airways of ex-smok-
ers with mild COPD and mucus hypersecretion compared with current smokers, 
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although the type of cells was not specified. Our observation that large airway 
inflammation in COPD persists after smoking cessation is in line with previous 
results in smaller numbers of patients with chronic bronchitis (11). Rutgers et al 
(19) also reported ongoing airway inflammation in ex-smokers with COPD com-
pared with healthy ex-smokers but, in contrast to the present study, they did not 
include current smokers with COPD in the analysis. Our results of an association 
between T-lymphocytes and plasma cells and duration of smoking cessation in 
COPD are not in line with a previous study by Wright et al (20) which found no 
difference in general peripheral airway inflammation between patients with COPD 
who had quit >2 years, <2 years, and current smokers. However, Lams et al (12) 
reported that CD8/CD3 ratios in peripheral airways are inversely associated with 
duration of smoking cessation in patients with and without airflow limitation. 
Taken together, it can now be inferred that, within a group of COPD patients, 
T-lymphocytes and plasma cell numbers are related to current smoking status and 
duration of smoking cessation while other inflammatory cells are not.
It seems unlikely that our results are affected by methodological errors. To our 
knowledge, this is the largest study to date to include bronchial biopsies of 114 
well characterised patients with stable COPD of GOLD stages II and III, not using 
inhaled or oral steroids, and without a clinical diagnosis of asthma. It needs to be 
emphasised that this was a cross sectional study, and it cannot be ruled out that 
our ex-smoking group is a selected group of patients who quit smoking because 
they suffered more from smoking related symptoms and may already have had dif-
ferent cell numbers before quitting. Nevertheless, in the present study ex-smokers 
had significantly fewer respiratory symptoms than current smokers, while having 
similar pack-years and duration of smoking. In addition, in our analysis we did 
adjust for clinical differences between the groups. We did not confirm smoking 
status by laboratory tests and therefore cannot exclude the possibility that some 
ex-smokers were still smoking. However, this problem is comparable to those in 
other cross sectional studies in this area (10;11;19). A fully automated image 
analysis system was applied for cell counting in airway area sections (17). We 
are aware that counting cells in a two dimensional manner has limitations since 
it does not take into account the volume of the cell in a given sample; the small-
est cells have the least chance of being counted in a single biopsy. Nevertheless, 
we were able to demonstrate differences in the smallest cells (LY) between the 
groups. There is still debate in the literature as to whether the theoretic basis of 
stereology fits well with the limitations of endobronchial biopsies (21). However, 
most of the present data in the literature is based on counting profiles/area which 
allows comparison between studies, although this is somewhat limited by other 
methodological factors. Because we observed no granzyme B+ cells in most of 
Smoking cessation and bronchial inflammation in COPD  | 85
the biopsy sections analysed (56% of all sections) and no differences in a semi-
quantitative score between the groups, we did not use digital image analysis for 
granzyme B+ cell quantification which is a more time consuming procedure. We 
chose 3.5 years as a cut off time for short-term versus long-term smoking cessa-
tion groups because this was the median duration of smoking cessation, provid-
ing equal sample sizes in both groups.
How can we interpret these data? The ongoing inflammation in ex-smokers with 
COPD suggests the presence of a persistent stimulus that may act independently 
of cigarette smoking. There are several potential mechanisms - for example, 
chronic colonization of the airways with viral and/or bacterial pathogens in smok-
ers with COPD (22) may be responsible for the inflammatory response (23;24) 
and persist after smoking cessation. In agreement with this, it has been observed 
that latent adenovirus could persist in ex-smokers with COPD which is associ-
ated with enhanced inflammation (25;26). Smoking may also trigger self-perpet-
uating inflammatory mechanisms by altering the balance between endogenous 
pro- inflammatory and anti-inflammatory mechanisms or, as recently suggested, 
it may induce autoimmune-like phenomena (27;28). In addition, it was recently 
observed that apoptosis of airway epithelial cells persists after smoking cessation 
in patients with COPD (29), which may induce persistence of inflammation. It 
has been suggested that, in smokers without COPD or chronic bronchitis who 
stopped smoking, lung inflammation is at least partially reversible (9) but persists 
in patients with COPD. It is therefore possible that the aforementioned stimuli 
may not persist in ex-smokers without COPD or chronic bronchitis.
The initial increase in CD4+ and CD8+ cells and later increase in plasma cells after 
smoking cessation might be explained by reversal of immunosuppression. Since 
both CD4 and CD8 cell numbers returned to similar levels in long-term quitters as 
in current smokers, this reversal of immunosuppression seems transient for lym-
phocytes but persistent for plasma cells. Smoking cessation may result in reversal 
of smoking induced harmful effects on airway epithelial cells (30) such as a reduc-
tion in metaplastic secretory cell numbers in small airways (20;31), leading to 
improved lung defence mechanisms. The effector mechanisms of immunity to envi-
ronmental antigens could therefore be stimulated more efficiently in the absence 
of smoking, leading to a higher number of immunocompetent cells. Whereas the 
pro-inflammatory effects of active tobacco smoking have been extensively docu-
mented, it may also have selective anti-inflammatory effects as has been described 
for acute effects of smoking (32). Consistent with this and with our results, it 
was recently observed that cigarette smoke exposure reduced CD4 cell expan-
sion following virus infection (33). In addition, tobacco smokers have decreased 
serum levels of immunoglobulins IgG and IgA (33;34), suggesting that cigarette 
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smoke modulates the humoral arm of adaptive immunity. Indeed, Soutar et al (35) 
described decreased numbers of IgA+ cells in patients with fatal chronic bronchitis 
and suggested that these patients were deficient in plasma cells. These effects 
of decreased serum immunoglobulin levels appear to be reversible after smoking 
cessation (36). It is possible that smoking cessation leads to an improved capac-
ity to produce immunoglobulins in the airway mucosa of patients with COPD by 
causing an increase in plasma cell numbers. Loss of these suppressive effects with 
smoking cessation may also explain our findings of increased numbers of inflam-
matory cells in ex-smokers, thereby ameliorating lung defence mechanisms.
The decreased CD8/CD3 ratio after quitting for ?3.5 years compared with cur-
rent smokers and short-term quitters, and the lower CD8+ cell numbers in long-
term compared with short-term quitters, suggest that smoking cessation may 
eventually result in decreased CD8+ cell numbers. Since CD8+ cells have been 
implicated in the pathogenesis of COPD, a decrease in the number of these cells 
or their cytotoxic activity may have beneficial effects. However, our findings of 
very low numbers of these cells that stain positive for the CD8 effector molecule 
granzyme B in the airways of patients with COPD, in the absence of differences 
between current and ex-smokers, suggest that these cells may not be cytotoxic. 
This may be because granzymes are involved in the pathogenesis of emphysema 
rather than in the conducting airways (37). In this respect, it is interesting to note 
that antigen-specific CD8+ T-lymphocytes can persist in the lung long after clear-
ance of a respiratory virus, and that these cells are highly activated and can be 
stimulated to proliferate, but do not express constitutive effector functions (38). 
In line with these findings, we did observe high numbers of granzyme B positive 
cells in lung tissue from children with childhood bronchiolitis obliterans, a disease 
that is thought to result from acute viral bronchiolitis (39). In vitro studies may 
provide additional information by examining more extensively the possible lack of 
cytotoxicity of CD8+ T-lymphocytes in COPD.
What could be the clinical implications of our findings? There is good evidence 
that smoking cessation results in a decrease in respiratory symptoms (7), a lower 
decline in FEV1 (6), and a reduction of airway hyperresponsiveness (40;41). Our 
data suggest that T-lymphocytes and plasma cell numbers change after smoking 
cessation in COPD while other inflammatory cells persist. Whether these relatively 
small changes in T-lymphocytes and plasma cell numbers contribute to the clinical 
benefits of smoking cessation in patients with COPD remains to be established 
in longitudinal studies. The results suggest that smoking cessation may result in 
an improvement in local humoral immunity which may result in less respiratory 
infections and exacerbations and thereby a reduced progression of COPD. How-
ever, the data also suggest that the clinical benefits of smoking cessation do not 
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simply result form a reduction in inflammatory cells. The mechanisms causing this 
sustained inflammatory pattern after smoking cessation in COPD remain to be 
clarified.
In conclusion, this study has shown that ex-smokers with COPD have higher num-
bers of bronchial CD4+ and plasma cells than current smokers but the numbers of 
neutrophils, macrophages, and CD8+ cells do not different between both groups. 
T-lymphocytes are higher in short-term quitters, whereas a longer duration of 
smoking cessation is associated with lower CD8/CD3 ratios and higher numbers 
of plasma cells. This suggests that changes in T-lymphocyte and plasma cell num-
bers may contribute to the clinical benefits of smoking cessation in COPD.
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Abstract
Background: Chronic Obstructive Pulmonary Disease (COPD) is associated with 
bronchial epithelial changes, including squamous cell metaplasia and goblet cell 
hyperplasia. These features are partially attributed to activation of the epidermal 
growth factor receptor (EGFR). Whereas smoking cessation reduces respiratory 
symptoms and lung function decline in COPD, inflammation persists. We deter-
mined epithelial proliferation and composition in bronchial biopsies from current 
and ex-smokers with COPD, and its relation to duration of smoking cessation.
Methods: 114 COPD patients were studied cross-sectionally: 99 males/15 females, 
age 62 ? 8 years, median 42 pack-years, no corticosteroids, current (n = 72) or ex-
smokers (n = 42, median cessation duration 3.5 years), postbronchodilator FEV1 
63 ? 9% predicted. Squamous cell metaplasia (%), goblet cell (PAS/Alcian Blue+) 
area (%), proliferating (Ki-67+) cell numbers (/mm basement membrane), and 
EGFR expression (%) were measured in intact epithelium of bronchial biopsies.
Results: Ex-smokers with COPD had significantly less epithelial squamous cell 
metaplasia, proliferating cell numbers, and a trend towards reduced goblet cell 
area than current smokers with COPD (p=0.025, p=0.001, p=0.081, respectively), 
but no significant difference in EGFR expression. Epithelial features were not 
different between short-term quitters (<3.5 years) and current smokers. Long-
term quitters (?3.5 years) had less goblet cell area than both current smokers 
and short-term quitters (medians: 7.9% vs. 14.4%, p = 0.005; 7.9% vs. 13.5%, 
p = 0.008; respectively), and less proliferating cell numbers than current smokers 
(2.8% vs. 18.6%, p<0.001).
Conclusions: Ex-smokers with COPD had less bronchial epithelial remodelling 
than current smokers, which was only observed after long-term smoking cessa-
tion (>3.5 years).
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Background
Chronic Obstructive Pulmonary Disease (COPD) is defined by progressive airflow 
limitation and airway inflammation (1), caused predominantly by cigarette smoking. 
Additionally, the airway epithelium undergoes alterations, including squamous cell 
metaplasia, goblet and basal cell hyperplasia (2). These findings are important for 
our understanding of the pathogenesis of COPD, since bronchial epithelial cells 
orchestrate an adequate maintenance of lung homeostasis by mucus production, 
ciliary beating, secretion of antimicrobial products and adequate immunological 
drive in response to noxious stimuli. Goblet cell hyperplasia is more pronounced 
in smokers with COPD compared to those without, suggesting a role in the devel-
opment of airflow limitation (3). In addition, it contributes to mucus hypersecre-
tion, which is associated with morbidity and mortality in COPD (4;5). Squamous 
cell metaplasia impairs mucociliary clearance and contributes to the increased risk 
of squamous cell carcinoma as observed in COPD (6).
 The mechanisms underlying epithelial alterations in COPD are incompletely 
understood. The epidermal growth factor receptor (EGFR) cascade has been 
shown to be involved in mucin production and goblet cell hyperplasia (7;8), 
repair of damaged epithelium (7;8), as well as development of squamous cell car-
cinoma (9). A wide variety of stimuli can induce EGFR activation in vitro and in 
animals, including cigarette smoke (7;8). Additionally, epithelial EGFR expression 
is increased in bronchial biopsies from smokers with (10;11) and without (11;12) 
COPD compared to non-smokers. Previously, we have observed higher epithe-
lial EGFR expression in ex-smokers with COPD compared to non-COPD, but not 
in current smokers, suggesting that current smoking may obscure differences in 
EGFR expression (13). Therefore, EGFR activation may play a role in epithelial 
phenotypic alterations observed in COPD through active smoking.
 Smoking cessation improves respiratory symptoms and lung function decline in 
COPD, mostly within the first year after cessation (14;15), but interestingly bron-
chial airway inflammation persists or even worsens (16;17). To our knowledge, 
there are no studies comparing bronchial epithelial features between current and 
ex-smokers with established COPD. Possibly, smoking cessation contributes to 
restoration of epithelial characteristics in the large airways of COPD patients, 
which are directly and continuously exposed to the noxious substances present in 
cigarette smoke, thereby contributing to the clinical benefits observed after smok-
ing cessation. Therefore, it needs to be addressed whether bronchial epithelial 
alterations and EGFR expression in large airways are reversible with smoking ces-
sation and related to the duration of smoking cessation in COPD.
 We hypothesised that bronchial epithelial cell proliferation and differentiation 
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in patients with COPD is more pronounced in active smokers than in those who 
stopped smoking, and that this difference is influenced by the duration of smoking 
cessation. Additionally, we questioned whether the epithelial changes are associ-
ated with EGFR expression. We therefore investigated the extent of epithelial gob-
let cell hyperplasia, proliferation, squamous cell metaplasia, and EGFR expression 
in bronchial biopsies of current and ex-smokers with established COPD in a large 
cross-sectional study.
Methods
Subjects
114 patients with COPD, who participated in a two-centre trial (Groningen Leiden 
Universities and Corticosteroids in Obstructive Lung Disease; GLUCOLD study), 
were included in this cross-sectional study. Patient characteristics and methods 
have been described in detail previously (17;18). In brief, all patients had irrevers-
ible airflow limitation (postbronchodilator FEV1 and FEV1/IVC < 90% confidence 
interval [CI] of predicted value) and chronic respiratory symptoms, they were all 
current or ex-smokers (quit ≥1 month), with at least 10 pack-years of smoking. 
Patients did not use a course of steroids during the last three months, and did 
not have maintenance treatment with inhaled or oral steroids during the last six 
months. They were allowed to use short-acting bronchodilators, and were in clini-
cal stable condition. The medical ethics committees of each centre approved the 
study and all patients gave their written informed consent.
Lung function
Spirometry, reversibility to salbutamol, and diffusing capacity were measured 
according to previously described methods in order to characterise the patients 
(18).
Bronchoscopy
Fiberoptic bronchoscopy was performed using a standardised protocol accord-
ing to recent recommendations (19) as described previously (17). Smokers were 
requested to refrain from smoking on the day of the bronchoscopy. Patients received 
premedication (400 Ng salbutamol p.i., 20 mg codeine p.o., 0.5 mg atropine s.c.) 
and local anaesthesia (lidocaine). The bronchoscopies were performed by experi-
enced pulmonary physicians using a fiberoptic bronchoscope (18X, outer diam-
eter 6 mm, Pentax Optical Co., Japan) and pairs of cup forceps (Reda, Tuttlingen, 
Germany). Six macroscopically adequate bronchial biopsy specimens were taken 
from (sub) segmental carinae in the right or left lower lobe.
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Biopsy processing and staining
Four paraffin-embedded biopsies were cut in 4 Nm thick sections and haematoxy-
lin/eosin staining was used for evaluation and selection of the two morphological 
best biopsies per patient for analysis (without crushing artefacts, large blood clots, 
or only epithelial scrapings). Sections were stained with Periodic acid-Schiff/Alcian 
blue (PAS/AB) and counterstained with Nuclear Fast Red to identify all secretory 
cells. Immunohistochemistry was performed as described previously for inflamma-
tory cells (17), using specific antibodies against Ki-67 as a marker of proliferation 
(Dako M7240, dilution 1:100), and EGFR (Biogenex nr MU207-UC, dilution 
1:50). Antigen retrieval was obtained using citrate for Ki-67 and pepsin for EGFR.
Analysis of bronchial biopsies
Total biopsy images were prepared with a 3-chip colour camera and analysed by 
means of image analysis software (Zeiss Vision KS400 system, Carl Zeiss, Göttingen, 
Germany) as follows. First, the length of the basement membrane was traced of 
all intact non-squamous metaplastic epithelium (A), intact squamous metaplastic 
epithelium (B), and damaged epithelium (C) in PAS/AB stained sections, in order 
to calculate the % intact epithelium ([A+B]/[A+B+C]) and the % metaplastic epi-
thelium (B/[A+B]). In addition, the presence of metaplastic epithelium was also 
scored as absent (0) or present (1). Intact epithelium (A+B) was defined as a layer 
of both basal and columnar cells without detachment from the basement mem-
brane, including areas of goblet cell hyperplasia or squamous metaplasia (20). 
Consequently, damaged epithelium (C) was defined as all remaining epithelium, 
including denuded basement membrane. Squamous cell metaplasia was defined as 
pseudostratisfied multilayered epithelium consisting of polygonal cells covered by 
flattened layer of squamous cells and absence of ciliated cells (21). Subsequently, 
the number of Ki-67 positively staining cells was counted in intact epithelium by a 
validated full automated procedure (22), and expressed as the number of Ki-67+ 
cells/mm basement membrane. Densitometric analysis of PAS/AB and EGFR in 
intact epithelium (A+B) was also performed fully automated as follows (22). A lin-
ear combination of Red-, and Blue-filtered greyscale images was used, in order to 
derive a greyscale image (range 0-255) in which the “purple” staining (PAS/AB) 
and the “brown-red” staining (EGFR) highlighted above background. Results were 
expressed as the percentage of intact epithelium stained by PAS/AB and EGFR. In 
addition, EGFR staining intensity of positive areas was expressed as the average grey-
value, after normalization of the distribution towards the background peak (white: 
greyvalue 255) and subsequent inversion of the greyvalue distribution. Mean values 
of two biopsies analysed per patient were used for analysis.
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Statistical analysis
Mean values and standard deviations (SD) were computed and presented, or 
median with interquartile range (IQR) in case of non-normal distributed vari-
ables. Since most epithelial markers were still non-normal distributed after log-
transformation, these data were analysed using non-parametric tests. Differ-
ences between smokers and ex-smokers were explored using Chi-square tests or 
2-tailed unpaired t tests for patient characteristics, and Mann Whitney tests for 
epithelial features. To study the association with duration of smoking cessation, 
we compared smokers with ex-smokers who quit <3.5 years and those who quit 
?3.5 years ago, since this was the median duration of smoking cessation, using 
Kruskal-Wallis tests. If these were significant, Mann Whitney tests were applied 
for further exploration of between-group differences. Univariate correlations were 
evaluated using Spearman rank correlation coefficient. To analyse correlations 
with years since smoking cessation, current smokers were included in the analysis 
as 0 years stopped. Multivariate linear regression analysis was applied to adjust 
for significant differences in patient characteristics between the groups, such as 
age, pack-years, and FEV
1/IVC. PAS/AB
+ area was measured in total intact epithe-
lium, including squamous cell metaplasia, which by definition does not contain 
goblet cells. Therefore, linear regression analysis was also applied to adjust for % 
squamous cell metaplasia when analysing PAS/AB+ differences between groups. 
SPSS 12.0 (SPSS Inc., Chicago, IL) software was used for statistical analysis.
Results
Patient characteristics
Patient characteristics of the 114 patients and subgroups of smokers and ex-
smokers have been described in detail previously (17;18) (Table 1). Patients had 
moderate to severe COPD, based on a postbronchodilator FEV1 of 63.0 (8.8)% 
predicted, and a median smoking history of 42 pack-years. Of the 114 COPD 
patients included in this study, 72 were current smokers and 42 were ex-smokers. 
Median duration of smoking cessation in ex-smokers was 3.5 years (IQR: 1-10 
years). Differences in patient characteristics between the groups are presented in 
table 1.
Epithelial features in smokers versus ex-smokers with COPD
All 114 patients underwent bronchoscopy; from one patient (ex-smoker) none 
of the biopsies taken were adequate for analysis. The median analysed base-
ment membrane length per biopsy was 5.03 (IQR: 3.64-6.14) mm, of which 1.12 
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(0.59-2.11) mm was intact epithelium. Characteristics of intact epithelium in the 
total group of patients were: 9.74 (3.54-34.0) Ki-67+ cells/mm BSM, 0 (0-19.7)% 
squamous cell metaplasia (37.3% of patients showed squamous cell metaplasia), 
12.4 (4.69-18.9)% PAS/AB+ area, and 10.4 (3.25-18.9)% EGFR+ area.
 Ex-smokers had significantly less Ki-67+ cell numbers, and % of patients with 
squamous cell metaplasia as well as % of epithelium with squamous cell metapla-
sia (p = 0.001, p = 0.016, p = 0.025; respectively, Table 2) than current smokers. 
PAS/AB+ area also tended to be lower in ex-smokers, but this was not statistically 
significant (p = 0.081, Table 2). When adjusting for the presence of squamous 
metaplasia (which by definition does not contain goblet cells), the difference in 
PAS/AB+ area became significant (p = 0.014). When differences in sex, age, and 
FEV1/IVC were taken into account in multivariate linear and logistic regression 
Table 1. Patient characteristics.
COPD 
smokers
COPD Ex-smokers
combined 
group
quit <3.5 yrs quit ≥3.5 yrs
General
Sex (M/F, n) 59 / 13 40 / 2 * 20 / 1 20 / 1
Age (yrs) 60 ? 8 64 ? 7 * 61 ? 8 67 ? 4 *†
Pack-years (yrs) 43 (32-56) 37 (28-53) 45 (29-65) 35 (26-41) *
Duration of smoking 
cessation (yrs)
– 3.5 (1-10) 1.0 (1.0-2.0) 10 (6.5-14.5)
Smoking duration (yrs) 44 ? 8 41 ? 10 43 ? 11 39 ? 8
Chronic bronchitis (%) 55.6 31.0 * 23.8 * 38.1
Lung Function
Postbronchodilator 
FEV1 (% pred)
63.3 ? 8.3 62.5 ? 9.6 62.6 ? 10 62.5 ? 9.4
Postbronchodilator 
FEV1/IVC (%)
49.5 ? 8.5 46.0 ? 8.3 * 45.3 ? 8.6 * 46.7 ? 8.1
%FEV1 (% pred) 6.9 ? 5.2 6.8 ? 4.5 6.9 ? 3.9 6.8 ? 5.1
KCO (% pred) 73.3 ? 25.1 80.4 ? 25.9 75.3 ? 24.9 85.7 ? 26.5 *
Data are presented as mean ? standard deviation or median (IQR: 25th - 75th percentile), ex-smokers are 
divided in two groups based on median duration of smoking cessation (3.5 years). FEV1 = Forced expiratory 
volume in one second, IVC = Inspiratory vital capacity, %FEV1 = Reversibility to salbutamol (change in FEV1 
as percentage of predicted), KCO = Diffusing capacity for carbon monoxide per liter alveolar volume, pred = 
predicted. Patient characteristics have been described before (17).
* p<0.05: compared to COPD smokers [Chi-square tests for sex differences, 2-tailed unpaired t tests for 
other (log-transformed) data].
† p<0.05: compared to COPD ex-smokers who quit <3.5 yrs (2-tailed unpaired t tests).
| Chapter 598
analyses, all epithelial differences remained significant, except for PAS/AB+ area. 
Epithelial EGFR+ areas and intensities of positive areas showed no differences 
between smokers and ex-smokers with COPD (Table 2).
Duration of smoking cessation and epithelial features in COPD
Ki-67+ cell numbers, the presence of squamous cell metaplasia, and the % PAS/
AB+ area, were different between current smokers, ex-smokers who quit <3.5 
years ago, and ex-smokers who quit ?3.5 years ago (Kruskal Wallis: p = 0.011, p < 
0.001, p = 0.049; respectively, Table 2, Figure 1). Percentage squamous cell meta-
plasia and EGFR+ areas and intensities were not significantly different between 
these three groups (Table 2, Figure 1). There were no differences between current 
smokers and those who quit <3.5 years ago for any of the epithelial features. In 
contrast, those who quit ?3.5 years ago had significantly less Ki-67+ cell numbers, 
presence of squamous cell metaplasia, and % PAS/AB+ area than current smokers 
(p < 0.001, p = 0.029, p = 0.005, respectively; Table 2, Figure 1). The differences 
in PAS/AB and Ki-67 remained significant when adjusting for age and pack-year 
differences between both groups. Moreover, the % PAS/AB+ area was also lower 
in long-term quitters than those who quit <3.5 years ago (p = 0.008), and tended 
Table 2. Bronchial epithelial features of smokers and ex-smokers with COPD.
COPD 
Smokers
COPD Ex-smokers
p-value §combined 
group quit <3.5 years quit ≥3.5 years
SCM 
(% of epithelium)
0 (0-27.5) 0 (0-0)* 0 (0-10.4) 0 (0-0) 0.076
SCM 
(% of patients)
45.7 22.5* 26.3 19.0* 0.049
PAS/AB+ area 
(%)
14.4 (5.2-20.7) 8.1 (3.7-17.2)† 13.5 (6.6-19.6) 7.9 (2.2-16.2)*‡ 0.011
Ki-67+ cells 
(/mm BSM)
18.6 (5.3-38.8) 6.2 (1.5-15.6)* 6.9 (4.4-27.6) 2.8 (0.23-13.1)* <0.001
EGFR+ area 
(%)
11.4 (3.2-17.6) 8.2 (3.2-20.4) 6.7 (2.4-20.4) 8.6 (3.9-21.5) 0.95
Intensity EGFR+ 
area (grey value)
697 (175-1182) 513 (203-1479) 372 (125-1479) 517 (215-1424) 0.95
Data represent median (IQR: 25th - 75th percentile). PAS/AB = Periodic acid-Schiff/Alcian blue, 
SCM = squamous cell metaplasia, EGFR = Epidermal growth factor receptor.
* p<0.05: compared to COPD smokers.
† p<0.05: compared to COPD smokers adjusted for differences in squamous cell metaplasia (linear 
   regression).
‡ p<0.05: compared to COPD ex-smokers who quit <3.5 yrs.
§ p-value from Kruskal-Wallis test between current smokers, < and ?3.5 yrs ex-smokers with COPD.
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to be lower for Ki-67+ cell numbers (p = 0.050). When adjusting for differences in 
age, PAS/AB significance was lost (p = 0.061).
 There was a significant inverse relationship between the duration of smoking 
cessation (including current smokers as 0 years stopped) and Ki-67+ cell numbers 
(rs = -0.354, p < 0.001), % squamous cell metaplasia (rs = -0.212, p = 0.004), and 
% PAS/AB+ area (rs = -0.235; p = 0.013), but not with EGFR expression.
Relation of epithelial features with smoking, symptoms and lung function
The duration of smoking tended to be associated with the number of Ki-67+ cells 
(rs = 0.180, p = 0.065), whereas the number of pack-years smoked was not associ-
ated with epithelial features. 46.5% of all patients reported symptoms of chronic 
bronchitis, and although ex-smokers had significantly less symptoms of chronic 
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Figure 1. Epithelial phenotype in smokers (S) and ex-smokers with COPD.
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bronchitis (Table 1) and % of PAS/AB+ area, there was no relation between the 
presence of these symptoms and the % of PAS/AB+ area (p = 0.78). Epithelial fea-
tures were not associated with the degree of airflow limitation.
Relation between epithelial cell proliferation and differentiation
Ki-67+ cell numbers and the % squamous cell metaplasia were positively associ-
ated with one another (rs = 0.586, p < 0.001). Finally, Ki-67
+ cell numbers were 
also positively associated with % EGFR+ area (rs = 0.210, p = 0.031).
Discussion
In the present study, we demonstrated that long-term ex-smokers with COPD had 
less bronchial epithelial mucin stores, proliferating cells, and squamous cell meta-
plasia than current smokers with COPD. Moreover, these epithelial differences in 
ex-smokers were only significant after a long-term period of smoking cessation 
(>3.5 years). In contrast, epithelial EGFR expression was not different between 
current and ex-smokers with COPD. These results may indicate that smoking ces-
sation reverses smoking-induced bronchial epithelial cell proliferation and differ-
entiation in patients with COPD, and the magnitude of this effect increases with 
longer duration of smoking cessation. In addition, our results suggest that these 
smoking cessation-induced epithelial changes in COPD are not accompanied by 
reduced EGFR expression.
 Our observation of lower bronchial epithelial mucin stores, proliferating cells, 
and squamous cell metaplasia in large airways of ex-smokers as compared to 
current smokers with COPD, and the association with duration of cessation, is 
novel. These results are in contrast to other, smaller studies showing no differ-
ences in epithelial features in ex-smokers compared to smokers both with and 
without COPD (21;23). However, the finding that ex-smokers with chronic bron-
chitis (with or without airflow limitation), had less goblet cell metaplasia in small 
airways than current smokers (24) is in line with our findings in COPD patients. 
The effect of smoking cessation and duration of cessation on squamous cell meta-
plasia and proliferation has been examined previously in bronchial biopsies (25). 
Although it was not mentioned whether these patients had respiratory symptoms 
and/or COPD, the latter study also reported less squamous cell metaplasia and 
epithelial proliferation in ex-smokers. Our result of similar EGFR expression in ex-
smokers compared to current smokers with COPD, is also novel and in contrast 
with observations in smokers without COPD, where lower bronchial EGFR expres-
sion was observed in ex-smokers (12). Taken together, it can now be inferred that 
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smoking cessation results in decreased epithelial mucin stores, proliferation, and 
squamous cell metaplasia, in large airways of patients with COPD, but that it 
does not affect EGFR expression.
 There are a few important considerations when interpreting our results. We 
included a large (n = 114) group of well-characterised patients with stable COPD, 
not inhaling steroids for at least six months or oral steroids for at least three 
months, and without a clinical diagnosis of asthma. First, it needs to be empha-
sised that this was a cross-sectional study, and it cannot be ruled out that our 
ex-smoking group is a selected group of patients who quit smoking because they 
suffered more from smoking related symptoms, and may already have had a dif-
ferent epithelial morphology before quitting. Yet, in the present study ex-smokers 
had significantly less respiratory symptoms than current smokers, whilst having 
similar pack-years and duration of smoking. In addition, we also reported analy-
ses adjusted for clinical differences between the groups (sex, age, FEV1/IVC, pack-
years). Second, comparable to previously published cross-sectional studies we did 
not confirm smoking status by laboratory tests, and therefore cannot rule out 
that some ex-smokers were still smoking. Third, our definitions of intact epithe-
lium and squamous cell metaplasia were very strict, which could have led to an 
underestimation. Fourth, we cannot exclude the possibility that mechanical injury 
induced during bronchoscopy may have interfered with our analyses of epithelial 
damage. Fifth, we applied fully automated image analysis for quantification of 
cell numbers, positively stained areas, and densitometry analyses, and therefore 
minimised potential observer biases. Finally, we did not include a control group 
of smokers without COPD and therefore cannot conclude whether the observed 
effects of smoking cessation are specific to COPD. Taken together, it seems unlikely 
that our results are strongly affected by methodological errors.
 How can we interpret these data? The (partial) reversibility of mucin stores, 
squamous cell metaplasia, and proliferation after smoking cessation, supports 
a causal relationship between cigarette smoke exposure and these epithelial fea-
tures in COPD. In vivo, the proliferative response in smokers may be due to a direct 
mitogenic effect of cigarette smoke (26), but may also result from chronic inflam-
mation, tissue damage and wound healing (26). An inadequate repair response to 
smoke-induced injury may lead to a sustained increase in epithelial proliferation 
and/or altered differentiation. Increased proliferation may accompany squamous 
cell metaplasia (21;25), which is in line with our observation that squamous cell 
metaplasia is related to proliferating cell numbers. This squamous metaplasia 
may serve to protect the underlying tissue against the injurious effects of cigarette 
smoke. According to our results, smoking cessation may reverse this process in 
COPD, at least partially.
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 The observed decrease in mucin stores in long-term ex-smokers with COPD, and 
its relation with duration of smoking cessation, can be explained by decreased gob-
let cell numbers, decreased mucin production, and/or increased mucin secretion. 
The few previous studies examining goblet cell hyperplasia in relation to smoking 
cessation in humans used semi-quantitative scoring systems, but not cell num-
bers (23;24). Animal studies suggest that a reduction in secretory cell numbers 
occurs after smoking cessation (27). The observed decrease in mucin stores in 
ex-smokers in our study probably reflects a decrease in the major mucin in surface 
epithelium, MUC5AC (28). MUC5AC and total mucin in bronchial epithelium are 
correlated, and both are increased in smokers compared to non-smokers (11). 
In addition, small airway epithelial MUC5AC expression is lower in ex-smokers 
compared to current smokers with and without COPD (29), which is also in line 
with our conclusion. Although ex-smokers exhibited fewer symptoms of chronic 
bronchitis and a smaller amount of mucin stores, chronic bronchitis was not asso-
ciated with mucin stores. This can be explained by the fact that mucin is produced 
by both goblet cells in the surface epithelium and by submucosal glands (30), 
whereas these latter were not included in the present analysis. This conclusion is 
supported by the results of a recent study that also failed to reveal differences in 
epithelial mucin expression in peripheral airways of COPD patients with or with-
out chronic bronchitis (29). Finally, it needs to be noted that our study focused 
on mucin expression and not on secretion, whereas the latter is the main feature 
of chronic bronchitis.
 The changes in epithelial mucin stores, proliferating cells, and squamous cell 
metaplasia were most pronounced in COPD patients who had stopped smoking 
more than 3.5 years ago. Correspondingly, inflammation initially persists after 
smoking cessation (17;31). This suggests a long-term effect of smoking on bron-
chial regulatory networks, which is not restored immediately after removing the 
initial stimulus, i.e. cigarette smoke. In contrast, the greatest improvements in 
respiratory symptoms and lung function decline occur within the first year after 
cessation (14;15). Therefore, other pathological mechanisms that reverse more 
rapidly after cessation should be involved in these clinical beneficial effects of 
smoking cessation.
 Cigarette smoke causes both mucus hypersecretion and increases the number 
of goblet cells through activation of the EGFR system (32). In the present study, 
there were no differences between current and ex-smokers with COPD in EGFR 
expression, suggesting that differences in EGFR activation, rather than expres-
sion, are present in ex- versus current smokers with COPD. We did not pursue 
this possibility further, since recent attempts in our laboratory to demonstrate in 
situ EGFR phosphorylation in lung tissue by immunohistochemical methods using 
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phosphospecific antibodies were not successful (13). Since pro-inflammatory 
cytokines, such as TNF-B, increase EGFR expression (33), our observation that 
there is no difference in EGFR expression between ex- and current smokers may 
be related to the persistence of bronchial inflammation (16;17) in ex-smokers 
with COPD. The large inter-individual differences in EGFR expression could also 
explain why there were no differences between the groups in this cross-sectional 
analysis. Alternatively, EGFR independent pathways may contribute to epithelial 
mucin production.
 What could be the clinical implications of our findings? There is good evidence 
that smoking cessation results in less respiratory symptoms (14), less decline in 
FEV1 (15), and less severe airway hyperresponsiveness (34;35), whereas inflamma-
tion persists (16;17). Our data suggest that smoking-induced bronchial epithelial 
goblet cell hyperplasia, proliferation, and squamous cell metaplasia are reduced 
with long-term smoking cessation. These epithelial features might contribute to 
COPD by facilitating colonization of the airways by respiratory pathogens, sec-
ondary to loss of cilia, increased mucus secretion, and epithelial injury (36). The 
chronic colonization of the airways may enhance airway inflammation and further 
epithelial injury. In addition, mucus hypersecretion may cause airways obstruc-
tion in peripheral airways (37). Reversal of epithelial remodelling may therefore 
contribute to reduced progression of COPD attributable to restored mucociliary 
clearance, resulting in reduced respiratory colonization (38) and exacerbations, 
and less small airways obstruction. In addition, reduced epithelial proliferation 
and squamous cell metaplasia in ex-smokers with COPD may decrease the risk of 
squamous cell carcinoma development. Whether the observed (partial) reversibil-
ity of epithelial remodelling is associated with the clinical benefits of smoking ces-
sation in patients with COPD, remains to be established in longitudinal studies.
Conclusions
The present study has shown that ex-smokers with COPD have less bronchial 
epithelial mucin stores, proliferating cells, and squamous cell metaplasia than 
current smokers with COPD, whereas epithelial EGFR expression was not dif-
ferent between both groups. These epithelial changes in ex-smokers were more 
pronounced with longer duration of smoking cessation, and significant after 3.5 
years smoking cessation. This suggests that the clinical benefits of smoking ces-
sation in COPD patients may be in part attributable to a restoration of epithelial 
homeostasis.
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Abstract
Background: Inhaled corticosteroids (ICS) and long-acting beta2-agonists (LABAs) 
are used to treat moderate to severe chronic obstructive pulmonary disease 
(COPD).
Objective: To determine whether long-term ICS therapy, with or without LABAs, 
reduces inflammation and improves pulmonary function in COPD.
Design: Randomized, placebo-controlled trial. (ClinicalTrials.gov registration 
number: NCT00158847)
Setting: 2 university medical centers in The Netherlands.
Patients: 114 steroid-naïve current or former smokers with moderate to severe 
COPD.
Measurements: Cell counts in bronchial biopsies and sputum (primary outcome); 
methacholine responsiveness at baseline, 6 and 30 months; and clinical outcomes 
every 3 months.
Intervention: Random assignment by minimization method to receive fluticasone 
propionate, 500 μg twice daily, for 6 months (n=31) or 30 months (n=26); flutica-
sone , 500 μg twice daily, and salmeterol, 50 μg twice daily, for 30 months (single 
inhaler; n=28); or placebo twice daily (n=29).
Results: 101 Patients were greater than 70% adherent to therapy. Fluticasone 
therapy decreased counts of mucosal CD3+ cells (-55% [95% CI, -74% to -22%]; 
p = 0.004), CD4+ cells (-78% [CI, -88 to -60%]; p < 0.001), CD8+ cells (-57% [CI, 
-77% to -18%]; p = 0.010), and mast cells (-38% [CI, -60% to -2%]; p = 0.039] and 
reduced hyperresponsiveness (p = 0.036) versus placebo at 6 months, with effects 
maintained after 30 months. Fluticasone therapy for 30 months reduced mast cell 
count and increased eosinophil count and percentage of intact epithelium, with 
accompanying reductions in sputum neutrophil, macrophage, and lymphocyte 
counts and improvements in FEV1 decline, dyspnea, and quality of life. Reductions 
in inflammatory cells correlated with clinical improvements. Discontinuing fluti-
casone therapy at 6 months increased counts of CD3+ cells (120% [CI, 24% to 
289%]; p = 0.007), mast cells (218% [CI, 99% to 407%]; p < 0.001), and plasma 
cells (118% [CI, 9% to 336%)]; p = 0.028) and worsened clinical outcome. Adding 
salmeterol improved FEV1 level.
Limitations: The study was not designed to evaluate clinical outcomes. Measure-
ment of primary outcome was not available for 24% of patients at 30 months.
Conclusions: ICS therapy decreases inflammation and can attenuate decline in lung 
function in steroid-naïve patients with moderate to severe COPD. Adding LABAs 
does not enhance these effects.
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Introduction
Chronic obstructive pulmonary disease (COPD) is characterized by a progressive 
decrease in lung function, accompanied by worsening respiratory symptoms and 
health status (1). These clinical features are associated with airway inflamma-
tion (such as that resulting from neutrophils, macrophages, lymphocytes, and mast 
cells) (2-5) and alterations of the bronchial epithelium (such as that resulting from 
squamous cell metaplasia or goblet and basal cell hyperplasia) (6).
Current guidelines (1) recommend treating patients who have severe COPD and 
frequent exacerbations with inhaled corticosteroids (ICSs) and adding long-act-
ing C2-agonists (LABAs) for patients with moderate to severe COPD. Regular ICS 
treatment leads to clinical benefits in terms of symptoms, exacerbation rates, and 
initial improvements in FEV1 (7-10). However, withdrawal of ICS treatment results 
in deterioration of clinical outcome (11;12). Combining a LABA with an ICS pro-
vides additional clinical improvements (13;14). A recent analysis of the TORCH 
(Towards a Revolution in COPD Health) study suggests that prolonged therapy with 
ICS and LABA attenuates FEV1 decline in COPD (15), in contrast to previous studies 
(13;14;16-19).
The clinical benefits of ICS therapy for COPD, with or without a LABA, may be 
at least partially mediated its anti-inflammatory efficacy. Short-term treatment of 
COPD (2-3 months) with ICS reduced the number of bronchial mast cells but not 
CD8+ cells, neutrophils, or macrophages (20;21). Combination therapy with ICS 
and LABAs for 3 months provided more anti-inflammatory effects than ICS mono-
therapy by reducing bronchial CD8+ cells and macrophages (22). No long-term 
anti-inflammatory effects have been reported for these interventions. Our goal 
was to link pathological and clinical efficacy during 30-month treatment.
We hypothesized that: 
1. long-term maintenance therapy with ICS provides anti-inflammatory effects 
(primary outcome) in the airways of patients with COPD; 
2. such effects are associated with clinical improvements; 
3. discontinuing ICS therapy induces a flare-up of inflammation and clinical dete-
rioration; 
4. adding a LABA to ICS therapy provides no further anti-inflammatory effects.
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Methods
Our study is investigator-initiated, with a double-blind, parallel, 4-group, placebo-
controlled, randomized design.
Setting and participants
The GLUCOLD (Groningen Leiden Universities Chronic Obstructive Lung Dis-
ease) project (23) enrolled patients with COPD who were aged 45 to 75 years, 
were current or former smokers, had smoked for 10 or more pack-years, and 
had lung function levels compatible with Global Initiative for Chronic Obstructive 
Lung Disease (GOLD) stages II and III (1). Exclusion criteria were asthma and 
receipt of ICS within 6 months before random assignment. We determined the 
presence of asthma on the basis of a physician ‘s diagnosis or selfreported history, 
symptoms, treatment, or diagnosis of asthma. Patients were clinically stable and 
were allowed to continue taking short-acting bronchodilators. We determinec 
smoking status on the basis of self-reports and gave standard clinical advice to 
quit smoking in accordance with Dutch national guidelines. We recruited almost 
all patients from family practices by electronically selecting patients aged 45 to 75 
years who did not have an International Classification of Primary Care code for 
asthma (R96). Their general practitioner sent them a letter asking for participa-
tion in research. A telephone interview revealed 4617 potentially eligible patients, 
who received spirometry. In addition, were recruited patients by advertising in 
local newspapers. We performed chest radiography and electrocardiography to 
rule out important comorbid conditions. Recruitment and follow-up was between 
2000 and 2007. Both centers’ ethics committees approved the study, and all 
patients provided written informed consent.
Random assignment and interventions
We randomly assigned patients to receive 1 of 4 regimens: fluticasone propionate, 
500 μg twice daily, for the first 6 months followed by placebo, twice daily, for 24 
months; fluticasone, 500 μg twice daily, for 30 months; fluticasone, 500 μg twice 
daily, and salmeterol, 50 μg twice daily, in a single inhaler for 30 months; or pla-
cebo, twice daily, for 30 months. Study medications were individually numbered, 
and we used Diskus dry-powder inhalers (GlaxoSmithKline, Zeist, The Nether-
lands) with 60 doses per inhaler; all active treatment medication and placebo 
were identical in appearance. The placebo consisted of lactose monohydrate (also 
included in other treatment groups). At entry, an independent randomization cen-
ter provided patient and medication numbers by using a minimization procedure 
that balanced treatment groups for center, sex, smoking status, FEV
1/IVC (<60% 
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or ≥ 60%), and methacholine PC20 (the provocative concentration of methacho-
line that causes a 20% decrease in FEV1) (<2 mg/mL or ≥ 2 mg/mL).
Outcomes and Measurements
Our predefined primary outcome was inflammatory cell counts in bronchial 
biopsies and induced sputum. We performed fiberoptic bronchoscopy, biopsy 
processing, and quantification as described elsewhere (24). We stained paraffin-
embedded biopsy sections with Periodic acid-Schiff/Alcian blue to identify goblet 
cells, epithelial intactness, and squamous metaplasia as described elsewhere (25). 
We performed immunohistochemistry by using specific antibodies against T lym-
phocytes (CD3, CD4, and CD8), macrophages (CD68), neutrophil elastase, mast 
cell tryptase (AA1), eosinophils (EG2), plasma cells (CD138), and proliferating 
cells (Ki-67). We expressed subepithelial cells as number of cells per 10-7 m2 by 
fully automated image analysis (26). We used the full sample method (23) to 
perform sputum induction.
Secondary outcomes included postbronchodilator spirometry and hyperrespon-
siveness to methacholine PC20, assessed by using standardized procedures (23), 
dyspnea score by the modified Medical Research Council (MRC) dyspnea scale 
(range, 1 to 5); and health status by the St. George's Respiratory Questionnaire 
(SGRQ) (range, 0 to 100; 100 = maximum disability) (27) and Clinical COPD 
Questionnaire (CCQ) (range, 0 to 6; 6 = worst) (28).
Follow-up Procedures
We measured symptoms, health status, self-reported smoking status, medication 
adherence, and spirometry every 3 months. We checked adherence by counting 
the doses on the inhalers. We performed bronchoscopy, sputum induction, and 
methacholine challenge at baseline and at 6 and 30 months.
Statistical analysis
We based our sample size on the latest data released in 2002 (29) regarding 
the standard deviation (0.77) of the fluticasone-induced short-term change in 
submucosal CD8 cell count in patients with COPD. A 2-fold difference in change 
from baseline to 6 months and from 6 to 30 months in the fluticasone group ver-
sus placebo should be detectable with 80% power with 20 patients per treatment 
group. Because this was an efficacy trial, per-protocol analysis included all avail-
able data from randomly assigned patients who adhered to their therapy regimen 
(using ≥70% of the prescribed dose), including data from patients who did not 
complete follow-up.
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We used linear mixed-effects models with a random intercept at the patient level 
to analyze the data and assumed that data were missing at random. We used 
STATA, version 9.0 (StataCorp, College Station, Texas) for analysis. The linear 
mixed models included the main effect of treatment (3 indicators), the main effect 
of time (2 indicators), and the interaction of treatment and time. For outcomes 
with 3-month measurements, we replaced the time effect with terms that allowed 
a shift or linear change in the average outcome during the first 6 months and a 
subsequent linear change in the average outcome after 6 months. Because of the 
considerable number of model parameters and the sample size, we did not include 
center, age, or sex as covariates in the baseline model. We performed a post hoc 
analysis to adjust for smoking status at baseline and during the study. We pres-
ent the effects as adjusted means in the figures and as percentage of change in 
estimates, CIs, and P values in the text.
We analyzed correlations between statistically significant treatment effects on 
inflammatory outcomes and lung function by using the Spearman correlation 
coefficient (Rs). Data are presented as means (SDs) or medians (interquartile 
ranges). We considered 2-sided P values less than 0.05 to be statistically signifi-
cant.
Role of the funding source
This was an investigator-initiated trial. The study was funded by the Netherlands 
Organization for Scientific Research, Netherlands Asthma Foundation, GlaxoS-
mithKline of The Netherlands, University Medical Center Groningen, and Leiden 
University Medical Center. The funding sources had no role in the design, con-
duct, and analysis of the study or in the decision to submit the manuscript for 
publication.
Results
Of the 114 randomly assigned patients, we analyzed 101 adherent patients 
(Figure 1). Mean postbronchodilator FEV1 was 63% predicted (SD, 9%) (91 
patients were GOLD stage II and 10 were GOLD stage III) and geometric mean 
methacholine PC20 was 0.6 mg/mL (SD, 2.6 doubling dose). Seven patients had 
ever received a short course of corticosteroids and only 5 had ever received ICS 
maintenance therapy.
Baseline patient characteristics were similar among the 4 treatment groups 
(Table 1). Sputum and biopsy inflammatory cells counts did not differ. The 
amount of missing data, including missing data due to dropouts, for each study 
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measure were 12% for FEV1, 13.9% for methacholine PC20, 12.5% for MRC score, 
13.9% for SGRQ score, 14.7% for CCQ score, 12.5% for bronchial inflammatory 
cells, 14.2% for epithelial features, and 14.2% sputum cells.
Short-term therapy with ICS
Fluticasone therapy decreased counts of bronchial CD3+ cells (-55% [CI, -74% to 
Random assignment (n = 114)
Withdrew
(n = 4)
Fluticasone, 
30 mo (n = 26;
26 adherent)
Fluticasone, 6 mo,
then placebo,
24 mo
(n = 31; 
26 adherent)
Withdrew
(n = 1)
Withdrew
(n = 3)
Withdrew
(n = 1)
Withdrew
(n = 2)
Withdrew
(n = 1)
Withdrew
(n = 3)
Fluticasone and
salmeterol, 
30 mo (n = 28; 
25 adherent)
Placebo, 30 mo
(n = 29; 
24 adherent)
Baseline;
received
bronchoscopies
(n = 26)
Baseline;
received
bronchoscopies
(n = 26)
Baseline;
received
bronchoscopies
(n = 25)
Baseline;
received
bronchoscopies
(n = 24)
6-mo assessment
(n = 26; 
25 received
bronchoscopies)
6-mo assessment;
switched to
placebo (n = 24; 
23 received
bronchoscopies)
6-mo assessment
(n = 24; 
22 received
bronchoscopies)
6-mo assessment
(n = 21; 
20 received
bronchoscopies)
30-mo
assessment
(n = 22; 20 received
bronchoscopies)
30-mo
assessment
(n = 23; 20 received
bronchoscopies)
30-mo
assessment
(n = 21; 19 received
bronchoscopies)
30-mo
assessment
(n = 20; 18 received
bronchoscopies)
Total number of patients randomized and compliant (>70% medication use) per treatment group. At each 
stage of the study (0, 6 and 30 months) the numbers are listed of those who underwent bronchoscopy 
amongst the number of patients remaining in the study. 
Definition of abbreviations: n = number.
Figure 1. Study flow diagram.
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-22%]; p = 0.004), CD4+ cells (-78% [CI, -88% to -60%]; p < 0.001), CD8+ cells 
(-57% [CI, -77% to -18%]; p = 0.010), and mast cells (-38% [CI, -60% to -2%]; 
p = 0.039) at 6 months compared with placebo (Figure 2 and Table 2]. This was 
accompanied by an increase in methacholine PC20 (1.5 doubling dose [CI, 0.1 
to 3.0]; p = 0.036) (Figure 3B) and CCQ mental score (0.2 point [CI, 0.01 to 
0.4 points]; p = 0.037) compared with placebo. We found no other statistically 
significant effects of 6 months of fluticasone therapy. The change in FEV1 after 6 
months did not significantly differ between patients who were randomly assigned 
to continue fluticasone therapy and those assigned to switch to placebo.
Long-term continuation of ICS therapy
Continuing fluticasone therapy from 6 to 30 months maintained the reduction in 
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Figure 2. Pathological outcomes.
Adjusted mean change in log-transformed bronchial cell numbers (/10-7 m2 lamina propria) over time dur-
ing treatment with fluticasone (500 μg bid) for 30 months (FP30), fluticasone (500 μg bid) for 6 months 
(FP6), the combination of fluticasone/salmeterol (500/50 μg bid) for 30 months (FP/S) and placebo for 
30 months in patients with COPD. Error bars represent 95% confidence intervals (CI). Data of bronchial 
CD3+ cells (2A), CD4+ cells (2B), CD8+ cells (2C), and mast cells (2D) are presented.
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CD3+, CD4+ and CD8+ cell counts (Figure 2 and Table 2) after 30 months, com-
pared with placebo. This was accompanied by a further -56% change in mast cell 
count (CI, -73% to -29%; p = 0.001), a 125% increase in eosinophil count (CI, 2% 
to 399%; p = 0.046), and a 101% increase in the percentage of intact epithelium 
in bronchial biopsies (CI, 10% to 268%; p = 0.024) after 30 months (Figure 2 and 
Tables 2 and 4). In addition, the 30-month fluticasone group had lower counts of 
sputum neutrophils (-58% [CI, -82% to -1%); p = 0.047), macrophages (-57% [CI, 
-81% to -3%]; p = 0.041), and lymphocytes (-52% [CI, -76% to -5%]; p = 0.035) 
at 30 months than did the placebo group (Table 3).
The rates of FEV1-decline from 6 to 30 months were -79 mL/y (CI, -112 to -46 
mL/y) for the placebo group, -62 mL/y (CI, -93 to -31 mL/y) for the 6-month flu-
ticasone group, 7.3 mL/y (CI, -21 to 35 mL/y) for the 30-month fluticasone group, 
and -16 mL/y (CI, -46 to 15 mL/y) for 30-month fluticasone and salmeterol group. 
Fluticasone significantly diminished annual FEV1 decline over the last 2 years of 
the study compared with placebo (difference, 86 mL/y [CI, 43 to 129 mL/y]; p < 
0.001) (Figure 3A). The improvement in methacholine PC20 by fluticasone com-
pared with placebo that we observed during the first 6 months was maintained 
during the following 2 years (Figure 3B). In addition, maintaining fluticasone ther-
apy reduced dyspnea scores more than placebo over the last 2 years of the study 
(-0.2 point/y [CI, -0.3 to -0.06 point/y]; p = 0.003) (Figure 3C), and significantly 
improved SGRQ activity score (-3.1 points/y [CI, -5.5 to -0.7 points/y]; p = 0.012) 
and CCQ total score (-0.1 point/y [CI, -0.2 to -0.01 points/y]; p = 0.036), symp-
tom score (-0.1 points/y [CI, -0.3 to -0.02 points/y]; p = 0.026), and functional 
score (-0.1 points/y [CI, -0.2 to -0.01]; p = 0.027) (Figure 3D).
Discontinuation of ICS therapy
Discontinuing fluticasone therapy after 6 months increased CD3+ cell count by 
120% (CI, 24% to 289%; p = 0.007), mast cell count by 218% (CI, 99% to 407%; p 
< 0.001), and plasma cell count by 118% (CI, 9% to 336%; p = 0.028) at 30 months 
versus continuing therapy (Figure 2 and Table 2). Bronchial epithelial parameters 
and sputum inflammatory cells did not change significantly (Tables 3 and 4).
Discontinuing fluticasone therapy after 6 months worsened subsequent FEV1 
decline compared with continuing therapy during the last 2 years of follow-up 
(difference in slope, -70 mL/y [CI, -111 to -28 mL/y]; p = 0.001) (Figure 3A), 
with an accompanying deterioration in methacholine PC20 (-2.6 doubling dose 
[CI, -4.1 to -1.2 doubling dose]; p < 0.001) (Figure 3B). Stopping fluticasone 
therapy also worsened dyspnea scores by 0.2 points/y (CI, 0.08 to 0.3 points/y; p 
= 0.001) (Figure 3C), SGRQ total score by 1.7 points/y (CI, 0.19 to 3.2 points/y; 
p = 0.028) and activity score by 2.9 points/y (CI, 0.6 to 5.3 points/y; p = 0.015), 
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and CCQ total score by 0.1 point/y (CI, 0.04 to 0.2 points/y; p = 0.003) and 
symptom score by 0.2 points/y (CI, 0.1 to 0.3 points/y; p < 0.001), compared 
with continuing therapy (data not shown).
Addition of LABAs to ICS therapy
At 6 months, combination treatment provided no additional anti-inflammatory 
effects compared with fluticasone alone; however, at 30 months, CD3+ cell count 
had increased by 126% (CI, 27% to 303%; p = 0.006) and plasma cell count by 
144% (CI, 21% to 393%; p = 0.013) (Figure 2 and Table 2), and eosinophils in 
bronchial biopsies had changed by -55% (CI, -79% to -1%; p = 0.047). Salmeterol 
had no additional effect on bronchial epithelial parameters or sputum inflamma-
Adjusted mean change ? 95% CI over time during treatment with fluticasone (500 μg bid) for 30 months 
(FP 30), fluticasone (500 μg bid) for 6 months (FP 6), followed by placebo (as indicated by the vertical 
line), the combination of fluticasone/salmeterol (500/50 μg bid) for 30 months (FP/S 30) and placebo 
(bid), in patients with moderately severe COPD. Changes in PC20 are expressed as mean doubling doses. 
Data are presented for forced expiratory volume in one second (FEV1) (3A), log-transformed provocation 
concentration of methacholine causing a 20% fall in FEV1 (PC20) (3B), Medical Research Council dyspnea 
score (3C) and Clinical COPD Questionnaire (CCQ) (3D). 
Figure 3. Clinical outcomes.
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tory cells (Table 3 and 4).
At 6 months, combination therapy increased postbronchodilator FEV1 (96 mL [CI, 
16 to 176 mL]; p = 0.018) (Figure 3A) and improved dyspnea scores (-0.4 points 
[CI, -0.7 to -0.04 points]; p = 0.027) (Figure 3C) more than fluticasone alone. 
Improved FEV1 was maintained during prolonged combination therapy without 
further alteration of FEV1 decline, compared with fluticasone alone, but the dys-
pnea score increased after 30 months (0.1 points/y [CI, 0.01 to 0.3 points/y]; p 
= 0.029). During the first 6 months, combination therapy resulted in a change of 
-0.3 points (CI, -0.5 to -0.07 points; p = 0.007) in CCQ total score, -0.3 points 
(CI, -0.6 to -0.04; p = 0.028) in symptom score, and -0.3 points (CI, -0.6 to -0.08 
points; p = 0.008) in functional score (Figure 3D). The minimal clinically impor-
tant difference of 0.4 was not reached (30). During the subsequent 24 months, 
combination therapy did significantly worse than fluticasone alone on these out-
comes, with a change of 0.1 point/y (CI, 0.04 to 0.2 points/y; p = 0.003) in total 
score, 0.1 point/y (CI, 0.03 to 0.3 points/y; p = 0.013) in symptom score, and 0.1 
point/y (CI, 0.03 to 0.2 points/y; p = 0.012) in functional score.
We analyzed the data by using a model that also included individual variances of 
the slopes and obtained similar results. 
Smoking and treatment effects
During the study, 3 patients started smoking and 13 patients stopped smok-
ing (balanced among groups). All above results remained statistically significant 
when adjusted for smoking status throughout the study, except for the reduction 
in sputum lymphocyte numbers by long-term fluticasone therapy.
Relation of treatment effects with pathology and lung function
Analyses of patients that received either fluticasone or placebo for 30 month 
showed that decreases in CD4+ cells were associated with improvements in pre-
dicted postbronchodilator FEV1 (Rs, -0.35; p = 0.037) (Figure 4). Improvements 
in methacholine PC20 were associated with reductions in CD3
+ cells (Rs, -0.36; 
p = 0.041), CD4+ cells (Rs, -0.38; p = 0.034), and mast cells (Rs, -0.46; p = 0.007), 
and increases in percentage intact epithelium (Rs, 0.40; p = 0.024) (Figure 4).
Discussion
Our study shows that 2.5-year maintenance therapy with ICS in COPD reduces 
bronchial T-lymphocyte and mast cell numbers and increases eosinophils and 
the integrity of bronchial epithelium, with an accompanying reduction in sputum 
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cell counts. These effects are associated with a reduced rate of FEV1 decline and 
improvements in airway hyperresponsiveness, dyspnea, and health status. Stop-
ping ICS therapy at 6 months leads to relapse of bronchial inflammation and 
hyperresponsiveness, dyspnea, and poorer health status, with acceleration of 
FEV1 decline. Combination therapy with ICS and a long-acting C2-agonist does 
not provide further anti-inflammatory effects compared with fluticasone alone 
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Figure 4. Correlation between pathological and clinical outcomes.
Upper panel. Correlation of changes (30 months minus baseline) in postbronchodilator forced expiratory 
volume in one second (FEV1, % predicted) with changes in log-transformed CD4
+ cell numbers (/10-7 m2) 
(4A) and changes in log-transformed mast cell numbers (/10-7 m2) (4B) in the lamina propria of bronchial 
biopsies in COPD patients treated with fluticasone propionate 30 months or placebo.
Lower panel. Correlation of changes (30 months minus baseline) in log-transformed provocative concentra-
tion of methacholine causing a 20% fall in FEV1 (PC20) with changes in log-transformed CD4
+ cell numbers 
(/10-7 m2) (4C) and changes in log-transformed mast cell numbers (/10-7 m2) (4D) in the lamina propria of 
bronchial biopsies in COPD patients treated with fluticasone propionate 30 months or placebo.
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but improves the level of FEV1 without further influencing FEV1 decline. Our find-
ings indicate that a subphenotype of patients with COPD who are steroid-naïve 
and have moderate airway obstruction and airway hyperresponsiveness are sen-
sitive to long-term ICS therapy. These prolonged effects on inflammation and 
lung function do not imply causality but suggest that disease modification can be 
achieved in particular phenotypes of patients with COPD.
We observed differential effects of ICS on inflammatory cell counts. Although 
smoking may reduce corticosteroid responsiveness (31), our data show that at 
least part of the inflammation in COPD remains sensitive to this treatment. The 
contribution of CD8+ cells to inflammation and the relevant antigen-specific trig-
gers in COPD are still unknown. CD4+ cells may contribute to activation and 
memory formation of CD8+ cells, as well as provide help for B cells (32). Mast cells 
and their secreted enzymes can drive various processes relevant to inflammation 
and remodeling (33). Although in vitro studies suggest that corticosteroids are 
less effective in inhibiting activation of mast cells than activation of T-cells (34), 
our data indicate corticosteroids can have selective anti-inflammatory effects in 
COPD. The observed increase in intact epithelium by ICS has also been found in 
persons with asthma (35).  Corticosteroid-induced changes in epithelial integ-
rity and inflammation correlated with improvements in methacholine PC20, which 
supports the notion that airway hyperresponsiveness in COPD can be a marker of 
disease activity (36;37).
The clinical novelty of our findings is that anti-inflammatory effects observed with 
long-term ICS treatment associate with reduced FEV1 decline in COPD. Previous 
short-tem studies that investigated patients with COPD and similar degrees of 
airway obstruction (20;21;38) have shown anti-inflammatory effects of ICS in 
COPD. We show that these beneficial effects are maintained during long-term 
treatment up to 30 months. The detrimental effects of discontinuing ICS ther-
apy on bronchial inflammation are also novel. Previous short-term studies of the 
combination of a LABA and ICS demonstrated anti-inflammatory effects versus 
placebo (39) or additional reductions of bronchial CD8+ cells and macrophages 
versus ICS alone (22). Our data suggest that this is not a long-lasting additional 
effect; we observed a slight increase in CD3+ and plasma cells. The attenuated 
FEV1 decline in our patients with COPD contrasts with large COPD trials from 
the 1990s (7-9). The more recent TORCH study (15) did show reductions of FEV1 
decline in patients with COPD who received therapy ICSs, LABAs, or both. Our 
results suggest that the improvement in the level of FEV1 in the combination group 
might be due to a residual bronchodilator effect of salmeterol and not further dis-
ease modification. Discrepancies between the previous trials and our study may 
be due to differences in study samples, which may provide a clinical message.
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Our study comprised a common subset of patients with COPD. First, by choos-
ing steroid-naïve patients, we aimed to exclude patients with unknown previous 
benefits from ICS at baseline and avoid the problem of selective dropouts in the 
placebo group. Second, our patients had predominantly moderate degrees of air-
way obstruction and most demonstrated airway hyperresponsiveness or modest 
reversibility of FEV1. Recent studies (10;40) show that these characteristics, previ-
ously attributed to asthma alone, can also be components of COPD. This COPD 
phenotype may be particularly sensitive to ICS, similar to the documented ben-
eficial effects of smoking cessation (37). Of note, the decrease in postbroncho-
dilator FEV1 in the placebo group was quite similar to that observed in previous 
studies (8;10;15). We were particularly careful to exclude patients with a previous 
or concurrent diagnosis of asthma by carefully taking histories, checking family 
practice medical records, and obtaining clinical judgments from chest physicians. 
Furthermore, most patients had low numbers of eosinophils in sputum and biop-
sies (similar to those reported by Bourbeau and colleagues (22)), had smoked for 
many years, and had a mean reversibility of FEV1 to salbutamol of only 7% of pre-
dicted value, and most (83%) were nonreversible according to European Respira-
tory Society criteria - yet all adhered to the GOLD criteria. This is consistent with 
the patient characteristics of short-term COPD studies that show benefits with 
ICS therapy (22;39). Airway hyperresponsiveness was similar to that in the Lung 
Health COPD study (10), which measured long-term changes in airway hyperre-
sponsiveness. Finally, our post hoc analysis showed that actual smoking through-
out the study was unlikely to be a major confounder. Taken together, our findings 
suggest that ICS therapy, when given for the first time and for longer duration 
to steroid-naïve patients with relatively moderate disease, has the potential to 
change the clinical course of COPD.
Our study has limitations. First, only 77 of 101 analyzed patients had biopsies 
at 30 months because patients dropped out or were unwilling to have another 
bronchoscopy. This might have resulted in selection bias; however, lost-to-biopsy 
rates were similar among treatment groups. Second, our study was not powered 
to examine clinical outcomes. Nevertheless, the primary and secondary outcome 
parameters were all pre-specified. According to international standards on clini-
cal investigations (41), the secondary outcomes point toward a clinically relevant 
treatment benefit, given our positive findings in the primary outcome. In addi-
tion, the positive findings on FEV
1 decline are consistent with the symptomatic 
benefit we observed (42). Third, because this was an efficacy trial, we used data 
from adherent patients. As expected, the placebo group had more nonadherent 
patients, which may have led to underestimate the treatment effect. Fourth, the 
pathologic changes in COPD are not uniformly distributed among central and 
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peripheral airways (43;44). We inevitably focused on the central airways. Fifth, 
despite its beneficial effects, long-term ICS treatment has potentially meaningful 
adverse effects, such as increased frequency of pneumonia (14). Our sample size 
was too small to draw conclusions on this.
Our study should lead to subsequent analyses of the benefits of inhaled steroids 
in COPD. Histological outcomes need to include inflammatory and epithelial cell 
activity and aspects of airway wall remodeling and fibrosis. Studies are also needed 
to determine the best inflammatory and clinical predictors of steroid efficacy in 
COPD. Finally, our results indicate a need to study the cost benefit of changing 
disease progression by using maintenance ICS therapy.
In conclusion, long-term maintenance therapy with ICS can reduce inflammation 
in bronchial biopsies and sputum in COPD. This is mirrored by attenuated lung 
function decline, airway hyperresponsiveness, dyspnea, and improved quality of 
life. Adding a LABA provided supplementary benefit for lung function but did 
not further alter the course of FEV1 decline. Clinicians who are treating patients 
recognize that COPD is a heterogeneous disease that includes various phenotypes 
(45). Our observations indicate that progressive decline in lung function can be 
attenuated in steroid-naïve patients with moderate COPD, a long history of smok-
ing, and airway hyperresponsiveness. The observed treatment response by this 
particular subphenotype of COPD underscores the potential of tailored therapy 
in COPD to achieve clinical benefit.
References
 1.  Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagno-
sis, management and prevention of chronic obstructive pulmonary disease. NHLBI/WHO 
workshop report. www goldcopd com, accessed June 2009.
 2.  Saetta M, Turato G, Maestrelli P, Mapp CE, Fabbri LM. Cellular and structural bases of 
chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;163:1304-1309.
 3.  Hogg JC, Chu F, Utokaparch S, Woods R, Elliott WM, Buzatu L, Cherniack RM, Rogers 
RM, Sciurba FC, Coxson HO, Pare PD. The nature of small-airway obstruction in chronic 
obstructive pulmonary disease. N Engl J Med 2004;350:2645-2653.
 4.  Grashoff WF, Sont JK, Sterk PJ, Hiemstra PS, de Boer WI, Stolk J, Han J, van Krieken JM. 
Chronic obstructive pulmonary disease: role of bronchiolar mast cells and macrophages. 
Am J Pathol 1997;151:1785-1790.
 5.  O’Shaughnessy TC, Ansari TW, Barnes NC, Jeffery PK. Inflammation in bronchial biopsies 
of subjects with chronic bronchitis: inverse relationship of CD8+ T lymphocytes with FEV1. 
Am J Respir Crit Care Med 1997;155:852-857.
Effect of fluctasone with and without salmeterol in COPD  | 127
 6.  Puchelle E, Zahm JM, Tournier JM, Coraux C. Airway epithelial repair, regeneration, and 
remodeling after injury in chronic obstructive pulmonary disease. Proc Am Thorac Soc 
2006;3:726-733.
 7.  Pauwels RA, Löfdahl C-G, Laitinen LA, Schouten JP, Postma DS, Pride NB, Ohlsson SV. 
Long-term treatment with inhaled budesonide in persons with mild chronic obstructive 
pulmonary disease who continue smoking. N Engl J Med 1999;340:1948-1953.
 8.  Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, dou-
ble blind, placebo controlled study of fluticasone propionate in patients with moderate 
to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000;320:1297-
1303.
 9.  Vestbo J, Sorensen T, Lange P, Brix A, Torre P, Viskum K. Long-term effect of inhaled budes-
onide in mild and moderate chronic obstructive pulmonary disease: a randomised con-
trolled trial. Lancet 1999;353:1819-1823.
10.  The Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in 
pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 2000;343:1902-
1909.
11.  van der Valk P, Monninkhof E, van der Palen J., Zielhuis G, van Herwaarden C. Effect of 
discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary 
disease: the COPE study. Am J Respir Crit Care Med 2002;166:1358-1363.
12.  Wouters EF, Postma DS, Fokkens B, Hop WC, Prins J, Kuipers AF, Pasma HR, Hensing CA, 
Creutzberg EC. Withdrawal of fluticasone propionate from combined salmeterol/flutica-
sone treatment in patients with COPD causes immediate and sustained disease deteriora-
tion: a randomised controlled trial. Thorax 2005;60:480-487.
13.  Calverley P, Pauwels R, Vestbo J, Jones P, Pride N, Gulsvik A, Anderson J, Maden C. Com-
bined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary dis-
ease: a randomised controlled trial. Lancet 2003;361:449-456.
14.  Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, Vestbo J. 
Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary dis-
ease. N Engl J Med 2007;356:775-789.
15.  Celli BR, Thomas NE, Anderson JA, Ferguson GT, Jenkins C, Jones PW, Vestbo J, Knobil K, 
Yates JC, Calverley PM. Effect of pharmacotherapy on rate of decline of lung function in 
COPD: results from the TORCH study. Am J Respir Crit Care Med 2008;178:332-38.
16.  Sutherland ER, Allmers H, Ayas NT, Venn AJ, Martin RJ. Inhaled corticosteroids reduce 
the progression of airflow limitation in chronic obstructive pulmonary disease: a meta-
analysis. Thorax 2003;58:937-941.
17.  van Grunsven PM, van Schayck CP, Derenne JP, Kerstjens HA, Renkema TE, Postma DS, 
Similowski T, Akkermans RP, Pasker-de Jong PC, Dekhuijzen PN, van Herwaarden CL, van 
Weel C. Long term effects of inhaled corticosteroids in chronic obstructive pulmonary dis-
ease: a meta-analysis. Thorax 1999;54:7-14.
18.  Highland KB, Strange C, Heffner JE. Long-term effects of inhaled corticosteroids on FEV1 
in patients with chronic obstructive pulmonary disease. A meta-analysis. Ann Intern Med 
2003;138:969-973.
| Chapter 6128
19.  Soriano JB, Sin DD, Zhang X, Camp PG, Anderson JA, Anthonisen NR, Buist AS, Burge PS, 
Calverley PM, Connett JE, Petersson S, Postma DS, Szafranski W, Vestbo J. A pooled analy-
sis of FEV1 decline in COPD patients randomized to inhaled corticosteroids or placebo. 
Chest 2007;131:682-689.
20.  Hattotuwa KL, Gizycki MJ, Ansari TW, Jeffery PK, Barnes NC. The effects of inhaled fluti-
casone on airway inflammation in chronic obstructive pulmonary disease: a double-blind, 
placebo-controlled biopsy study. Am J Respir Crit Care Med 2002;165:1592-1596.
21.  Gizycki MJ, Hattotuwa KL, Barnes N, Jeffery PK. Effects of fluticasone propionate on 
inflammatory cells in COPD: an ultrastructural examination of endobronchial biopsy tis-
sue. Thorax 2002;57:799-803.
22.  Bourbeau J, Christodoulopoulos P, Maltais F, Yamauchi Y, Olivenstein R, Hamid Q. Effect 
of salmeterol/fluticasone propionate on airway inflammation in COPD: a randomized con-
trolled trial. Thorax 2007;62:938-43.
23.  Lapperre TS, Snoeck-Stroband JB, Gosman MM, Stolk J, Sont JK, Jansen DF, Kerstjens 
HA, Postma DS, Sterk PJ, The Glucold Study Group. Dissociation of lung function and 
airway inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 
2004;170:499-504.
24.  Lapperre TS, Postma DS, Gosman MME, Snoeck-Stroband JB, ten Hacken NH, Hiemstra 
PS, Timens W, Sterk PJ, Mauad T, The Glucold Study Group. Relation between duration of 
smoking cessation and bronchial inflammation in COPD. Thorax 2006;61:115-121.
25.  Lapperre TS, Sont JK, van Schadewijk A, Gosman MM, Postma DS, Bajema IM, Timens W, 
Mauad T, Hiemstra PS. Smoking cessation and bronchial epithelial remodeling in COPD: a 
cross-sectional study. Respir Res 2007;28:85-93.
26.  Sont JK, de Boer WI, van Schadewijk WA, Grunberg K, van Krieken JH, Hiemstra PS, Sterk 
PJ. Fully automated assessment of inflammatory cell counts and cytokine expression in 
bronchial tissue. Am J Respir Crit Care Med 2003;167:1496-1503.
27.  Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure of health 
status for chronic airflow limitation. The St. George’s Respiratory Questionnaire. Am Rev 
Respir Dis 1992;145:1321-1327.
28.  van der Molen T, Willemse BW, Schokker S, ten Hacken NH, Postma DS, Juniper EF. Devel-
opment, validity and responsiveness of the Clinical COPD Questionnaire. Health Qual Life 
Outcomes 2003;1:13.
29.  Verhoeven GT, Hegmans JP, Mulder PG, Bogaard JM, Hoogsteden HC, Prins JB. Effects 
of fluticasone propionate in COPD patients with bronchial hyperresponsiveness. Thorax 
2002;57:694-700.
30.  Kocks JW, Tuinenga MG, Uil SM, van den Berg JW, Stahl E, van der MT. Health status 
measurement in COPD: the minimal clinically important difference of the clinical COPD 
questionnaire. Respir Res 2006;7:62.
31.  Ito K, Ito M, Elliott WM, Cosio B, Caramori G, Kon OM, Barczyk A, Hayashi S, Adcock IM, 
Hogg JC, Barnes PJ. Decreased histone deacetylase activity in chronic obstructive pulmo-
nary disease. N Engl J Med 2005;352:1967-1976.
32.  Castellino F, Germain RN. Cooperation between CD4+ and CD8+ T cells: when, where, and 
how. Annu Rev Immunol 2006;24:519-540.
Effect of fluctasone with and without salmeterol in COPD  | 129
33.  Sommerhoff CP. Mast cell tryptases and airway remodeling. Am J Respir Crit Care Med 
2001;164:S52-S58.
34.  Belvisi MG. Regulation of inflammatory cell function by corticosteroids. Proc Am Thorac Soc 
2004;1:207-214.
35.  Laitinen LA, Laitinen A, Haahtela T. A comparative study of the effects of an inhaled corti-
costeroid, budesonide, and a beta 2-agonist, terbutaline, on airway inflammation in newly 
diagnosed asthma: a randomized, double-blind, parallel-group controlled trial. J Allergy 
Clin Immunol 1992;90:32-42.
36.  Postma DS, de Vries K, Koeter GH, Sluiter HJ. Independent influence of reversibility of air-
flow obstruction and nonspecific hyperreactivity on the long-term course of lung function 
in chronic air-flow obstruction. Am Rev Respir Dis 1986;134:276-280.
37.  Tashkin DP, Altose MD, Connett JE, Kanner RE, Lee WW, Wise RA. Methacholine reactiv-
ity predicts changes in lung function over time in smokers with early chronic obstructive 
pulmonary disease. The Lung Health Study Research Group. Am J Respir Crit Care Med 
1996;153:1802-1811.
38.  Gan WQ, Man SF, Sin DD. Effects of inhaled corticosteroids on sputum cell counts in 
stable chronic obstructive pulmonary disease: a systematic review and a meta-analysis. 
BMC Pulm Med 2005;5:3.
39.  Barnes NC, Qiu YS, Pavord ID, Parker D, Davis PA, Zhu J, Johnson M, Thomson NC, Jeffery 
PK. Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive 
lung disease. Am J Respir Crit Care Med 2006;173:736-743.
40.  Tashkin DP, Celli B, Decramer M, Liu D, Burkhart D, Cassino C, Kesten S. Bronchodilator 
responsiveness in patients with COPD. Eur Respir J 2008;31:742-750.
41.  Committee for proprietary medicinal products. Points to consider on multiplicity issues 
in clinical trials. Available from http://www.emea.europa.eu/pdfs/human/ewp/090899en.
pdf, accessed September 2008 .  2002. 
 Ref Type: Internet Communication
42.  Committee for proprietary medicinal products. Points to consider on clinical investigation 
medicinal products in the chronic treatment of patients with chronic obstructive pulmo-
nary disease (COPD). 1999. Available from http://www.emea.europa.eu/pdfs/human/
ewp/056298en.pdf, accessed September 2008 .  1999. 
Ref Type: Internet Communication
43.  Battaglia S, Mauad T, van Schadewijk A, Vignola AM, Rabe KF, Bellia V, Sterk PJ, Hiemstra 
PS. Differential distribution of inflammatory cells in large and small airways in smokers. J 
Clin Pathol 2007;60:907-911.
44.  Battaglia S, Mauad T, van Schadewijk A, Bellia V, Vignola AM, Rabe KF, Sterk PJ, Hiemstra 
PS. Neutrophils inflammation in large and small airways in (ex-)smokers with or without 
COPD [abstract]. Am J Respir Crit Care Med 2003;167:A873.
45.  Rennard SI, Vestbo J. The many “small COPDs”: COPD should be an orphan disease. Chest 
2008;134:623-627.
Chapter  7
Conclusions and 
General discussion

Summary and general discussion  | 133
Introduction
Chronic obstructive pulmonary disease (COPD) is characterized by progressive 
airflow limitation and airway inflammation mainly caused by tobacco smoking. 
COPD is a heterogeneous disease in terms of clinical, physiological, and patho-
logical presentation. Hence, COPD has multiple disease domains that each can 
be highly relevant for disease monitoring, progression and treatment. This thesis 
has focused on: the potential independent roles of airway inflammation and func-
tional impairment in COPD, the monitoring of airway function and inflammation 
in patients with COPD, the effects of smoking cessation on inflammation and 
epithelial remodeling in COPD, and the integrative effects of anti-inflammatory 
treatment on each of the disease domains in COPD.
This thesis comprises cross-sectional and follow-up analyses of data from the 
GLUCOLD study (Groningen Leiden Universities and Corticosteroids in Obstruc-
tive Lung Disease). The GLUCOLD Study is a prospective, four-arm, placebo-con-
trolled, and double-blind study, comparing the effects of 30 months treatment 
with inhaled steroids, inhaled steroids and a long-acting C2-agonist combination 
therapy, placebo, and 6 months inhaled steroids followed by 24 months placebo 
on clinical and pathological outcome parameters. First, the conclusions of the 
studies in this thesis will be summed up, followed by a general discussion and 
directions for future research.
Conclusions of the thesis
Relation between airway inflammation and pathophysiology in COPD
- Airflow limitation, asthma-like components (i.e. airway responsiveness and 
IgE), exhaled nitric oxide and sputum inflammatory cell counts (neutrophils and 
eosinophils) offer separate and additive information about the pathophysiologi-
cal condition of COPD patients (Chapter 2).
- Uneven distribution of ventilation and airway closure in patients with stable 
COPD are associated with neutrophil numbers in bronchial biopsies and bron-
choalveolar lavage (BAL) fluid, and with neutrophil elastase and its local inhibi-
tor secretory leukocyte proteinase inhibitor (SLPI) in BAL (Chapter 3).
Effect of smoking cessation on airway pathology in COPD
- Ex-smokers with COPD have higher numbers of bronchial CD4+ and plasma cells 
than current smokers, whereas numbers of neutrophils, macrophages, and CD8+ 
cells are not different between both groups. T-lymphocytes are higher in short-
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term quitters, whereas longer duration of smoking cessation is associated with 
lower CD8/CD3 ratios, and higher numbers of plasma cells (Chapter 4).
- Ex-smokers with COPD have less bronchial epithelial mucin stores, proliferating 
cells, and squamous cell metaplasia than current smokers with COPD, whereas 
epithelial epidermal growth factor receptor (EGFR) expression is not different 
between both groups. These epithelial changes in ex-smokers were more pro-
nounced with longer duration of smoking cessation, and only significant after 
3.5 years smoking cessation (Chapter 5).
Treatment effects on airway pathology in COPD
Long-term treatment with fluticasone propionate in COPD patients reduces the 
number of bronchial T-lymphocytes and mast cells, whilst increasing the integrity 
of bronchial epithelium and number of bronchial eosinophils, which was accom-
panied by a reduction in sputum cell counts. This is accompanied by a reduced 
rate of decline in FEV1 and improvements in airway hyperresponsiveness, dyspnea 
and quality of life (Chapter 6).
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- Fluticasone propionate-induced improvement in FEV1 after long-term treat-
ment in patients with COPD is associated with a reduction in bronchial CD4+ 
cells, whilst the improvement in airway hyperresponsiveness is associated with 
a reduction in CD3+, CD4+, and mast cells and with an increase in intact epithe-
lium (Chapter 6).
- Discontinuation of fluticasone at 6 months leads to a relapse of bronchial inflam-
mation and airway hyperresponsiveness, dyspnea and quality of life, with accel-
eration of FEV1-decline (Chapter 6).
- Adding salmeterol to fluticasone propionate does not provide further anti-
inflammatory effects compared to fluticasone alone, but improves FEV1-level 
without further influencing FEV1-decline (Chapter 6).
General discussion
Airway inflammation and airflow limitation in COPD are not simply related 
A crucial pathologic feature of COPD is airway inflammation and remodeling. The 
chronic inflammation in COPD is characterized by an accumulation of neutrophils, 
macrophages, B-cells, lymphoid aggregates and CD8+ T-cells, particularly in and 
near the small airways (1). Multiple cross-sectional studies have demonstrated 
relationships between this inflammatory profile and airflow limitation in COPD, 
suggesting a role for inflammation in the pathogenesis of the disease. Increased 
airflow obstruction is associated with a higher degree of airway inflammation (2), 
and more specifically with increased numbers of CD8+ cells (3-5), B-lymphocytes 
(2), neutrophils (6-10), macrophages (10), dendritic cells (11), and in some 
COPD patients even with eosinophils (12). In addition, one prospective study has 
shown that patients with an accelerated decline in lung function have an increased 
baseline sputum neutrophil differential count (13). However, prospective data 
examining the natural course of airway inflammation in relation to FEV1 decline 
within COPD patients are still lacking. Also, cross-sectional correlations do not 
differentiate properly between cause and effect. So is chronic airway inflammation 
involved in COPD progression?
To clarify relationships between various parameters, without reference to a spe-
cific criterion, we performed a factor analysis using sputum inflammatory and 
functional parameters in patients with COPD. Interestingly, our data suggest that 
airflow limitation is greatly independent of neutrophilic and eosinophilic inflam-
mation in the larger airways (chapter 2). Neutrophils are involved in the induction 
of mucous metaplasia and tissue damage through the release of serine proteases 
and oxidants (14). However, emphysema is not a prominent feature of other 
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pulmonary diseases where chronic airway neutrophilia is even more prominent, 
such as cystic fibrosis and bronchiectasis (15). In addition, increased neutrophil 
numbers are found in the airway lumen, but they are not a prominent feature of 
the inflammation in the airway wall or parenchyma in patients with COPD (16). 
This suggests that other factors are involved in the generation of emphysema. 
Obviously, sputum does not cover all the inflammatory and structural changes 
of the airways in COPD. It may well be that selection of other inflammatory cell 
types characteristic for COPD, such as CD8+ T-lymphocytes and macrophages, or 
selection of cells in other compartments of the lung, would have given different 
results of the factor analysis. This is also supported by our observation that small 
airways dysfunction (uneven distribution of ventilation and early airway closure), 
as measured with the sbN2-test, is associated with neutrophil numbers in bron-
choalveolar lavage fluid and bronchial biopsies, and with NE and NE/neutrophil 
ratio, but not with sputum neutrophils or other inflammatory cell types (chapter 
3). In patients with established airflow limitation the sbN2-test contributes to pre-
diction of the decline in FEV1 (17). Therefore, we may speculate that neutrophilic 
inflammation is indirectly involved in the progression of COPD by contributing to 
small airways and/or alveolar pathology.
Dissociation of inflammation and lung function is partly supported by the results 
of intervention studies in COPD. For instance, although smoking cessation reduces 
lung function decline in COPD (18), inflammation persists (chapter 4) (19-21). 
On the other hand, intervention with inhaled steroids is able to slow down FEV1 
decline in a subgroup of COPD patients which is correlated with suppressive 
effects on the number of bronchial T-lymphocytes, but not with other inflamma-
tory cells (chapter 6). This latter result suggests a role for at least T-lymphocytes 
in COPD progression.
Apparently airflow limitation requires more than the presence of inflammatory 
cells per se. Activity of these cells will obviously be of importance, and would 
therefore be of interest to investigate in more detail in future studies. Addition-
ally, the degree of airflow limitation is also correlated with airway wall thickness 
(2), and in a recent study the annual changes in airway thickening assessed by CT 
measurements correlated with annual decline in air flow limitation (22). These 
data provide indirect evidence for a role for airway wall remodeling in airflow 
obstruction in COPD. This remodeling includes epithelial remodeling, including 
squamous metaplasia and mucous metaplasia, increased smooth muscle mass, 
and peribronchial fibrosis. In addition, breakdown of extracellular matrix occurs 
in parenchymal tissues, also resulting in airflow limitation.
COPD has been recognized as a heterogeneous disorder in terms of clinical pre-
sentation, physiological and pathological characteristics (23;24). This suggests 
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that distinct pathophysiological pathways contribute to COPD development. In 
agreement with this, we observed that multiple functional and inflammatory char-
acteristics were categorized into 4 independent dimensions using factor analysis. 
Factor 1 included airflow limitation and hyperinflation; factor 2 features com-
monly associated with asthma (C2-response, total serum IgE, airway hyperrespon-
siveness); factor 3 exhaled nitric oxide; and factor 4 sputum % neutrophils and 
eosinophils (chapter 2). Our data suggest that these four dimensions offer sepa-
rate and additive information about the pathophysiological condition of COPD 
patients. Therefore, prospective long-term studies monitoring different aspects of 
pathological changes in the airways and different functional parameters may fur-
ther explore the mechanisms leading to progressive airflow limitation in various 
phenotypic subgroups of COPD patients.
Ongoing airway inflammation and reversal of epithelial remodeling after 
smoking cessation in COPD
Smoking cessation is able to reduce COPD progression (18), respiratory symp-
toms and hyperresponsiveness as compared to continued smoking (25;26), and 
improves survival (27). What are the exact changes that occur in the airways and 
lung parenchyma after smoking cessation? Since airway inflammation is a key char-
acteristic of COPD, it was hypothesized that this inflammation might be reduced 
after cessation. However, we have shown that ex-smokers with COPD have higher 
numbers of bronchial CD4+ and plasma cells than current smokers, whereas num-
bers of neutrophils, macrophages, CD8+ and mast cells are not different between 
both groups (chapter 4). The persistence of airway inflammation in ex-smokers 
is in line with other recent studies (19-21), although decreased numbers of mac-
rophages in ex-smokers with COPD have been reported (19). In contrast, in sub-
jects without COPD inflammatory changes are at least partially reversible with 
cessation (28). These results suggest that inflammation becomes or remains self-
perpetuating after stopping smoking in COPD patients, which could be related 
to latent adenovirus or bacterial colonization, an auto-immune response (29), 
persistent apoptosis (30), or persistent and/or aberrant repair processes. The 
discrepancy between the improvement in FEV1 decline and the ongoing airway 
inflammation suggests that inflammation does not necessarily contribute sub-
stantially to disease progression. 
Interestingly, we observed increased bronchial CD4+ and plasma cells in ex-smok-
ers compared to current smokers (chapter 4). In addition, a more recent study 
demonstrated that current smokers with COPD have lower numbers of bronchial 
dendritic cells which reversed upon smoking cessation (31). These results might 
be explained by reversal of immunosuppressive effects induced by tobacco smoke, 
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and thereby ameliorating lung defence mechanisms. Alternatively, smoking cessa-
tion may contribute to restoration of epithelial characteristics in the large airways 
of COPD patients, which are directly and continuously exposed to the noxious 
substances present in cigarette smoke, thereby contributing to the clinical benefits 
observed after smoking cessation. Consistent with this, we demonstrated that 
long-term ex-smokers with COPD had less bronchial epithelial mucin stores, pro-
liferating cells, and squamous cell metaplasia than current smokers with COPD 
(chapter 5). These epithelial features might contribute to COPD by facilitating 
colonization of the airways by respiratory pathogens, secondary to loss of cilia, 
increased mucus secretion, and epithelial injury (32). The chronic colonization 
of the airways may enhance airway inflammation and further epithelial injury. In 
addition, mucus hypersecretion may cause airways obstruction in peripheral air-
ways (2). Reversal of epithelial remodeling may therefore contribute to reduced 
progression of COPD attributable to restored mucociliary clearance, resulting in 
reduced respiratory tract colonization (33) and exacerbations, and less small air-
ways obstruction.
Finally, our results demonstrate that longer duration of smoking cessation (>3.5 
years) in COPD patients is associated with higher plasma cell numbers, lower 
CD8/CD3 ratios, and more pronounced reductions in epithelial mucin stores, 
proliferating cells, and squamous cell metaplasia (chapter 3 and 4). This sug-
gests a long-term effect of smoking on bronchial regulatory networks, which is 
not restored immediately after removing the initial stimulus, i.e. cigarette smoke. 
In contrast, the greatest improvements in respiratory symptoms and lung func-
tion decline occur within the first year after cessation (18;25). Therefore, other 
pathological mechanisms that reverse more rapidly after cessation should be 
involved in the mechanism leading to the clinical beneficial effects of smoking 
cessation. It could therefore be interesting to study effects of smoking cessation 
on for instance cell activity, oedema in de airways, vascular changes and airway 
smooth muscle. In addition, these results indicate that when studying the effects 
of smoking cessation the duration of cessation should be taken into account when 
interpreting the results.
Anti-inflammatory properties of inhaled steroids in COPD
Systemic and local inflammation has been implicated in the pathogenesis of 
COPD, and consequently the use of systemic and inhaled corticosteroids (ICS) 
has been considered critical to COPD treatment. As a result, ICS treatment has 
been clinical practice for decades in stable COPD patients; however, their precise 
role remains controversial. Previous studies have shown clinical benefits of ICS 
in patients in terms of symptoms, exacerbation rate, and initial improvement in 
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FEV1 (34;35). The attenuated decline in FEV1 in COPD patients in the present 
thesis (chapter 6) contrasts with large COPD trials from the 90’s showing initial 
improvement in FEV1 without benefits on the subsequent progressive FEV1-decline 
(34-36). Interestingly, the more recent TORCH study did show slight reductions 
of FEV1-decline in COPD patients by inhaled fluticasone, but also by LABA (37). 
Discrepancies between the negative trials and the present study may be due to dif-
ferences in study populations, which may provide a clinical message. We studied 
steroid-naïve patients, with predominantly moderate degrees of airway obstruction 
and the majority demonstrated airway hyperresponsiveness and/or modest revers-
ibility of FEV1, although patients with a previous or concurrent diagnosis of asthma 
were excluded. Recent studies showed that these characteristics, previously attrib-
uted to asthma, can also be components of COPD (38;39). It may well be that 
this COPD phenotype is particularly sensitive to inhaled corticosteroids, similar to 
beneficial effects of smoking cessation (40). Therefore, our findings raise the option 
that inhaled corticosteroids, when given for the first time and for longer duration to 
steroid-naïve patients as recruited from general practices having relatively moderate 
disease, have a realistic potential to change the clinical course of COPD. Moreover, 
there seems to be a great deal of patient-to-patient variability regarding efficacy of 
inhaled steroids. As a result, it would be highly valuable to identify phenotypic dis-
ease markers (clinical or pathophysiological) that can distinguish which patients 
with COPD experience the greatest benefit by inhaled corticosteroids. Previous 
studies have suggested that smoking cessation (34;41;42), larger bronchodila-
tor response (34;35;43), airway hyperresponsiveness (43-45), and eosinophilic 
airway inflammation (46;47) may be able to predict a beneficial response of ste-
roid treatment in patients with established COPD. However, larger long-term pro-
spective studies should confirm whether these markers can predict the effects of 
inhaled steroids on FEV
1 decline.
Clinical benefits of ICS in COPD may be mediated, at least partially, by their anti-
inflammatory efficacy. Short-term (2-3 months) ICS treatment in COPD was previ-
ously shown to reduce numbers of bronchial mast cells, but not CD8+ cells, neutro-
phils or macrophages (48;49), cells that are characteristic for COPD. We observed 
differential effects of ICS on inflammatory cell numbers with long-term treatment. 
Bronchial T-cells, mast cells and sputum neutrophils, macrophages, and lympho-
cytes were reduced, whereas bronchial neutrophils and macrophages were not 
(chapter 6). Although smoking may reduce corticosteroid responsiveness (50), our 
data show that at least part of the inflammation in COPD is not insensitive to this 
treatment. The contribution of CD8+ cells to inflammation and the relevant antigen-
specific triggers (e.g. microbial or autoantigens) in COPD are still unknown. CD4+ 
cells may contribute to activation and memory formation of CD8+ cells as well as 
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providing help for B cells (51). Mast cells and their secreted enzymes can drive a 
variety of processes relevant to inflammation and remodeling, including fibrosis, 
extracellular matrix turn-over, angiogenesis, smooth muscle and epithelial hyper-
plasia, and hypersecretion (52). This aspect requires follow-up studies including 
inflammatory cell activity in addition to cell numbers as outcome parameter. Nota-
bly, the observed increase in intact epithelium by long-term corticosteroid treatment 
has also been found in asthmatic patients (53). This might be due to alterations in 
inflammation and/or in fragility of the epithelium secondary to changes in epithelial 
integrity, apoptosis or proliferation status. We can exclude the latter since we did 
not find such treatment effects within the intact epithelium, or effects on mucin 
stores, squamous cell metaplasia or EGFR expression. Interestingly, corticosteroid-
induced changes in epithelial integrity (and inflammation) correlated with improve-
ments in PC20, supporting the notion that airway hyperresponsiveness in COPD can 
be a marker of disease activity (40;54).
The reduction in CD3+ cells and mast cells and the functional benefits are reversed 
after stopping inhaled steroids (chapter 6), indicating that the anti-inflammatory 
effects are not persistent and that those processes inducing ongoing inflamma-
tion in COPD are not affected permanently by steroids. This suggests a role for 
continuous and long-term treatment with inhaled steroids in COPD as opposed 
to intermittent treatment. We cannot infer from our study how fast inflammation 
increases after stopping steroids or whether duration of treatment influences this 
process. Previous biopsy studies included patients with COPD who withdrew for 
at least 4-8 weeks from inhaled steroid treatment before entry, and therefore may 
have interfered with the effects of stopping steroids on inflammation (44;48;55).
The next step required when examining effects of corticosteroid intervention in 
the airways of patients with COPD, is to focus on inflammatory and epithelial cell 
activity and on airway wall remodeling and fibrosis.
Although both smoking cessation and treatment with inhaled steroids are able to 
reduce FEV1 decline in COPD, airway inflammation is partly reduced with steroid 
treatment whereas it persists after smoking cessation. In addition, whereas smok-
ing cessation reverses epithelial remodeling, treatment with inhaled steroids does 
not. These apparent discrepancies indicate that other factors, next to inflamma-
tory cell numbers and epithelial remodeling, play a role in lung function decline 
in COPD. These may include for instance activity of inflammatory cells, remodel-
ing of the airway wall (matrix remodelling and airway smooth muscle hyperpla-
sia/hypertrophy), or alveolar destruction. It should be noted however that the 
observed discrepancies may also be a consequence of methodological differences 
between the studies on smoking cessation and inhaled steroid treatment in the 
present thesis (i.e. retrospective versus prospective, time effect).
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Limitations of the studies and methodological considerations
The patients recruited for the GLUCOLD study had to meet the in- and exclu-
sion criteria as discussed in the introduction. These comprised: GOLD stage II 
and III, no maintenance treatment with inhaled steroids in the past 6 months, no 
asthma, willing to undergo three bronchoscopies, and participate in a long-term 
follow-up study with 3-monthly outpatient clinic visits. It turned out to be diffi-
cult to find these patients, because the majority of these patients diagnosed with 
COPD already were treated with inhaled steroids. Therefore, we had to change 
our recruitment strategy to find those patients who were not yet diagnosed with 
the disease. It took 2.5 years of intensive recruitment in outpatient clinics and 
general practices, including approximately 40,000 letters send to potential candi-
dates and 3600 lung function screenings in Leiden only. Finally, we included 114 
patients in the study, which was less than the aimed number, but still one of the 
largest studies including bronchial biopsies world-wide. Steroid withdrawal has 
shown to result in detoriation of clinical as well as inflammatory parameters in 
COPD (55-57) (chapter 6). Therefore, we believe that the fact that we included 
mainly steroid-naïve patients is one of the strengths of the study. It should be 
taken into account that COPD is a heterogeneous disease in terms of clinical, 
physiological and pathological presentation. As a result of our inclusion criteria 
we selected a specific subgroup of the total COPD population, and therefore our 
results may not be representative for COPD in general.
It needs to be emphasised that the studies on smoking cessation (chapter 4 and 
5) were cross-sectional studies, and it cannot be ruled out that our ex-smoking 
group is a selected group of patients who quit smoking because they suffered 
more from smoking related symptoms, and may already have had different cell 
numbers before quitting. Nevertheless, ex-smokers had significantly less respira-
tory symptoms than current smokers, whilst having similar pack-years and dura-
tion of smoking. In addition, in the analysis we did adjust for clinical differences 
between the groups.
Bronchoscopy with biopsy and induced sputum access the proximal bronchi only, 
and we have therefore not been able to assess the effects of therapy on small 
airways and lung parenchyma, the site considered to contribute most to reduced 
lung function in COPD (2). However, the predominance of CD8+ cells is seen in 
both proximal and small airways and the correlation between this cell type and 
impaired lung function is similar in both large and small airways and lung paren-
chyma (2;3). This and other data (58) suggest that similar processes of inflamma-
tion and airway wall thickening appear to be taking place in both large and small 
airways. Thus, biopsy samples of large airways may be a reasonable surrogate 
for assessing the potential effects of treatment on small airway inflammation and 
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remodeling. Additionally, most studies examining peripheral airways pathology 
have used resection material from patients with lung cancer. It may well be that 
airway inflammation is influenced by these malignant processes in the airways. 
We attempted to investigate treatment effects on peripheral airways inflamma-
tion assessed in bronchoalveolar lavage fluid. Unfortunately, because of ethical 
considerations, the BAL procedure was discontinued (i.e. a few patients reported 
side effects in relation to the BAL) and therefore it was performed only in the first 
half of patients. An alternative approach of studying treatment effect on smaller 
airways pathology could be using ultra thin bronchoscopes.
A fully automated image analysis system was applied for cell counting in airway 
area sections (59). We are aware that counting cells in a 2 dimensional manner 
has limitations, since it does not take into account the volume of the cell in a given 
sample – the smallest cells have the least chance to be counted in a single biopsy. 
Nevertheless, we were able to demonstrate differences in the smallest cells (lym-
phocytes) in our studies. There is still debate in the literature whether the theo-
retic basis of stereology fits well with the limitations of endobronchial biopsies 
(60). Still, most of the present data in the literature is based on counting profiles/
area, which allows, although somehow limited by other methodological factors, 
comparison among studies.
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Directions for future research
The studies described in this thesis have provided more insight into the role of 
airway inflammation in the pathogenesis and treatment of patients with COPD. 
However, many issues remain to be explored. Interesting questions for future 
studies may include:
- Are airflow limitation, airway responsiveness, and airway inflammation in bron-
chial biopsies separate entities underlying the pathophysiology of COPD by using 
factor analysis?
- What is the natural course of airway pathology in relation to FEV1 decline within 
COPD patients in a prospective long-term study? (this is currently ongoing)
- Can the long-term clinical and pathological course of COPD in patients with usual 
medical care, in a long-term follow-up study of patients from the GLUCOLD study, 
be predicted by phenotypic disease markers of cellular, physiological and clinical 
origin? (this is currently ongoing)
- What is the effect of long-term smoking cessation on inflammatory cell activity 
and airway remodeling in COPD?
- What is the effect of long-term treatment with inhaled corticosteroids on inflam-
matory cell activity and regulation of matrix remodelling and airway smooth 
muscle hyperplasia/hypertrophy in airways of COPD patients?
- Is it possible to predict which COPD patients benefit from treatment with inhaled 
corticosteroids? (this currently ongoing)
- Which non-invasive markers are useful for monitoring COPD patients and treat-
ment effects?
- Can development of novel treatments for COPD result in reversal of disease pro-
gression and reduction in mortality?
- How can the apparent discrepancy between beneficial effects of smoking cessa-
tion and ICS on lung function decline in COPD, but differential effects on airway 
inflammation and epithelial features be explained?
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Achtergrond
Wat is COPD?
COPD is een Engelse afkorting van chronic obstructive pulmonary disease, in het 
Nederlands chronisch obstructieve longziekten. COPD omvat chronische bronchi-
tis en longemfyseem. Chronische bronchitis wordt gekenmerkt door klachten van 
chronisch hoesten en sputum opgeven. Bij longemfyseem is er verlies van long-
weefsel door destructie van longblaasjes, ook wel “rek uit de longen” genoemd. 
Patiënten met COPD hebben klachten van kortademigheid, vooral bij inspanning, 
productieve hoest, piepende ademhaling en/of prikkelbaarheid van de luchtwe-
gen voor bepaalde prikkels als rook, mist en kou (hyperreactiviteit). COPD wordt 
gekenmerkt door een versnelde achteruitgang van de longfunctie. Een deel van de 
patiënten maakt periodes door met toename van klachten, welke “exacerbaties” 
worden genoemd. Deze exacerbaties worden vaak veroorzaakt door luchtwegin-
fecties met virussen en/of bacteriën en leiden frequent tot ziekenhuis opname. 
In 2003 hadden 316.400 mensen in Nederland COPD: 176.500 mannen en 
139.900 vrouwen. Het aantal mensen met COPD stijgt met de leeftijd. COPD 
komt voornamelijk voor bij mensen van 55 jaar en ouder. In 2004 stierven 3.381 
mannen en 2.281 vrouwen ten gevolge van COPD: 4,1% van de totale sterfte in 
Nederland wordt veroorzaakt door COPD. Hiermee behoort COPD tot de ziekten 
met de hoogste sterfte. Internationaal gezien is de sterfte aan COPD in Nederland 
relatief hoog.
Risicofactoren voor het krijgen van COPD
De belangrijkste risicofactor voor COPD is roken. Hoe meer en hoe langer men 
heeft gerookt, des te groter is de kans op COPD. De trends in COPD volgen de 
trends in het rookgedrag. 90% van alle COPD patiënten heeft gerookt of rookt 
nog steeds. Naar schatting ontwikkelt 15-20% van alle rokers in de loop van het 
leven deze aandoening. Er is dus een zekere mate van gevoeligheid voor sigaret-
tenrook nodig voor het ontstaan van COPD. Waardoor deze gevoeligheid wordt 
bepaald is nog onbekend, maar er zijn aanwijzingen dat erfelijkheid een rol speelt. 
Tevens dragen luchtverontreiniging (onder andere passief roken) en luchtwegin-
fecties mogelijk ook bij aan COPD ontwikkeling.
Longfunctie en COPD
Bij patiënten met COPD is de longfunctie verminderd. Daarom is het noodza-
kelijk om deze longfunctie te meten voordat de diagnose gesteld kan worden. 
Ten gevolge van luchtwegvernauwing, ook wel obstructie genoemd, ontstaat bij 
de uitademing een toegenomen weerstand tegen de luchtstroom. De uitademing 
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kost hierdoor meer moeite, terwijl dit bij gezonde mensen een passief proces is. 
De ernst van de luchtwegobstructie kan gemeten worden door het volume lucht 
te meten dat een patiënt in 1 seconde kan uitademen, de zogenaamde 1-seconde-
waarde (FEV1). Hoe lager deze waarde is, hoe ernstiger de ziekte is. Als de lucht-
wegobstructie ernstig is, lukt het de patiënt niet meer om alle lucht uit te blazen 
voordat een nieuwe inademing begint. Hierdoor wordt de hoeveelheid lucht, die in 
de longen achterblijft, steeds groter. Dit noemt men hyperinflatie en kan bepaald 
worden met een bodybox meting.
Bij toenemend verlies van longweefsel en daardoor destructie van longblaasjes 
neemt de capaciteit van gastransport (zuurstof en koolstofdioxide) af. Een dif-
fusiecapaciteit meting geeft weer in welke mate gastransport kan plaatsvinden en 
zegt daarmee indirect iets over de mate van weefselverlies.
Daarnaast kan de aanwezigheid van hyperreactiviteit gemeten worden door een 
provocatietest. Hierbij wordt een prikkelende stof ingeademd die luchtwegvernau-
wing kan veroorzaken bij gevoelige luchtwegen.
Ook de functie van de kleine luchtwegen kan gemeten worden met longfunctie 
tests. De stikstof uitwascurve (single breath nitrogen test) is een dergelijke test, 
waarbij men het “closing volume” en de “stikstof helling” meet. Het “closing 
volume” is het uitademingsvolume waarbij kleine luchtwegen dichtklappen. De 
stikstof helling geeft de mate van ongelijkmatige distributie van luchtstroom in 
de long weer. Bij toegenomen luchtwegontsteking en bij emfyseem klappen kleine 
luchtwegen eerder dicht en is er meer ongelijkmatige distributie van luchtstroom.
Luchtwegontsteking en veranderde anatomie bij COPD
Het langdurig inademen van sigarettenrook, wat duizenden schadelijke stoffen 
bevat, heeft een irriterend effect op de luchtwegen. De cellaag die normaal de 
luchtwegen bekleed (trilhaardragend epitheel) is slecht bestand tegen de scha-
delijke stoffen en wordt vervangen door een epitheel bestaande uit meerdere cel-
lagen plaveiselcelepitheel, vergelijkbaar met de bekleding van wang of slokdarm 
(squameuze metaplasie). Echter dit epitheel heeft geen trilharen waardoor slijm 
niet meer naar de mond wordt getransporteerd. Daarbij is er een toename van 
slijmproducerende cellen (goblet cellen) en klieren, waardoor er meer sputum 
productie is. Dit stilstaande slijm in de luchtwegen vormt een risico voor het ont-
staan van infecties. De tabaksrook veroorzaakt een chronische ontsteking van het 
slijmvlies in de luchtwegen. Deze ontsteking bestaat voornamelijk uit neutrofiele 
granulocyten, macrofagen en CD8+ T-lymfocyten. De ontstekingscellen worden 
geactiveerd en scheiden een scala aan eiwitten uit, die deels schadelijk zijn voor het 
longweefsel. Hierdoor verandert de structuur van de luchtwegen met als gevolg 
een verdikte luchtwegwand, terwijl de longblaasjes worden afgebroken. Deze pro-
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cessen worden voornamelijk in de kleine luchtwegen gezien en spelen een rol bij 
het ontstaan van de verminderde longfunctie in COPD.
Behandeling van COPD
Stoppen met roken is het uitgangspunt van de behandeling en het voorkomen van 
COPD. Stoppen met roken heeft een gunstig effect op klachten, de achteruitgang 
in longfunctie en de overleving van patiënten met COPD. Tot nu toe is er geen 
behandeling met medicijnen die de ziekte kan genezen. Wel zijn er medicijnen die 
ingeademd worden (inhalatie medicatie) die gunstige effecten hebben: luchtweg-
verwijders en inhalatiecorticosteroïden (ontstekingsremmers). Luchtwegverwij-
ders bewerkstelligen ontspanning van de kleine spiertjes rondom de luchtwegen 
en dragen zo bij aan een verbetering van klachten en kwaliteit van leven. Echter dit 
gaat niet gepaard met een verbetering in achteruitgang van longfunctie. Inhalatie-
corticosteroïden lijken vooral een gunstig effect te hebben op het aantal exacer-
baties dat een patiënt doormaakt; echter het effect op de versnelde achteruitgang 
in longfunctie is niet geheel duidelijk. Enkele grote studies uit de jaren 90 laten 
zien dat inhalatiecorticosteroïden wel een initiële verbetering van longfunctie kun-
nen geven, maar de versnelde achteruitgang in longfunctie op lange termijn niet 
kunnen voorkomen; een recente grote studie laat dat echter wel zien. COPD exa-
cerbaties worden behandeld met prednison tabletten of per infuus, met of zonder 
antibiotica. Indien er tevens sprake is van zuurstoftekort kan zuurstof toegediend 
worden. Het is nog onduidelijk wat de invloed is van stoppen met roken en de 
langdurige behandeling met luchtwegverwijders en inhalatiecorticosteroïden op 
de veranderingen in de luchtwegen en de chronische ontsteking.
Heterogeniteit
COPD is een heterogene ziekte met betrekking tot klinische presentatie, longfunc-
tie afwijkingen, pathologische veranderingen die in de longen worden gezien en 
reactie op behandeling. Daaruit blijkt dat waarschijnlijk verschillende mechanis-
men een rol spelen in de ontwikkeling, klinische presentatie en het beloop van 
COPD. Deze heterogeniteit biedt mogelijkheden voor gerichter behandeling van 
subgroepen van COPD patiënten.
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Dit proefschrift
Dit proefschrift gaat over de luchtwegontsteking bij patiënten met COPD. Hierbij 
is op verschillende manieren naar ontsteking gekeken.
- Rol van luchtwegontsteking bij verminderde longfunctie
- Stoppen met roken en luchtwegontsteking
- Behandeling en luchtwegontsteking
De GLUCOLD studie
De GLUCOLD studie (GLUCOLD = Groningen Leiden Universities Corticoste-
roids in Obstructive Lung disease) is een gezamenlijk project van de universitair 
medische centra van Leiden en Groningen. Alle onderzoeken beschreven in dit 
proefschrift betreffen data die afkomstig zijn van deze studie. De belangrijkste 
vraagstellingen van de GLUCOLD studie zijn:
- Wat is het effect van langdurig behandelen met inhalatiecorticosteroïden op de 
longfunctie en luchtwegontsteking?
- Maakt het uit of COPD patiënten kortdurend (6 maanden) of langdurig (2,5 
jaar) behandeld worden met inhalatiecorticosteroïden?
- Heeft het stoppen van behandeling met inhalatiecorticosteroïden nadelige effec-
ten op klachten, longfunctie en luchtwegontsteking?
- Heeft het toevoegen van lang werkende luchtwegverwijders aan inhalatiecortico-
steroïden (combinatietherapie) additionele gunstige effecten?
Voor de GLUCOLD studie werd een groot aantal vrijwilligers (114 in totaal) gere-
kruteerd met matig tot ernstig COPD. Deelnemers werden bij aanvang van de 
studie uitgebreid onderzocht, waarbij gegevens verzameld werden met betrekking 
tot: luchtwegklachten, kwaliteit van leven, longfunctie, hyperreactiviteit en lucht-
wegontsteking. Dit laatste werd gemeten door de verschillende ontstekingscellen 
te tellen in opgegeven sputum, in longspoeling (lavage) en in kleine stukjes weef-
sel afkomstig uit de luchtwegwand (biopt). Lavage en biopt kunnen uitsluitend 
worden verkregen door het verrichten van een kijkonderzoek van de luchtwegen 
(bronchoscopie), wat een veilig maar belastend onderzoek is voor de patiënt. Ver-
volgens werden de deelnemers door loting ingedeeld in een van de vier behan-
delgroepen (figuur 1). Zowel de deelnemers als de onderzoekers waren niet op 
de hoogte van de behandelgroep waartoe deelnemers behoorden (dubbelblind). 
Patiënten werden geïnstrueerd de studiemedicatie tweemaal per dag te gebruiken 
gedurende 2,5 jaar en bezochten elke drie maanden de polikliniek longziekten. Tij-
dens deze driemaandelijkse bezoeken werd de longfunctie gemeten, vragenlijsten 
ingevuld over klachten en kwaliteit van leven. Na 6 maanden behandeling en aan 
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het einde van de studie werden alle metingen die voor aanvang van de behandeling 
verricht werden herhaald. 
Door het grote aantal patiënten met COPD waarbij zeer veel informatie werd ver-
zameld, uiteenlopend van kwaliteit van leven, longfunctie tot ontsteking in biop-
ten, kon ook veel geleerd worden over de ziekte op zich.
Rol van luchtwegontsteking bij verminderde longfunctie
 
Hoofdstuk 2: Dissociatie tussen luchtwegobstructie en luchtwegontsteking in COPD
COPD wordt gekenmerkt door verminderde longfunctie en luchtwegontsteking. 
COPD is een heterogeen ziektebeeld met betrekking tot klinische presentatie, 
longfunctie afwijkingen, pathologische veranderingen die in de longen worden 
gezien en reactie op behandeling. Daaruit blijkt dat waarschijnlijk verschillende 
mechanismen een rol spelen in de ontwikkeling, presentatie en het beloop van 
COPD. Eerdere onderzoeken lieten zien dat COPD patiënten met een slechtere 
longfunctie ook meer ontstekingscellen in de luchtwegen hebben. Dat suggereert 
dat ontsteking een rol speelt in de ontwikkeling van COPD. In dit hoofdstuk heb-
ben we onderzocht of luchtwegobstructie, hyperinflatie, diffusiecapaciteit, hyper-
30
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Figuur 1. De vier behandelgroepen.
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reactiviteit, de mate van reversibiliteit van luchtwegobstructie en verschillende 
onderdelen van luchtwegontsteking, overlappende of onafhankelijke dimensies 
zijn in het ontstaan van COPD. Dit werd onderzocht door middel van een factor 
analyse op deze verschillende parameters. Factor analyse is een statistische ana-
lyse die verschillende ziektekenmerken groepeert in enkele onafhankelijke groepen 
(factoren genoemd) van onderling geassocieerde ziektekenmerken. Een dergelijke 
factor analyse resulteerde in 4 verschillende factoren (groepen geassocieerde ziek-
tekenmerken). 
- Factor 1: luchtwegobstructie en hyperinflatie
- Factor 2: reversibiliteit, hyperreactiviteit, diffusie capaciteit en IgE in bloed
- Factor 3: uitgeademd NO (ontstekingskenmerk in uitgeademde lucht)
- Factor 4: ontstekingscellen in sputum
De parameters in de eerste factor passen bij luchtwegobstructie. De tweede factor 
omvat parameters die vaak bij astma patiënten gezien worden. De derde en vierde 
factor omvatten ontstekingskenmerken. Hieruit werd geconcludeerd dat lucht-
wegobstructie en luchtwegontsteking en kenmerken passend bij astma verschil-
lende onafhankelijke kenmerken van COPD zijn en daarmee aanvullende informa-
tie geven. Dit suggereert dat deze verschillende factoren meegenomen dienen te 
worden in de evaluatie van COPD patiënten en in de beoordeling van behandel-
effecten.
Hoofdstuk 3: Kleine luchtweg functie en luchtwegontsteking in COPD
De luchtwegveranderingen die optreden bij COPD patiënten en tot verminderde 
longfunctie leiden, spelen zich vooral af in de kleine luchtwegen en in de longblaas-
jes. Deze veranderingen kunnen alleen bestudeerd worden in longweefsel wat door-
middel van een operatie verwijderd is. De stikstof uitwascurve is een longfunctie 
meting die de functie van de kleine luchtwegen kan meten. Eerder onderzoek heeft 
laten zien dat hoe meer veranderingen van de kleine luchtwegen en longblaasjes in 
operatiemateriaal van COPD patiënten gezien worden, hoe slechter de functie van 
kleine luchtwegen gemeten met de stikstof uitwascurve. Deze longfunctie test zegt 
dus iets over wat er in de periferie van de long gebeurd. In dit hoofdstuk hebben 
we onderzocht in welke mate de ontstekingscellen gemeten in sputum, lavage en 
biopten uit grote luchtwegen gerelateerd is aan de kleine luchtwegfunctie gemeten 
met de stikstof uitwascurve. De belangrijkste uitkomsten van dit onderzoek zijn:
- COPD patiënten met meer ongelijkmatige distributie van luchtstroom (stikstof 
helling) hadden meer ontsteking met neutrofiele granulocyten in biopten en meer 
geactiveerde neutrofiele granulocyten in lavage.
- Hoe groter het uitademingsvolume waarbij kleine luchtwegen samenvallen (clo-
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sing volume) in COPD patiënten, hoe meer ontsteking met neutrofiele granulo-
cyten in lavage.
- Kleine luchtwegfunctie was niet gerelateerd aan andere ontstekingscellen in spu-
tum, biopten en lavage.
Deze resultaten suggereren dat de neutrofiele ontsteking in de luchtwegwand en 
in de longblaasjes een rol speelt bij de ontwikkeling van slechtere kleine luchtweg-
functie bij patiënten met COPD. Deze longfunctie test is een eenvoudige en niet 
belastende manier om de ontsteking en veranderingen in kleine luchtwegen en 
longblaasjes indirect te evalueren bij COPD patiënten. 
Stoppen met roken en luchtwegontsteking
Hoofdstuk 4: Duur van stoppen met roken beïnvloedt luchtwegontsteking in COPD
Stoppen met roken heeft gunstige effecten op symptomen en vermindert de ach-
teruitgang in longfunctie bij COPD patiënten. Deze gunstige effecten treden al 
binnen 1 jaar na stoppen op. Het is nog onduidelijk wat het mechanisme hier-
achter is, en het is mogelijk dat een vermindering in luchtwegontsteking na stop-
pen een rol speelt. Recente onderzoeken hebben laten zien dat ex-rokers evenveel 
luchtwegontsteking hebben als rokers. Echter hierbij is niet onderzocht of de duur 
van stoppen met roken een rol speelt en hoe eventueel de aard van de ontsteking 
verandert. In dit hoofdstuk hebben we het aantal ontstekingscellen in sputum en 
biopten onderzocht van rokers en ex-rokers met COPD (ex-rokers waren minstens 
1 maand gestopt). Daarbij hebben we onderzocht of er verschillen in ontsteking 
waren tussen patiënten die kort (<3.5 jaar) of lang (?3.5 jaar) gestopt waren met 
roken. De belangrijkste resultaten van dit onderzoek zijn:
- Patiënten die langer gestopt zijn met roken hebben lagere aantallen CD8+ T-lym-
focyten in biopten dan zowel rokers als patiënten die kort gestopt zijn. Deze 
groep heeft ook meer plasma cellen dan rokers.
- Ex-rokers hebben meer T-lymfocyten en plasma cellen in luchtweg biopten dan 
rokers met COPD.
- Andere ontstekingscellen en aantal ontstekingscellen in sputum zijn niet verschil-
lend tussen de 3 groepen.
Uit deze resultaten blijkt dat de duur van stoppen met roken het ontstekingspro-
fiel van T-lymfocyten en plasma cellen beïnvloedt in COPD patiënten. Daarnaast 
blijkt dat alle andere ontstekingscellen verhoogd aanwezig blijven na stoppen. 
Dit geeft aan dat de gunstige effecten van stoppen met roken op symptomen en 
longfunctie niet simpelweg verklaard kunnen worden door een vermindering in 
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luchtwegontsteking. Tevens lijkt er een andere prikkel dan roken te zijn die het 
ontstekingsproces in stand houdt; gedacht kan worden aan virussen of bacteriën, 
auto-immuun prikkels of een afwijkend proces van weefselherstel na longschade.
Hoofdstuk 5: Herstel van veranderingen in epitheelcellen na stoppen met roken in COPD
Bij patiënten met COPD worden veranderingen in de bekledende cellaag van de 
luchtwegen (epitheelcellen) gezien. Deze veranderingen zijn: toename van slijm-
producerende cellen, verandering van de epitheellaag in plaveiselcelepitheel 
(metaplasie) en toegenomen proliferatie van epitheelcellen. In navolging van het 
vorige hoofdstuk, werd onderzocht of de veranderingen aan de epitheellaag her-
stellen na stoppen met roken en of dit afhankelijk is van de duur van stoppen. De 
bevindingen van dit onderzoek zijn:
- Ex-rokers met COPD hebben minder metaplasie en proliferatie van epitheelcel-
len dan rokers. Er was tevens een trend voor minder slijmproducerende cellen in 
ex-rokers, maar deze was niet statistisch significant.
- Er is geen verschil in epitheel kenmerken tussen rokers en COPD patiënten die 
kort gestopt zijn met roken.
- Bij patiënten met COPD die lang gestopt zijn worden minder slijmproducerende 
cellen gezien dan bij zowel rokers als patiënten die kort gestopt zijn, en minder 
proliferatie van epitheelcellen dan rokers.
Deze resultaten laten zien dat de veranderingen van de epitheelcellaag reversibel 
zijn na stoppen met roken. Echter de afname in proliferatie, metaplasie en slijm-
producerende cellen is pas na langdurig stoppen zichtbaar (>3.5 jaar). Dit herstel 
van de epitheelcellaag zou kunnen bijdragen aan de gunstige effecten van stoppen 
met roken op symptomen en longfunctie door minder slijm productie en stase van 
slijm in de luchtwegen. Dat zou mogelijk kunnen leiden tot minder luchtweginfec-
ties en exacerbaties.
Behandeling en luchtwegontsteking
Hoofdstuk 6: Klinische en ontstekingsremmende effecten van inhalatiecorticosteroïden met 
of zonder langwerkende luchtwegverwijders bij COPD
Eerder onderzoek heeft aangetoond dat inhalatiecorticosteroïden een gunstig 
effect hebben op klachten en het aantal exacerbaties bij COPD patiënten. Daar-
naast is er een verbetering in longfunctie in de eerste maanden na starten van de 
behandeling, maar de meeste studies laten geen effect op longfunctie achteruit-
gang zien op lange termijn. In dit hoofdstuk hebben we onderzocht wat het effect 
is van langdurig (2,5 jaar) versus kortdurend (6 maanden) behandelen met inha-
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latiecorticosteroïden op de longfunctie en luchtwegontsteking. Daarnaast hebben 
we onderzocht wat de additionele effecten van een langwerkende luchtwegverwij-
der zijn. De belangrijkste resultaten van dit onderzoek zijn:
- Langdurig behandelen met inhalatiecorticosteroïden vermindert de achteruit-
gang in longfunctie, hyperreactiviteit en kortademigheidklachten van COPD 
patiënten.
- Deze gunstige klinische effecten gaan gepaard met een vermindering in ontste-
kingscellen in de biopten (lymfocyten en mestcellen) en in sputum (lymfocyten, 
neutrofielen, macrofagen) en een toename in intact epitheel in biopten.
- Stoppen met inhalaticorticosteroiden na 6 maanden behandeling doet de ach-
teruitgang in longfunctie, hyperreactiviteit en kortademigheidklachten weer toe-
nemen. Daarnaast treedt er een toename van lymfocyten, plasmacellen en mest-
cellen op in de biopten na stoppen.
- Toevoegen van een langwerkende luchtwegverwijder aan inhalatiecorticoste-
roïden geeft een initiële verbetering in longfunctie en kortademigheidklachten, 
maar heeft geen additioneel effect op achteruitgang in longfunctie op lange ter-
mijn. Zo’n combinatie behandeling heeft geen additionele ontstekingsremmende 
werking in de luchtwegen.
Deze resultaten suggereren dat progressie van luchtwegobstructie in COPD ver-
traagd kan worden door behandeling met inhalatiecorticosteroïden. Daarnaast 
hebben inhalatiecorticosteroïden een ontstekingsremmende werking in de lucht-
wegen. Echter, het verschil in respons op behandeling en de karakteristieken van 
de onderzochte patiënten met andere onderzoeken suggereert dat binnen de hete-
rogene groep van COPD patiënten er een subgroep bestaat die meer baat heeft bij 
inhalatiecorticosteroïden.
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Perspectief voor toekomstig onderzoek
De onderzoeken in dit proefschrift hebben bijgedragen aan het inzicht in de rol 
van luchtwegontsteking in ontstaan en behandeling van COPD. Uiteraard roepen 
deze nieuwe bevindingen nieuwe vragen op. 
Wat is het natuurlijk beloop van luchtwegontsteking in biopten op lange termijn 
in COPD patiënten?
Wat is het effect van stoppen met roken en van behandeling met inhalatiecortico-
steroïden op andere pathologische kenmerken (zoals activiteit van ontstekingscel-
len, bindweefselvorming en spiercellen) in de luchtwegen van COPD patiënten?
Zijn er kenmerken te identificeren in patiënten die voorspellend zijn voor een gun-
stig effect van behandeling met inhalatiecorticosteroïden?
Zijn er nieuwe behandelingen voor COPD te ontwikkelen die progressie van de 
ziekte kunnen stoppen en mortaliteit aan COPD kunnen verminderen?
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